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Abstract 
Chronic infection with hepatitis B virus is a global health issue, leading to liver 
cirrhosis and hepatocellular carcinoma that accounts for more than six 
hundred thousand deaths annually. Recent work has focused on the role of 
Natural killer (NK) cells in liver fibrosis in other contexts. In CHB, NK cells 
have been shown to play an anti-viral as well as an immunoregulatory role. 
Here we investigate the role of NK cells in the context of CHB-driven liver 
fibrosis, using primary hepatic stellate cells (HSC) isolated from healthy 
human liver margins. Our results demonstrate that NK cells from CHB 
patients have a highly variable and limited potential to kill hepatic stellate 
cells, which is increased in patients with progressive liver fibrosis, is further 
enhanced by interferon-alpha pre-activation in vitro and is abrogated by 
antiviral therapy with nucleos(t)ide inhibitors. We have explored the role of the 
death ligand TRAIL expressed on NK cells in inducing apoptosis of stellate 
cells that express high levels of the death-inducing receptor TRAIL-R2. We 
observed that blockade of TRAIL on the NK cells was only able to reduce 
killing of HSC in selected cases but not in the whole cohort, suggesting other 
levels of regulation. Moreover TRAIL ligand (SuperKillerTRAIL) treatment of 
primary HSC did not induce a degree of apoptosis commensurate with their 
high expression of the death-inducing receptor TRAIL-R2. We therefore 
probed the expression of the inhibitory receptors TRAIL-R3 and R4. We found 
expression of these receptors on primary human HSC both ex vivo and after 
in vitro culture. The level of expression of TRAIL-R4 showed a remarkably 
strong correlation with the susceptibility of primary HSC to undergo apoptosis. 
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Furthermore, blockade of these inhibitory receptors rendered primary HSC 
more susceptible to apoptosis by SuperKillerTRAIL and by TRAIL-expressing 
NK cells. Our results are the first to demonstrate a functional role for TRAIL-
R3 and -R4 in regulating susceptibility to apoptosis in primary cells.  These 
novel findings will help us to define potential biomarkers and therapeutic 
targets for liver fibrosis. 
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1. Introduction 
The liver is one of the most resilient organs of the human body. It can endure 
chronic injury and undergo repair over extended periods of time. When 
infected with a non-cytopathic virus such as Hepatitis B virus (HBV), the 
immune response elicited in response to infection causes liver injury. In 
chronic infections this can lead to years of continued liver damage, which in 
turn leads to cirrhosis and/or hepatocellular carcinoma (HCC). The liver 
myofibroblasts, in particular hepatic stellate cells (HSC), produce extra-
cellular matrix that forms the architecture of the liver while new cells are being 
generated. In chronic injury these cells deposit new collagen that leads to 
pathological liver fibrosis. The cellular elements and biological mechanisms 
involved in liver fibrosis have been described and novel treatments directed at 
preventing or slowing fibrosis are now entering clinical trials (Ikenaga, 2013).  
 
In chronic viral hepatitis evidence from randomized controlled clinical trials 
has demonstrated that eradication of hepatitis C virus (HCV) (Poynard et al., 
1998) or control of HBV infection (Marcellin et al., 2013) can result in reversal 
of liver fibrosis. However in HBV infection, control of vireamia with nucleotide 
or nucleoside analogues does not result in viral clearance and so the 
manipulation of immunity to clear HBV without causing liver damage has been 
a goal of research in recent decades. The role of immune response in liver 
fibrosis has increasingly become the focus of research in recent years and 
understanding these interactions will help us understand the progression of 
fibrosis in chronic HBV infection better.  
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Liver microanatomy 
The liver is an organ of hemodynamic confluence, which receives blood from 
the hepatic artery and portal vein. Blood from the portal vein carries by-
products of digestion including nutrients and food antigens from the intestines. 
The arterial and venous blood mingle in the liver leading to hypoxic conditions 
and slow blood flow in the microvessels also known as the liver sinusoid. 
Micro-anatomically, the liver comprises of a meshwork of sinusoids where an 
exchange of nutrients occurs between the hepatocytes and blood (Thomson 
and Knolle, 2010). As illustrated in Figure 1.1, the hepatocytes, which are the 
main parenchymal cells of the liver, are separated from the hepatic sinusoid 
by non-parenchymal cells (NPC). The liver sinusoidal endothelial cells 
(LSECs) line the sinusoid with fenestrations around them. In between the 
LSECs and the hepatocytes lie the HSC. The kupffer cells (KCs), which are 
the liver resident macrophages, along with liver resident DC lie in the sinusoid 
and are in direct contact with the blood and therefore serve an important 
antigen presentation function in the liver (Thomson and Knolle, 2010). The 
intra-hepatic lymphocytes (IHL) also lie in the sinusoid and are able to migrate 
through the fenestrations in a healthy liver (Crispe, 2009).  
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Figure 1-1: Liver microanatomy.  
This diagram illustrates the microanatomy of the liver sinusoidal space. 
Hepatocytes form the parenchyma of the liver and are supplied with blood by a fine 
meshwork of narrow-lumen vessels making up the sinusoidal vasculature. The 
space between the sinusoid and parenchyma, within which HSC lie, is referred to 
as the Space of Disse. The sinusoid is lined with LSECs. Liver resident 
macrophages, KC and IHL lie in the sinusoid where they come in direct contact with 
the blood.  
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Hepatitis B infection – influence on public health and treatment 
One of the most common causes of liver disease world-wide is infection with 
HBV. Chronic infection with HBV (CHB) leads to liver inflammation and 
fibrosis, which over an extended period of time leads to severe liver disease 
such as cirrhosis and hepatocellular carcinoma (HCC). According to the World 
Health Organisation (WHO) an estimated six hundred thousand people die 
due to these complications annually making chronic hepatitis B (CHB) a 
problem of great importance for global public health. In 2012, mortality 
associated with HBV infection ranked 15th in the global causes of death 
(Lozano et al., 2012). According to WHO reports, an estimated two billion 
people are infected with HBV, of which around 350 million have persistent 
infection. HBV can be transmitted vertically (perinatal route) or horizontally 
(parenteral or sexual routes). Most adults infected with HBV are able to 
resolve infection as the result of vigorous and effective antiviral immune 
responses, leading to lifetime immunity (Penna et al., 1996; Rehermann et al., 
1996; Rehermann et al., 1995). However, HBV transmitted from mother to 
child neonatally or acquired in infancy commonly results in chronic infection 
which in turn leads to CHB (Liaw and Chu, 2009). Even though a prophylactic 
vaccine for HBV does exist and is very effective, it is futile as a therapeutic 
vaccine (Lavanchy, 2004).  
 
The global incidence of HBV infection can be stratified geographically based 
on areas of high, moderate and low prevalence. West Africa, South-East Asia, 
Western Pacific and Eastern Europe make up areas of high prevalence (5-
13%) (Liaw and Chu, 2009; Ott et al., 2012). Rest of Europe, South America, 
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Australia and Japan are areas of moderate frequency (2-4%) and Central 
America that of low frequency (<2%) (Ott et al., 2012). Majority of cases in 
areas of low prevalence of infection are by the horizontal route whereas most 
individuals infected in the high prevalence areas are infected vertically 
(Lavanchy, 2004).  
 
For CHB, targets for therapy include suppression of viral replication, 
immunomodulation leading to remission of biochemical changes in the liver 
and prevention of liver damage which eventually cause cirrhosis and HCC. 
Currently there are two types of drugs being used to treat CHB, the first are 
nucleot(s)ide analogs that are anti-viral and are administered orally and the 
second is the pegylated form of Interferon-α (Peg-IFN-α) which has both 
antiviral and immunomodulatory effects and is administered subcutaneously 
(Papatheodoridis et al., 2008b).  Oral anti-viral drugs, Entecavir and Tenofovir 
have improved the treatment of CHB as they have a high barrier to genetic 
resistance; however, clearance of the virus is rarely achieved 
(Papatheodoridis et al., 2008b). Even though treatment with peg-IFN-α is 
short-term (12 months), only a minority of patients achieve lasting virologic 
control or immune seroconversion (Papatheodoridis et al., 2008b). Patients 
with genotypes A and B respond better than those with genotype C and D 
when treated with peg-IFN-α but no genotypic difference are observed in 
patients treated with oral anti-virals (Lok and McMahon, 2007).  
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HBV replication, natural history and clinical course 
HBV belongs to the Hepadnaviridae family of viruses with a small DNA 
genome of ~3200 nucleotides. It is a hepatotropic virus that infects and 
replicates in the hepatocytes that make up most of the parenchyma of the 
liver. HBV has a spherical structure. The HBV genome is made of relaxed 
circular partially double-stranded DNA that encodes four overlapping open 
reading frames (ORFs): the pre S/S encoding the three viral surface proteins, 
the precore/core encoding the core, forming the antigenic structure of the viral 
capsid and the non-structural precore, as secreted hepatitis B e-antigen 
(HBeAg); the pol ORF encoding the polymerase, which includes 
transcriptases that are necessary for RNA encapsidation and DNA synthesis; 
and the X protein (HBx), essential for viral replication (Dandri and Locarnini, 
2012) (Figure 1.2). Towards the exterior of the genome are the three 
envelope proteins of different sizes; large (L), medium (M) and small (S) that 
share the same C-terminal domain and contain the hepatitis B surface antigen 
(HBsAg) (Glebe and Urban, 2007). 
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Figure 1-2: HBV genome. 
The genome of HBV is 3.2kb. It encodes four overlapping ORFs. In blue is 
precore/core encoding HBeAg and HBcAg. In red is the viral Pol, green 
illustrates the S,M and L env ORFs and finally the HBx ORF is shown in 
purple.  
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HBV infects hepatocytes. The point of entry of virions into the cells has been 
recently described to be sodium taurocholate cotransporting polypeptide 
(NTCP) (Yan et al., 2012). Once in the cell cytoplasm, the virions are 
uncoated and the relaxed circular DNA (rcDNA) is released into the nucleus 
via the nuclear pore complex (Schmitz et al., 2010). Inside the nucleoplasm, 
the viral rcDNA depends on the host cells replicative machinery to remove 
and repair terminal proteins and complete the synthesis of the positive DNA 
strand to yield a covalently closed circular (ccc) supercoiled DNA molecule 
(Urban et al., 2010). cccDNA undergoes transcription essential to produce 
proteins and facilitate viral replication in the cytoplasm after reverse-
transcription of the pre-genomic RNA (pgRNA) (Nassal, 2008). In the 
cytoplasm, the viral RNAs serve as mRNAs to translate into viral structural 
and non-structural proteins: HBV surface, core, polymerase and X proteins 
(Block et al., 2007; Summers, 1988). Inside these capsids, the RNA 
undergoes reverse transcription to produce the first single stranded viral 
cDNA which acts as a template for the synthesis of the second strand and 
leads to the formation of the relaxed circular double stranded DNA genome. 
These mature DNA containing capsids are transported bi-directionally within 
the cytoplasm: one pathway ends at the endoplasmic reticulum (ER) where 
they interact with the envelope proteins to initiate budding which results in the 
formation and secretion of non-infectious sub-viral particles (SVP) and 
infectious virions that are released from the cell; the other pathway transports 
them back into the nucleus to expand the cccDNA pool (Dandri and Locarnini, 
2012; Urban et al., 2010). The replication cycle of HBV is illustrated in figure 
1.3. 
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Lack of proofreading of viral polymerases and mutations in cccDNA give rise 
to genetic heterogeneity of HBV (Balmasova et al., 2014; Locarnini and 
Zoulim, 2010). These mutations allow the virus to evade and escape host 
immune-mediated viral clearance and anti-viral drugs. There are ten known 
HBV genotypes with described geographical prevalence (Balmasova et al., 
2014). HBV genotypes influence the clinical outcome of the disease and 
response to anti-viral drugs (Tanwar and Dusheiko, 2012).  
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Figure 1-3: HBV life cycle. 
The HBV virion enters hepatocytes through NTCP. In the cytoplasm the virion 
uncoats and the rcDNA is released into the nucleus. In the nucleus, the rcDNA 
is synthesized to form ccc DNA. cccDNA undergoes transcription to produce 
proteins to facilitate viral replication in the cytoplasm. In the cytoplasm, the viral 
RNA is translated into viral structural and non-structural proteins, eventually 
leading to the formation of viral cDNA which acts as a template for formation of 
rcDNA. The mature DNA containing capsid is transported bi-directionally in the 
cytoplasm; one towards ER to form and secrete SVP and the other back to the 
nucleus to expand the pool of cccDNA.  
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Along with the SVP, HBV replication in an infected cell also leads to the 
secretion of non-structural part of the nucleoprotein, HBeAg. This antigen has 
no role in viral replication, however it has been suggested to have immune-
modulating functions (Wieland and Chisari, 2005). HBeAg and HBsAg have 
been shown to skew the adaptive immune response in HBV mouse models 
and may contribute to T cell exhaustion (Chen et al., 2005; Guidotti and 
Chisari, 2006). Studies done by some groups have demonstrated that these 
secreted viral particles have the capacity to suppress toll-like receptor (TLR) 
mediated innate immune responses against HBV (Visvanathan et al., 2007; 
Wu et al., 2009). Along with these, the HBx protein when overexpressed can 
hinder the processing and presentation of viral antigens (Wieland and Chisari, 
2005). These attributes of the virus contribute to viral persistence and provide 
tolerance against effector immune response.  
 
The outcome of infection is determined in part by the age at which an 
individual is infected with HBV. Acute infection with HBV is characterised by a 
long incubation period in which the virus undergoes active replication before 
effector host immune responses produce a marked decline in virus levels. 
Clinical symptoms (malaise, anorexia, nausea, pruritus, jaundice) signs and 
abnormal investigations (raised levels of alanine aminotransferase, cell 
mediated immune responses) can be observed at between 1 and 6 months 
after infection (Dunn et al., 2009; Guidotti et al., 1996; Webster and Bertoletti, 
2002; Webster et al., 2000). 1-5% of perinatal infections, around 50% 
childhood infections and more than 95% adult are cleared spontaneously 
within a period of 6 months since the time of infection, resulting in loss of 
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HBsAg and leading to lifelong immunity in most cases (Liaw and Chu, 2009). 
This is because an effective immune response is able to contain the virus 
rather than completely eradicate it (Rehermann et al., 1996). In instances of 
immunosuppression, the virus has the potential to reactivate.   
 
Inability to resolve the infection leads to CHB. The natural history of CHB can 
be generally regarded to comprise five phases, which may not be experienced 
sequentially (2012) : the immune tolerant phase; the immune reactive HBeAg-
positive phase; the inactive HBV carrier phase; HBeAg-negative CHB; and the 
HBsAg-negative phase. The immunotolerant phase is more frequent and 
long-lasting in individuals infected perinatally or in early childhood compared 
to those infected in adulthood. This phase is characterised by serum HBeAg 
positivity, high levels of HBV DNA, normal ALT. The immune reactive phase 
usually occurs after many years of immune tolerance in perinatally infected 
individuals, however, this stage is more rapidly reached in individuals infected 
in adulthood. It is characterised with decreased levels of HBV DNA, increased 
levels of ALT and a more rapid progression of fibrosis compared to the 
previous phase. This stage is terminated by reduction of HBeAg and 
seroconversion with the production of detectable levels of anti-HBe 
antibodies. (Dandri and Locarnini, 2012). Most frequently seroconversion to 
eAg negative CHB is followed by an inactive HBV carrier stage. This phase is 
charachterised by low (<2000 IU/ml) or undetectable levels of HBV DNA and 
normal ALT levels (EASL, 2012). The majority of patients in this phase for a 
long period of time have low risk of developing HCC or cirrhosis (Chen et al., 
2012; 2012; Tai et al., 2009). HBeAg negative CHB is thought to be caused 
 32 
by late immune reactivity to eAg negative variants of HBV and is 
characterised by persistently elevated or fluctuating levels of viral load and 
ALT (Papatheodoridis et al., 2008a). It may follow serconversion to anti-HBe 
at the end of immune reactive phase or it may develop years after the inactive 
HBV carrier state. The HBsAg-negative phase is characterised by the loss of 
HBsAg and may be accompanied by emergence of sAb. However low levels 
of viral replication may be detectable in the liver and not in the serum. 
Immunosuppression in these individuals may result in reactivation of HBV 
(EASL, 2012). If this phase is reached before the onset of cirrhosis, it is 
associated with a reduced risk of developing HCC and cirrhosis and 
decompensation.  
 
These phases are useful in the clinical stratification of patients, however, they 
do not entirely define the complexity of immune responses during these 
stages. The innate and adaptive immune response, play an important role in 
resolving acute infection. 
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Innate immune responses   
The liver is rich in cells that have the capacity to detect pathogens via pattern 
recognition receptors (PRRs). These include the hepatocytes that make up 
most of the liver parenchyma, the non-parenchymal cells (NPCs): liver 
sinusoidal endothelial cells (LSECs), hepatic stellate cells (HSCs) and bone 
marrow-derived liver immune cells such as resident macrophages, kupffer 
cells (KC) and resident dendritic cells (DCs) (Protzer et al., 2012). Prototypic 
early responses to infection are characterised by the production of type I 
interferons (IFNs). However, in intrahepatic gene expression studies 
conducted in the chimpanzee model, in the early phases of HBV infection 
(entry and expansion) there were no detectable interferon-inducible genes 
(Wieland et al., 2004). Studies conducted with blood samples from patients 
with acute HBV infection confirmed these finding, as very low levels of 
circulating type I IFNs were detected (Dunn et al., 2009). Unlike infections 
with other viruses, such as human immunodeficiency virus (HIV), dengue 
virus and human cytomegalovirus (HCMV), acute infection with HBV often has 
a paucity of typical ‘flu-like’ symptoms and defective production of type I IFNs.  
HBV is often referred to as the ‘stealth’ virus owing to its capacity to evade 
host innate responses (Wieland and Chisari, 2005). 
 
Studies conducted in the woodchuck model and virus-replicating cell lines 
have demonstrated that the levels of viral replication, size of viral inoculum 
and counteractive properties of NPCs influence the host innate immune 
responses and aftermath of infection (Asabe et al., 2009; Bertoletti et al., 
2010; Guy et al., 2008; Lucifora et al., 2010). Gene studies in chimeric HBV 
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mice have shown that hepatocytes transiently activate the IFN-α producing 
gene upon infection, in line with the emerging concept that innate immune 
responses to the virus might be rapidly down-regulated (Lutgehetmann et al., 
2011).  
 
Type III IFNs that are produced primarily in the liver have also been shown to 
have anti-HBV activity in murine model, which may compensate for the lack of 
early type I IFN activity (Bertoletti et al., 2010).  
 
HBV is a non-cytopathic virus. Liver injury and disease progression are 
attributed to host immune responses. 
 
Natural killer T (NKT) cells and natural killer (NK) cells form an important arm 
of innate immune response. NKT cells are a heterogeneous population of 
cells that express markers of NK cells along with a T cell receptor, that 
recognise antigens presented by non-classical MHC class I like molecule CD1 
(Seino and Taniguchi, 2005). In mice, around 30% of the intrahepatic 
lymphocyte population consists of NKT cells, while in humans it is less than 
1% (Gao et al., 2009). NKT cells are further classified into classical or 
invariant NKT (iNKT) cells (>95% of total NKT cell population in mice) and 
non-classical type II NKT cells. Early on in the course of infection, NKT cells 
have the capacity to produce cytokines that can activate NK cells, and cells of 
the adaptive immune response: T cells and B cells (Tupin et al., 2007). 
Studies using the HBV transgenic mouse model have demonstrated that in 
vivo activation of NKT cells leads to secretion of antiviral cytokines in the liver 
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and therefore they have the potential to control viral replication (Kakimi et al., 
2000). 
 
Another NKT cell-like cell, which exhibits some of the iNKT cells’ functional 
features along with a limited TCR repertoire diversity is called the mucosal-
associated invariant T (MAIT) cell (Martin et al., 2009). On stimulation they 
produce large quantities of pro-fibrotic cytokines TNF-α and IL17 (Dusseaux 
et al., 2011; Walker et al., 2012). It has now been demonstrated by Tang et al. 
that MAIT cells are highly enriched in the human liver environment; their role 
in CHB remains to be determined. (Tang et al., 2013). 
 
NK cells are typically amongst the first to become activated in early acute 
infection and have the potential to exert anti-viral functions in HBV infection 
(Dunn et al., 2009; Fisicaro et al., 2009; Guy et al., 2008; Kakimi et al., 2000; 
Yang et al., 2002). The frequency of NK cells is much higher in the healthy 
liver (30-40%) compared to their frequency in the periphery (~10%) (Cooper 
et al., 2001). Phenotypic studies of NK cells have demonstrated that 
activatory receptors NKp30, NKp46 and NKG2C are upregulated on NK cells 
of CHB patients compared to patients infected with HCV and healthy 
individuals (Bonorino et al., 2009; Rehermann, 2013). NK cells can exert 
antiviral effects through both cytolytic and non-cytolytic functions. Our group 
has shown that NK cells have the capacity to kill HBV infected hepatocytes 
and contribute to viral clearance along with causing liver injury in a TNF-
related apoptosis inducing ligand (TRAIL) dependent manner (Dunn et al., 
2007). NK cells also kill virus-specific CD8+ T cells via TRAIL and in this way 
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contribute to viral persistence (Peppa et al., 2013). The non-cytolytic effector 
function of NK cells which includes production of anti-viral cytokines such as 
IFNγ is dampened in both early acute (Dunn et al., 2009) and chronic HBV 
infection due to high levels of IL-10 and TGF-β in the liver environment; this 
defect has been shown to be restored by blocking these cytokines in vitro 
(Peppa et al., 2010). The contribution of NK cell TRAIL-mediated killing of 
stellate cells to their anti-fibrotic potential in CHB has been described in the 
results section; investigation of this forms one of the main objectives of this 
study.  
 
An overview of NK cells has been described in further detail in a subsequent 
sub-section. 
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Adaptive immune response  
Helper CD4+ T cells and effector CD8+ T cells have both been documented to 
have a strong response in acute HBV infection (Guidotti et al., 1999; 
Rehermann et al., 1995). The helper CD4+ T cells play a crucial role in 
influencing the quality and magnitude of eventual CD8+ T cell responses 
against the virus (Asabe et al., 2009). Murine studies have shown that if the 
CD4+ T cells are primed in the liver microenvironment, they fail to differentiate 
into Th1 cells and produce Th1 cytokines and this failure is thought to 
contribute to liver’s tolerogenic environment and may dampen responses 
against the virus (Knolle et al., 1999). In the setting of CHB, CD4+ T cells have 
a narrower virus-specific repertoire and a reduced proliferative potential 
(Ferrari et al., 1990). The role and frequency of typical regulatory T cells 
(Tregs), classified as CD4+ CD25high FoxP3+ cells, in the context of CHB is 
controversial, with conflicting evidence concerning their role (Li et al., 2012; 
Manigold and Racanelli, 2007).  The in vitro depletion of Tregs in CHB has 
shown to improve the function of virus-specific T cells, this has also been 
reported in resolved infection (Franzese et al., 2005; Peng et al., 2008).  
 
CD8+ T cells also have a major contribution towards the adaptive immune 
response to HBV.  The crucial role of CD8+ T cells in controlling the virus in 
acute infection has been demonstrated in the chimpanzee model (Thimme et 
al., 2003). In acute HBV infection, CD8+ T can directly kill virally infected 
hepatocytes cytolyticaly and contribute to liver injury leading to inflammation. 
CD8+ T cells also produce cytokines such as TNF-α and IFN-γ non-
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cytolytically to clear infection, as demonstrated in animal models and in in 
vitro cultures (Guidotti et al., 1996; Phillips et al., 2010). However, in chronic 
viral infection, due to prolonged antigen exposure, virus-specific effector CD8+ 
T cells are profoundly depleted and have impaired effector functions, showing 
phenotypic characteristics of ‘exhaustion’. This was first described in murine 
model of chronic disease with lymphocytic choriomeningitis virus (LCMV) 
(Wherry et al., 2003). This phenomenon has also been described in CHB and 
it has been observed that T cells of patients that are unable to control HBV 
viral replication have reduced production of IFNγ and exhibit a poorer 
proliferative potential (Boni et al., 2007; Das et al., 2008). In CHB, the level of 
HBV viral load and the duration of exposure of T cells to antigen correlates 
with changes in the effector functions of T cells (Bertoletti and Ferrari, 2012; 
Webster et al., 2004) HBV DNA levels have been observed to be inversely 
proportional to intra-hepatic virus-specific CD8+ T cells (Fisicaro et al., 2010). 
Extensive gene profiling of virus-specific T cells from CHB patients compared 
to T cells form HBV resolved patients has shown that the former have high 
levels of pro-apoptotic molecule of Bcl-2 family, Bim, implying that these 
exhausted virus-specific T cells are more prone to premature apoptosis 
(Lopes et al., 2008). Defective antigen presentation in the liver has been 
suggested to contribute to vulnerability to apoptosis and pre-mature 
elimination of virus-specific T cells (Maini and Schurich, 2010), as described 
in mouse models (Holz et al., 2008). In patients on anti-viral treatment (that 
can suppress viral replication but not have a marked effect on the production 
of sub-viral particles), it has been observed that there is only a transient 
recovery of virus-specific T cells suggesting that persistent exposure to HBV 
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antigens affects T cell function (Boni et al., 2003). The imbalance in co-
stimulatory versus co-inhibitory signals also contributes to the diminishing 
functions of CD8+ T and their progression towards exhaustion. Over the 
years, many co-inhibitory molecules such as programmed death-1 (PD-1), 
cytotoxic T-lymphocyte associated antigen-4 (CTLA-4), 2B4 and T cell 
immunoglobulin mucin-3 (Tim-3) have been described to be upregulated on 
virus-specific CD8+ T cells in CHB (Boni et al., 2007; Nebbia et al., 2012; 
Raziorrouh et al., 2010; Schurich et al., 2011). It is worth noting that the liver 
is subjected to repeated exposure to gastrointestinal antigens, and so a level 
of immune tolerance is essential if the liver is not to be overwhelmed by 
inflammatory responses to pathogens and other foreign antigens. The 
tolerogenic activation of T cells by hepatocytes and LSECs may contribute to 
their exhaustion and susceptibility to apoptosis (Protzer et al., 2012).  
 
Along with T cell responses, protective humoral responses by B cells also 
play an important role in the course of HBV infection. Antibodies against 
HBsAg are neutralising and these are associated with life-long protection 
against HBV infection and reinfection in an individual (Rehermann and 
Nascimbeni, 2005). Production of antibodies against Envelope protein have 
also been correlated with temporal clearance of the virus (Alberti et al., 1978). 
In CHB, the protective humoral immune response is affected by the 
dampened cellular immune response. Murine studies have demonstrated that 
B cells are able to produce regulatory cytokines such as IL-10, which 
influence other cells of the immune system (Fillatreau et al., 2002; Mauri et 
al., 2003). In CHB, a distinct population of B cells referred to as regulatory B 
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cells (Bregs) that are characterised by their production of IL-10 have been 
described as suppressing virus-specific CD8+ T cell responses (Das et al., 
2012).  
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NK cells: Overview  
NK cells are large granular lymphocytes that have traditionally been regarded 
as belonging to the innate arm of the immune system; they are able to kill 
target cells without priming and are not restricted by the MCH of the target cell 
(Kiessling et al., 1975; Lanier et al., 1986). However, advances in the field 
have put NK cells on the border between innate and adaptive immune 
responses, with accumulating evidence that they can mediate recall/”memory” 
responses and can utilize their receptors to respond in an antigen-specific 
manner (Cooper et al., 2009; Paust et al., 2010; Rolle et al., 2013)  
highlighting the multiple functions of NK cells including tumor surveillance and 
response against pathogens (Vivier et al., 2011).  
 
Conventionally, NK cells are phenotypically classified by the absence of CD3 
and expression of CD56, which is a neural cell adhesion molecule (NCAM) 
(Lanier et al., 1989). Murine NK cells do not express CD56 and can be 
classified by their expression of NKp46, which is expressed by all mammalian 
NK cells (Walzer et al., 2007). A minority of human NK cells express low 
levels of NKp46. The function of these is yet to be determined.  
 
NK cells primarily develop in the bone marrow. Bone marrow-derived CD34+ 
hematopoietic stem cells differentiate into common lymphoid progenitor cells 
that give rise to NK cell precursors that further develop into immature NK 
cells, eventually becoming functional mature NK cells after acquiring 
activating and inhibitory receptors (Lanier, 2005). In vitro experiments have 
 42 
demonstrated that hematopoietic stem cells are dependent on stromal factors 
such as IL-7, IL-2, IL-15, stromal cell factor and FLT3 ligand at least in the 
very early stages of development of NK cells (Di Santo, 2006). Knowledge of 
NK cell development pathways in humans is still incomplete. Recent studies 
have indicated that immune precursor cells that hold the potential to develop 
into NK cells can be found in secondary lymphoid tissue and other anatomical 
locations including the liver (Eissens et al., 2012; Male et al., 2010; Moroso et 
al., 2011). These NK cells could represent a separate lineage of NK cells or 
imply that bone marrow-derived peripheral NK cells are not fully mature. 
These questions remain to be answered. In humans, the most complete 
pathway of NK cell differentiation is attributed to the sequential expression of 
specific markers and functionality of NK cells, which is reported to take place 
in secondary lymphoid tissue (Freud et al., 2005; Sun and Lanier, 2011). The 
four stages of differentiation have been classified by the expression of CD34, 
CD117 and CD95; these include: stage 1 pro-NK (CD34+CD117−CD94−); 
stage 2, pre-NK, (CD34+CD117+CD94−); stage 3, immature NK, 
(CD34−CD117+CD94−); and stage 4 (CD34−CD117+/−CD94+) NK cells, 
corresponding to the CD56bright subset.  
 
In circulating blood, mature NK cells make up 10% of the peripheral blood 
lymphocyte population (Caligiuri, 2008). In lymphoid and non-lymphoid organs 
including liver, lung, thymus and uterus; different subsets of NK cells can be 
found (Colucci et al., 2003). Conventionally, human NK cells can be classified 
into two subsets depending in their cell surface expression of CD56: CD56 
bright and CD56 dim (Cooper et al., 2001). CD56 dim 
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peripheral blood, bone marrow and spleen; while the CD56 bright NK cells form 
the majority in secondary lymphoid tissue (Fehniger et al., 2003). Both CD56 
bright and CD56 dim subsets have distinct and crucial roles in immune response. 
The CD56 bright subset of NK cells is conventionally regarded as the primary 
source of NK cell-derived cytokines such as IFN-γ, TNF-β, Il-10, IL-13 and 
GM-CSF (Cooper et al., 2001), although more recently is has been 
recognised that the CD56 dim subset can also produce cytokines particularly 
upon target cell recognition (Fauriat et al., 2010). The CD56 bright subset of NK 
cells lack the low affinity Fcγ receptor CD16 and cytotoxic proteins perforin 
and granzyme and they express high levels of IL-2 receptor α chain (CD25) 
and inhibitory receptor complex CD94/NKG2A. By contrast, the CD56dim 
subset of NK cells express high levels of CD16 and contains large number of 
granules of perforin and granzyme, leading to their cytotoxic function (Cooper 
et al., 2001). CD16 binds to the Fc region of immunoglobulin, activating NK 
cells to cause lysis of target cells via perforin. This is referred to as antibody-
dependent cellular cytotoxicity (ADCC).  Advances in the field have revealed 
that mature CD56bright NK cells further mature to the CD56dim phenotype 
(Caligiuri, 2008; Huntington et al., 2009; Romagnani et al., 2007).  
 
NK cells express a wide array of activating and inhibitory receptors. The 
natural killer receptors (NKRs) can be classified into three categories; these 
are: the killer cell immunoglobulin-like receptors (KIR) that recognise classical 
MHC Class-I molecules (HLA A, B and C); the C-type lectins that recognise 
non-classical MHC Class-I molecules and class-I like molecules; and thirdly, 
the natural cytotoxicity receptors (NCR). Along with NKRs, NK cells also 
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express death ligands such as Fas-L and TRAIL. Interaction of death ligands 
with their respective ligands on target cells does not initiate cytotoxicity via NK 
cell degranulation but instead leads to caspase-mediated apoptosis of target 
cells.  Examples of NKRs within each category are listed below:  
 
 
KIRs C-type lectins NCRs Death ligands 
KIR2DL1-3 NKG2D NKp46 TRAIL 
KIR2DL5A-B NKG2A NKp44 Fas-L 
KIR2DS1-5 NKG2C NKp30  
  NKp80  
Table 1-1: List of some NKRs (classified as KIRs, C-type lectins and 
NCRs) and death ligands.  
In red are the inhibitory receptors expressed on NK cells and in black are the 
activatory receptors expressed on NK cells.  
 
NK cells express a greater variety of known activatory receptors compared to 
inhibitory receptors. The downstream signaling of activating receptors is 
varied and is dependent on the receptor. Activating receptors CD16, NCRs 
and C-type lectin NKG2C/CD94 interact with immunoreceptor tyrosine based 
activating motif (ITAM) containing adapters such as FcRγ, DAP12 and CD3ζ 
that activate further downstream signaling (Vivier et al., 2004). Other 
receptors such as NKG2D from the C-type lectin family initiates signalling 
upon interaction with its ligand via the DNAX-activating protein of 10kD 
(DAP10) (Lanier, 2005). The inhibitory pathways of NK cells express one or 
more intra-cytoplasmic immunoreceptor tyrosine based inhibition motif (ITIMs) 
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that activate and signal through SH2 protein tyrosine phosphatases (Vivier et 
al., 2004). The requirement for multiple signaling pathways remains unclear 
but may highlight the importance of multiple functions of NK cells.  
 
The functional consequence of NKRs is a result of both activating and 
inhibitory signals received from interaction with their respective ligands on the 
target cell. Autologous normal cells are protected from effector NK cell attack 
because they express self-MHC Class I that engage with the inhibitory 
receptors (KIRs and NKG2A/CD94) on NK cells. Once the inhibitory receptors 
are engaged, their signals override any activating signal, preventing NK cells 
from killing any MHC-Class I expressing cell (Bryceson et al., 2006). 
However, murine studies have demonstrated that NK cells from MHC Class I 
deficient mice are hypo-responsive, implying the role of this interaction in 
development of NK cells to their competent state (Liao et al., 1991). Inhibitory 
signaling through MHC Class I is crucial for this education or licensing of NK 
cells to develop and mature completely (Bryceson et al., 2006).  
 
Organ specific NK cells have the ability to adapt to the local microenvironment 
to facilitate tissue-specific functions, as seen in uterine NK cells during 
placentation (Hanna et al., 2006). In the liver, NK cells constitute around 40% 
of the total hepatic lymphocyte population. During viral infections in the liver, a 
further accumulation of NK cells is observed (Salazar-Mather et al., 1998). 
The production of chemokines by liver resident cells may be crucial for the 
selective homing of NK cells during disease. NK cells in the liver have a 
characteristic repertoire and cytokine profile (Lassen et al., 2010). The 
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majority of NK cells in the liver belong to the CD56 bright subset of NK cells, 
unlike the dominant circulating subset of mature CD56 dim CD16+ NK cells, 
suggesting that hepatic NK cells may constitute a liver-specific lineage, in line 
with their distinct transcriptional profile (Paust et al., 2010; Peng et al., 2013; 
Shi et al., 2011; Takeda et al., 2005). Recent studies in the field have 
demonstrated that all stages of NK cells can be found in an adult human liver 
and that peripheral NK cells recruited to the liver can attain a liver-specific 
phenotype (Moroso et al., 2011). The tolerogenic environment of a normal 
healthy liver maintains a functionally hyporesponsive state of liver NK cells by 
initiating the release of IL-10 by KCs to dampen down the effector functions of 
NK cells (Tu et al., 2008). IL-10 induces the expression of the inhibitory 
receptor NKG2A in liver resident NK cells to regulate their function (Krueger et 
al., 2011). In the liver, the number of licensed NK cells expressing inhibitory 
receptors for MHC Class I is less than in the periphery (Norris et al., 2003). In 
addition, hepatocytes express low level of self MHC Class I (Daar et al., 
1984). These factors may contribute to the functional tolerance of hepatic NK 
cells. However, inflammatory cytokines have the potential to activate NK cells 
and overcome their hyporesponsive status (Burt et al., 2009; Kim et al., 2005).  
 
In the liver, NK cells are primarily found in the hepatic sinusoid as illustrated in 
figure 1.1, however they can migrate via the fenestrations in the LSECs into 
the space of Disse and liver parenchyma, establishing a direct contact with 
HSCs and hepatocytes (Krueger et al., 2011).  
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Intrahepatic NK cells of healthy adults do not express TRAIL, however, in 
CHB, they have a preferential enrichment of TRAIL expression on CD56 bright 
subset (Dunn et al., 2007; Ishiyama et al., 2006). In CHB, NK cells can kill 
infected hepatocytes in a TRAIL-dependent manner (Dunn et al., 2007). NK 
cells have also been shown to lyse murine and human HSCs via TRAIL 
(Glassner et al., 2012; Radaeva et al., 2006). However, this has never been 
shown in CHB.  
 
Intrahepatic NK studies in humans have been limited owing to lack of 
availability of healthy liver tissue.  
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Liver Fibrosis 
Liver fibrosis refers to the accumulation of extra cellular matrix as a result of 
liver injury. It is a dynamic reversible wound-healing response in which matrix 
deposition is accompanied by matrix degradation. In cases of acute and self-
limiting injury the fibrosis may be cleared. However, in chronic injury, 
persistent accumulation of extra cellular matrix and insufficient tissue 
remodeling leads to the formation of scar tissue. In advanced stages of 
fibrosis, the liver has around six times more ECM rich in fibrillar collagen than 
a normal liver (depending on the etiology), along with reduced activity of 
certain matrix metalloproteinases (MMPs) that help remove ECM, owing to 
overexpression of tissue inhibitor of metalloproteinases (TIMPs) (Arthur, 2000; 
Bataller and Brenner, 2005). Clinically, liver fibrosis can be assessed 
histologically using liver biopsies. The two commonly used well-established 
scales are the Metavir (I-IV) and the Ishak score (I-VI). However liver biopsy is 
an invasive procedure that is not well tolerated by patients and yields a small 
sample of liver tissue that may not be representative of the pattern of fibrosis 
throughout the liver (sampling error). Examination and staging of the severity 
of liver fibrosis by a liver pathologist is somewhat subjective and may give rise 
to inter-observer variation. For these reasons there has been a systematic 
endeavor to identify reliable non-invasive tests for assessing liver fibrosis. 
Various non-invasive tests have been successfully reported, some of which 
measure biochemical markers of liver function such as the FibroTest while 
others look at molecules involved in the formation and degradation of liver 
fibrosis such as the Enhanced Liver Fibrosis (ELF™) test (Myers et al., 2003; 
Parkes et al., 2010; Rosenberg et al., 2004).   Progression of liver fibrosis 
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over a span of 30-40 years leads to cirrhosis, which is one of the main causes 
of mortality in CHB. Cirrhosis is characterised by distortion of normal liver 
architecture, formation of nodules, with disruption of the vascular architecture 
of the liver resulting in portal hypertension leading to variceal bleeding and 
ascites and eventually liver failure (Mormone et al., 2011). While some of the 
complications of cirrhosis can be treated presently, the only effective available 
treatment for cirrhosis is liver transplant and the shortage of donors poses a 
problem. Many cells have been implicated in liver fibrosis, these include peri-
portal myofibroblasts, bone marrow derived myofibroblasts and epithelial-
mesenchymal-transition (EMT); however, studies have repeatedly 
demonstrated that hepatic stellate cells (HSC), the resident mesenchymal 
cells, are the main cellular mediators of fibrogenesis in the liver (Friedman, 
2008b).  
 
HSC are located in the Space of Disse in the liver in between the liver 
sinusoidal epithelium and hepatocytes. In a normal healthy liver, HSC exist in 
a quiescent state. Quiescent HSC are characterised by the presence of large 
lipid droplets in the cytoplasm that have retinoids, fatty acids and triglycerides 
stored in them (Tacke and Weiskirchen, 2012). Around 80% of human body’s 
vitamin A is stored in quiescent HSC in the form of retinoid (Korner et al., 
1989). The quiescent cells have an elongated nucleus, enormous golgi 
apparatus and rather robust rough endoplasmic reticulum (ER), however they 
have poorly developed small ER and trifling numbers of mitochondria, 
lysosomes and peroxisomes (Tacke and Weiskirchen, 2012). They contribute 
to hepatic development and also play a vital role in liver regeneration in 
 50 
adults. HSC form a part of the progenitor cell niche of a normal regenerating 
liver (Roskams, 2006; Yin et al., 1999). Studies have shown increase in the 
expression of epimorphin, a mesenchymal morphogenic protein by quiescent 
HSC after partial hepactomy (Yoshino et al., 2006). HSC play an important 
role in hepatic development especially in the development of intrahepatic bile 
ducts (Libbrecht et al., 2002). They also have the potential to secrete and 
produce several hepatocyte mitogens including hepatocyte growth factor 
(HGF), epimorphin and pleiotrophin (Friedman, 2008a).  
 
As a result of insults producing liver injury, the quiescent HSC become 
activated and, as mentioned before, are the dominant cell type contributing to 
liver fibrosis. The activation of HSC broadly comprises two phases: initiation 
and perpetuation, which eventually lead to resolution if the source of liver 
injury is removed and the liver recovers (figure 1.4).  Initiation of activation of 
HSC is usually a consequence of changes in the surrounding liver 
environment. These include the secretion of paracrine stimulants in the liver 
milieu and exposure to by-products of apoptotic or necrotic hepatocytes 
(Friedman, 2008b; Henderson and Iredale, 2007). Initiation refers to the 
changes in gene expression and phenotype of HSC that makes them 
responsive to the stimuli created in the injured liver environment. The 
inflammatory cytokines and growth factors in the liver form an essential part of 
the changes in the liver microenvironment. As persistent inflammation almost 
always precedes fibrosis, these cytokines play a crucial role in activating 
HSC. Gene array studies in mouse models and humans have demonstrated 
that inflammatory cytokines such as IL-1β, IL-6, IL-10, IL-13, IFN-γ and TNF-α 
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all contribute to fibrogenic responses (Bataller and Brenner, 2005; Safadi et 
al., 2004; Shi et al., 1997; Streetz et al., 2003). Transforming growth factor  β 
(TGF-β) is one of the first cytokines to be activated from its latent form by 
neighbouring liver cells such as LSECs and KCs (Friedman, 2000). Injured 
LSECs also promote the production of fibrogenic cellular fibronectin (Jarnagin 
et al., 1994). KCs upon activation during liver injury activate HSC by 
stimulating matrix synthesis, secreting fibrogenic cytokines and reactive 
oxygen species (ROS) (Friedman, 2008a).  
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Figure 1-4: Fate of HSC. 
During liver injury, the activation of HSC is initiated, and if the injury persists 
it perpetuates the activated state of HSCs making them contractile, 
promoting their proliferation and migration along with the deposition of 
collagen. If the cause of liver injury is removed, it leads to resolution of 
fibrosis by reversion, induction of apoptosis or senescence. 
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In the next phase referred to as the ‘perpetuation’ phase, the activated 
phenotype of HSC is maintained by these autocrine as well as paracrine 
changes, leading to their transformation into myofibroblast phenotype by an 
increase in their contractility, proliferation, migration towards 
chemoattractants, re-modeling of liver ECM, loss of retinoid and generation of 
fibrosis (Bataller and Brenner, 2005; Jiao et al., 2009). TGF-β and platelet-
derived growth factor (PDGF) are the most extensively described fibrogenic 
and proliferative stimuli of HSC (Jiao et al., 2009). Other key growth factors 
and chemokines have also come to light. These include connective tissue 
growth factor (CTGF/CCN2) that functions via the TGF-β signaling pathway 
and is a potent fibrogenic agent and others such as insulin-like growth factor 
(IGF), epidermal growth factor (EGF) and chemokines such as CCL2 (also 
known as MCP-1) and CXCR3 that contributes to the chemotactic activity of 
HSC upon activation (Friedman, 2008a; Gao et al., 2004; Jiao et al., 2009; 
Marra et al., 1999). A characteristic feature of activated HSC is their increased 
expression of the cytoskeletal protein α-smooth muscle actin (α-SMA), which 
contributes to their contractile phenotype (Ramadori et al., 1990; Rockey et 
al., 1992). 
 
Liver injury, which leads to HSC activation, can be caused via multiple 
mechanisms, such as reactive oxygen species (ROS), chemical toxicity and 
immune-mediated cytolysis, all of which may then trigger disruption of the 
homeostatic balance between MMPs and TIMPs. In fibrosis, this balance tips 
in favour of the TIMPs. Human studies have proven direct correlation between 
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the expression of TIMP-1 and -2 and the degree of fibrosis (Benyon et al., 
1996).  
 
In the context of chronic viral hepatitis B and C, liver fibrosis characteristically 
starts to develop around the portal tracts and progresses towards central 
lobular vein creating a portal-central bridge (Hernandez-Gea and Friedman, 
2011; Pinzani, 1999). It has been demonstrated by treating rat HSC and LX2 
with conditioned media from hepatitis B X protein (HBx)-expressing 
hepatocytes, that they lead to activation and proliferation of HSC (Martin-
Vilchez et al., 2008). Histological longitudinal studies have shown that some 
CHB patients treated with NUCs have regression in cirrhosis (Hadziyannis et 
al., 2006; Marcellin et al., 2013). However, the mechanism behind these 
finding still remains to be investigated (Bedossa, 2015). 
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Role of Immune response in liver fibrosis: 
In response to liver injury, both the innate and adaptive arms of the immune 
system become activated. Depending on the cause and duration of injury, 
some immune cells contribute to progression of fibrosis while others play an 
anti-fibrotic role. The pro- and anti-fibrotic roles of various immune cell types 
have been illustrated in Figure 1.5.  
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Figure 1-5: Immune cells and fibrosis. 
The pro- and anti-fibrotic roles of various immune cells. Cells of the immune 
system that have been shown to have a pro-fibrotic effect include NKT cells, 
CD4 T cells, CD8 T cells, ILC and platelets. These cells produce cytokines and 
growth factors that activate HSC and perpetuate fibrosis. They also do so via 
ligand receptor interactions. Immune cells that have been shown to play an anti-
fibrotic role are Tregs, γδT cells and NK cells. They do so by, either producing 
cytokines that prevent activation of HSC or by direct ligand-receptor interactions 
that lead to death of activated HSC. Macrophages and DCs can play both pro- 
and anti-fibrotic roles depending on which cytokine they produce.  
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The first cells to be recruited at the site of tissue damage are platelets. Along 
with their characteristic function of facilitating coagulation, they are the first 
cells to release PDGF and TGF-β, which are known mitogens and stimulants 
of HSC (Henderson and Iredale, 2007).  The Guidotti group have used murine 
models to demonstrate that anti-platelet therapy is able to reduce the severity 
of fibrosis in HBV infection by reducing the capacity of platelets to drive an 
inflammatory infiltrate (Sitia et al., 2012; Sitia et al., 2013). However, a 
previous murine study has shown that in in vitro co-cultures, platelets are able 
to suppress the production of collagen-1 in HSC and the same study has 
demonstrated that thrombocytopenic mice have aggravated liver fibrosis, 
implying that platelets also have a potential anti-fibrotic role (Kodama et al., 
2010). These discrepancies could be due to the use different mouse models 
to study two different liver diseases.  Another immune cell type to infiltrate the 
site of injury early on is neutrophils. Casini et al. have demonstrated in co-
culture systems that human HSC can be stimulated by reactive oxygen 
species derived from neutrophils (Casini et al., 1997). However, subsequent 
studies conducted in rats have shown that depletion of neutrophils did not 
have any effect on hepatic fibrogenesis following bile-duct ligation (BDL) 
(Henderson and Iredale, 2007; Saito et al., 2003). The complement system 
forms an important part of the host innate immune response not only as a 
defense for microbes but also viral infections and chronic inflammatory 
disease. The role of the complement in liver injury and fibrosis has been 
evident in several animal model studies. Work done using quantitative gene 
studies in chronic HCV in humans has implicated complement factor 5 (C5) in 
influencing liver fibrosis (Hillebrandt et al., 2005). High levels of C5aR1 have 
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been observed in murine HSC during differentiation into their activated 
myofibroblastic phase in vitro (Xu et al., 2012). Mice deficient in C5 have been 
shown to have an impaired potential for liver regeneration (Mastellos et al., 
2001). In a cohort of one hundred and forty three CHB patients, in those with 
high ALT, serum complement 4 (C4) correlated with the degree of fibrosis 
established using a histological score (Bugdaci et al., 2011). The role of these 
various complement factors still remains to established in human livers.  
 
Macrophages are bi-functional in the context of liver fibrosis. They have an 
important role to play during liver injury and progression of fibrosis as well as 
during the recovery or resolution of fibrosis. Persistent liver injury leads not 
only to the heavy infiltration of monocytes/macrophages, but also activation of 
the liver’s resident macrophages, Kupffer cells, which make up the largest 
population of tissue resident macrophages in the human body. In animal 
studies, when monocyte/macrophage infiltration was suppressed during liver 
injury, the development of liver fibrosis was prevented (Ide et al., 2005; 
Imamura et al., 2005). Depletion of KCs from rat liver has been shown to 
attenuate chemical induced liver fibrosis, and this has been linked to reduced 
TGF-β in the liver environment (Rivera et al., 2001). Other groups have 
proven that depleting macrophages in advanced fibrosis reduced scar tissue, 
however, if they were depleted during recovery phase, the matrix failed to 
degrade (Duffield et al., 2005). Upon activation, macrophages and KCs are 
able to release multiple growth factors, cytokines and chemokines such as 
TGF-β, TNFα, IL8, CCL2 and CCL5 which are all highly pro-fibrogenic 
(Bataller and Brenner, 2005; Friedman, 2000; Henderson and Iredale, 2007; 
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Hernandez-Gea and Friedman, 2011). Macrophage derived lectin, Galectin-3 
has been shown to play a role in both liver and kidney fibrosis by promoting 
activation to myofibroblasts (Henderson et al., 2006). Recent studies in the 
field have led to classification of macrophages into pro-inflammatory M1 
macrophages and anti-inflammatory M2 macrophages (Laskin et al., 2011). In 
response to persistent injury, M1 macrophages contribute to inflammation and 
eventually fibrosis. Studies in HCV have emphasized the fibrogenic role of M1 
macrophages and kupffer cells. These studies show that via HCV induced 
inflammasome signaling, macrophages produced IL-1β (Negash et al., 2013; 
Shrivastava et al., 2013). IL-1β promotes survival of activated HSC via the 
NF-κB signaling pathway. By contrast, in HBV transgenic mouse model, Sitia 
et al. found that kupffer cells can limit the severity of immunopathology in the 
liver without having any affect on the function of effector CD8+ T cells (Sitia et 
al., 2011). M2 macrophages have been shown to suppress fibrosis by 
producing the anti-inflammatory cytokine IL-10, and matrix metalloproteinase 
13 (Fallowfield et al., 2007; Thomas et al., 2011).  
 
In the past few years the lineage of innate immune cells has been studied 
more thoroughly. Along with conventional NK cells, other cell types have been 
classified on the basis of their transcription factors under the umbrella of 
innate lymphoid cells (ILCs). ILCs are branched into two lineages, the 
cytotoxic conventional NK cells and the other helper ILCs (ILC1, ILC2 and 
ILC3) (Diefenbach et al., 2014). A recent elegant study has implicated a role 
for ILC2 in mediating liver fibrosis. The study reports that during 
hepatocellular distress, IL-33 in secreted in the liver microenvironment, which 
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activates ILC2 and accumulates them in the liver; these in turn produce the 
profibrotic cytokine IL-13 leading to activation and transdifferentiation of HSC, 
contributing to liver fibrosis (McHedlidze et al., 2013). NK cells form a part of 
the cytotoxic ILCs.  
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Figure 1-6: NK cell-HSC interactions. 
Reported pathways via which NK cells can kill HSC. NK cells express 
death ligands TRAIL and FasL that can interact with their respective 
receptors, TRAIL-R2 and Fas on HSC and induce apoptosis of HSC. NK 
cells express the C-type lectin NKG2D  that has been shown to activate NK 
cell cytotoxicity of HSC by interacting with their ligands ULBP-2 and 
MICA/B expressed on HSC. NKp46 expressed on the surface of NK cells 
has also been shown to drive NK cell cytotoxicity towards HSC. HSC have 
been shown to express the unknown ligand for NKp46 using fusion 
proteins. 
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Research in the field of NK cells in the context of liver fibrosis has gained 
interest in the past decade. NK cells have the capacity to kill hepatocytes in 
CHB (Dunn et al., 2007); through the induction of necroinflammation, they 
could contribute to the initiation of fibrosis. On the other hand, several groups 
have highlighted an anti-fibrotic role for hepatic NK cells. HSC express TRAIL 
receptor 2 and NKG2D ligands ULBP-2 and MICA/B (Glassner et al., 2012; 
Taimr et al., 2003). In animal models, it has been described that activated 
stellate cells downregulate MHC class I and upregulate TRAIL receptors, 
which renders them susceptible to killing by NK cells in a TRAIL and NKG2D-
dependent manner (Melhem et al., 2006). When NK cells were depleted from 
these animals, severe progression of fibrosis was observed (Melhem et al., 
2006; Radaeva et al., 2006). Recent studies performed by the Nattermann 
group have shown that NK cells from HCV infected patients are able to induce 
apoptosis of activated human stellate cells (Glassner et al., 2012). They have 
described that this is affected in a TRAIL, NKG2D and Fas-L-dependent 
manner (Glassner et al., 2012). The Safadi and the Mandelboim groups have 
together described that in mice, non-activated NK cells are able to kill HSC via 
NKp46, and on activation, other pathways contribute towards the killing of 
HSC. Even though the ligand for NKp46 is unknown, they have successfully 
shown that primary human HSC express the ligand using fusion proteins (Gur 
et al., 2012). There are no studies describing the role of NK cell mediated 
killing of HSC in HBV infection. The potential anti-fibrotic role of NK cells in 
CHB is one of the main focuses of this thesis and has been described in 
further details in the Results section. The various pathways via which NK cells 
can interact with HSCs are illustrated in figure 1.6.  
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NKT cells are a heterogeneous population of cells that express markers of NK 
cells along with a T cell receptor (Seino and Taniguchi, 2005). Studies 
conducted on animals by many groups over the years have described the 
important fibrotic role of NKT cells (Gao et al., 2009; Park et al., 2009). Jin et 
al. used an HBV transgenic mouse model to highlight their fibrogenic role via 
the secretion of IL-4 and IL-13 (Jin et al., 2011). Recent work done by Wehr et 
al. highlights the pro-fibrogenic role of NKT cells that is dependent on CXCR6 
(Wehr et al., 2013). In human liver studies they observed upregulation of 
CXCR6 in the liver of patients with HCV infection compared to healthy 
controls. In mouse models they showed that CXCR6-deficient mice did not 
develop hepatic fibrosis (Wehr et al., 2013). Another NKT cell-like cell, the 
MAIT cell upon stimulation have been shown to produce large quantities of 
pro-fibrotic cytokines TNFα and IL17(Dusseaux et al., 2011; Martin et al., 
2009; Walker et al., 2012). It has now been demonstrated by Tang et al. that 
MAIT cells are highly enriched in the human liver environment and are the 
pre-dominant cells (rather than CD4+ T cells) that produce IL-17A in the 
normal human liver (Tang et al., 2013). These studies implicate NKT cells in 
initiation and perpetuation of liver fibrosis.  
 
Various groups have studied the role of T cells in liver fibrosis using different 
models. One of the most prominent studies done by Safadi et al. showed that 
the adoptive transfer of CD8+ T cells from carbon tetrachloride induced 
fibrotic livers of wild type mice into SCID mice, led to significantly increased 
levels of alanine aminotransferase (ALT) in the recipients and these rats 
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developed progressive fibrosis compared to those receiving CD4+ T cells or 
splenocytes (Safadi et al., 2004). This study highlighted a crucial role of CD8+ 
T cells in the pathogenesis of liver fibrosis. They also demonstrated that 
exposure to IL-10 can suppress the fibrotic activity of CD8+ T cells. Type 1 T 
helper cells (Th1) have been shown to have anti-fibrotic potential as they 
produce IFN-γ and IL-12 (Muhanna et al., 2008). Studies of Schistosoma 
mansoni infection in mice have emphasized the role of CD4+ T cells in liver 
fibrogenesis (Chiaramonte et al., 1999). In the same experimental model, 
studies have highlighted the pro-fibrogenic role of type 2 helper (Th2) CD4+ T 
cells by the production of IL-13 (Pellicoro et al., 2014). An imbalance between 
the anti-fibrotic Th1 cells and pro-fibrotic Th2 in chronic liver injury may 
influence fibrosis. Apart from these two types of CD4+ T cells, the crucial and 
potent pro-fibrogenic role of IL-17 producing CD4+ T cells (Th17 cells) has 
been established by animal and human studies on liver disease (Lemmers et 
al., 2009; Meng et al., 2012; Weaver et al., 2007). IL-17 has a direct effect on 
HSC and promotes production of collagen I. It can also have an indirect effect 
by interacting with all liver cells expressing IL-17R (KCs, monocytes, 
cholagiocytes) and lead to the production of pro-inflammatory cytokines 
(Pellicoro et al., 2014). Intrahepatic and peripheral Th17 CD4+ T cells are 
enriched in CHB and are associated with progression and severity of fibrosis 
(Sun et al., 2012). Tregs form another subset of CD4+ T cells and are 
classified by the expression of CD25 and transcription factor FoxP3. The 
number of Tregs is upregulated in livers of patients with viral hepatitis. In 
chronic HCV, the fibrotic role of IL-8 producing Tregs has been described 
(Langhans et al., 2013). Tregs also produce immunosuppressive cytokine IL-
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10, which is known to inhibit activation of HSCs (Hammerich and Tacke, 
2014). The Tacke group has recently described the anti-fibrotic role of γδT 
cells. γδT cells are recruited to the injured liver via the CCR6-CCL20 
chemokine axis where they promote apoptosis of HSCs and have an anti-
fibrotic role (Hammerich et al., 2014).  
 
The role of B cells in liver fibrosis in the context of viral hepatitis is still not fully 
understood, however, studies in mice have shown that in a B cell deficient 
mouse model of liver fibrosis, there is reduced accumulation of collagen when 
compared to wild type mice (Novobrantseva et al., 2005). The development of 
liver fibrosis in this study was found to be antibody-independent.  
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Resolution of fibrosis 
The attenuation or resolution of liver fibrosis is key to prevention of the 
complications of cirrhosis that characterize advanced chronic liver diseases 
including end-stage CHB. If this is to be achieved, it is crucial to understand 
the pathways via which the activation of HSC is resolved. Regression of liver 
fibrosis is associated with a decrease in the numbers of myofibroblasts from 
the site of scar tissue (Pellicoro et al., 2014). As described in figure 1.4, there 
are three possible fates of activated HSCs: reversion to quiescence, 
clearance through apoptosis and cell senescence. Removal of the cause of 
liver injury leads to changes in the liver microenvironment, which leads to 
resolution. In persistent injury, the levels of cytokines such as TGF-β are 
higher than normal and these promote the survival and activation of HSCs. 
Biochemical changes in the liver are essential to support regression of 
fibrosis. Reversion of activated HSCs to quiescence was thought to be 
possible only in vitro using basement membrane matrix. However, recent 
independent murine studies have demonstrated that downregulation of genes 
associated with fibrosis occurs in myofibroblastic HSCs which is similar yet 
distinct from typical naïve quiescent HSCs (Kisseleva et al., 2012; Troeger et 
al., 2012). These studies also demonstrated that these reverted HSCs have a 
higher susceptibility to activation upon treatment with fibrogenic stimuli.  
Activated HSCs also express death receptors such as Fas and TRAIL-R2. 
Removal of pro-survival signals and engagement of these receptors with their 
respective ligands can induce apoptosis of activated HSCs. NK cells and 
intrahepatic γδT cells have the potential to induce apoptosis of HSCs and 
contribute to resolution of fibrosis. Another apoptotic pathway is the 
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overexpression of pro-apoptotic proteins such as B cell lymphoma 2 (BCL-2) 
and BCL-2 associated X protein (BAX) that can cause the apoptosis of HSCs 
via the caspase-9 route (Pellicoro et al., 2014). Since examination of 
apoptosis of HSC is one of the main objectives of this thesis, this pathway is 
described in greater detail in the next sub-section. The third potential pathway 
towards resolution of fibrosis is the senescence of myofibroblastic HSC 
characterised by their lack of cytokine synthesis and decreased ability to 
secrete MMP, eventually leading to their deletion by NK cells (Krizhanovsky et 
al., 2008).  
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Apoptosis 
Apoptosis is a mechanism of carefully orchestrated programmed cell death 
that leads to dismantling of intracellular components of a cell in a controlled 
manner, avoiding inflammation and damage to surrounding cells. Apoptosis is 
essential for development and aging and plays a role in homeostatic 
maintenance of cell numbers in tissue (Elmore, 2007). There are multiple 
physiological and pathological stimuli that can trigger apoptosis, however, not 
all cells respond to the same apoptotic stimulus (Norbury and Hickson, 2001). 
Some cells require specific receptor-ligand interactions to undergo apoptosis 
while other cells have death pathways switched on by default that need to be 
blocked by strong survival factors such as hormones or growth factors 
(Elmore, 2007). There are two known apoptotic pathways: the external or 
death receptor pathway, and the intrinsic or mitochondrial pathway. These are 
illustrated in figure I7. The caspase cascade coordinates the process of 
apoptosis. 
 
Caspases are primarily endoproteases that can hydrolyse peptide bonds 
(McIlwain et al., 2013). Mostly, caspases exist in an inactive monomeric state 
referred to as the procaspases that require to be dimerized and often cleaved 
for activation. They are assembled into dimers with the help of adapter 
proteins that can bind to specific regions of the procaspases (McIlwain et al., 
2013). In humans, caspases are broadly classified on the basis of their 
function in apoptosis and in inflammation. The apoptosis causing caspases 
are further sub-classified into ‘initiator’ caspases that activate ‘executioner’ 
caspases leading to the demolition of structural proteins and DNA 
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fragmentation of the cell. Initiator caspases include caspase-8, -9, -10 and -2 
that are produced as inactive procaspases. Upon dimerization they can 
catalyse cleavage of executioner caspase (caspase-3, -6 and -7) monomers 
into a large and a small subunit creating a stabilized functional mature dimer 
(Riedl and Shi, 2004). Upon activation a single executioner caspase has the 
capacity to activate other executioner caspases, creating a feedback loop of 
caspase activation. 
 
The two apoptotic pathways can be differentiated on the basis of the adapters 
and initiator caspases involved. The extrinsic apoptotic pathway involves 
transmembrane receptor mediated interactions in the form of ligands binding 
to death receptors. Death receptors are members of the TNF superfamily and 
include TNF receptor-1 (TNFR-1), Fas, TRAIL-receptor 1 (TRAIL-R1) and 
TRAIL-receptor 2 (TRAIL-R2) (McIlwain et al., 2013). The death receptor 
ligands for these receptors are TNF, Fas-ligand (Fas-L) and TRAIL. When 
these ligands bind to their respective receptors, it leads to the recruitment of 
procaspase-8 to the site via its death domain (DD) to the death-inducing 
signaling complex (DISC) at the tail end of the engaged death receptor ligand 
(Grimm et al., 1996; Hsu et al., 1995). This interaction leads to the auto-
catalytic activation of procaspase-8. Once caspase-8 is activated, it further 
activates executioner capase-3 (Walczak, 2013). Murine studies have 
demonstrated that mice deficient in caspase-8 are resistant to death receptor 
mediated apoptosis implying the crucial role of caspase-8 in the extrinsic 
apoptotic pathway (Juo et al., 1998).  
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Figure 1-7: Extrinsic and intrinsic apoptotic pathways. 
The extrinsic apoptosis pathway involves interaction of the transmembrane 
death receptor on target cells with its respective ligand. This leads to the 
recruitment of pro-caspase 8 at the site via the DD. Activation of caspase 8 
leads to further downstream activation of caspase 3 leading to cell death. 
The intrinsic pathway is triggered by non-receptor-mediated stimuli that 
initiate mitochondrion associated caspase signaling. The mitochondrial 
transmembrane is permeabilised leading to the release of the pro-apoptotic 
molecules CytC, Smac/DIABLO into the cytoplasm, which leads to activation 
of caspase 9 which in turn activates caspase 3 leading to cell death.   
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The intrinsic apoptotic pathway is initiated by non-receptor-mediated stimuli 
that produce intracellular signals targeting the mitochondrion associated 
caspase signaling (Elmore, 2007). The intracellular signals initiated by these 
stimuli could either be positive signals such as hypoxia, toxins, radiation, free 
radicals etc. that induce apoptosis or negative signals such as lack of growth 
factors or hormones that suppress the cell’s inherent death pathway, thereby 
triggering apoptosis. All these stimulations lead to the opening of 
mitochondrial permeability transition pores. The loss of the mitochondrial 
transmembrane facilitates the release of otherwise sequestered pro-apoptotic 
molecules cytochrome c, Smac/DIABLO and serine protease HTRA2/Omi into 
the cytosol (Du et al., 2000; Garrido et al., 2006; Saelens et al., 2004). 
Cytochrome c binds and activates procapase-9, while SMAC/DIABLO and 
HTRA2/Omi prevent the suppression of apoptosis by inhibitors of apoptosis 
proteins (IAP) (Hill et al., 2004; van Loo et al., 2002). Inhibiting IAP is not 
enough to initiate caspase, the second group of pro-apoptotic proteins are 
released from the mitochondria once the cell is committed to die; these 
include AIF, endonuclease G and CAD (Elmore, 2007). AIF and 
endonuclease G causes DNA fragmentation and chromatin condensation, 
while CAD is cleaved by activated caspase-3 to provide a further more 
pronounced second stage of chromatin condensation (Joza et al., 2001; Susin 
et al., 2000). The Bcl-2 family of proteins plays a crucial role in regulating 
mitochondrial events leading to apoptosis. The Bcl-2 family is in turn regulated 
by a tumour suppressor protein p53 (Schuler and Green, 2001). The Bcl-2 
family comprises both pro- and anti-apoptotic genes that regulate the intrinsic 
apoptotic pathway. The pro-apoptotic proteins include Bid, Bim, Bcl-10, Bik, 
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Bak, Bad and the anti-apoptotic proteins include Bcl-2, Bcl-X, Bcl-XL, Bcl-w, 
BAG (Elmore, 2007; Riedl and Shi, 2004). The main role of the Bcl-2 family of 
proteins is to manage the release of cytochrome c from the mitochondria by 
manipulating mitochorial membrane permeability.   
 
Once the initiator caspases of both extrinsic and intrinsic pathways have 
cleaved and activated executioner caspases, the executioner caspases 
further activate cytoplasmic endonucleases and proteases, causing the 
degradation of vital cellular and nuclear proteins (McIlwain et al., 2013). 
Executioner caspases cleave cytokeratins, cytoskeletal proteins, poly ADP 
ribose polymerase (PARP), nuclear proteins and others (Slee et al., 2001). 
Caspase-3 is the most important executioner caspase and has a unique 
ability to activate CAD from ICAD leading to degradation of chromosomal 
DNA and persistent chromatin condensation (Sakahira et al., 1998). Caspase-
3 also contributes to cytoskeletal disintegration by cleaving gelsolin, an actin-
binding protein (Kothakota et al., 1997).  
 
Phagocytic uptake of apoptotic cells is the final phase of apoptosis. In this 
phase, the cell externalizes phosphotidylserine on the surface of the apoptotic 
cell, facilitating non-inflammatory recognition of the cell, leading to early and 
efficient uptake without causing the spillage of any cellular components that 
may cause an inflammatory reaction (Fadok and Chimini, 2001). 
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In summary, the role of lymphocytes in eliciting an innate and adaptive 
immune response in CHB has been well documented, however, their role in 
CHB associated liver fibrosis still remains to be investigated. In CHB, NK cells 
may exert anti-viral effector function but can also delete virus-specific CD8 T 
cells to contribute to viral persistence. The anti-fibrotic role of NK cells has 
been established in animal models and other liver diseases that lead to 
fibrosis. Since NK cells have an altered phenotype and defective effector 
function in CHB, in this study we wanted to investigate their potential to limit 
HSC-mediated fibrosis in this context. We also investigate the pro-survival 
anti-apoptotic nature of activated HSC that maintains them in a fibrotic liver 
undergoing chronic injury.  
Hypothesis: 
Immune responses mounted in patients with CHB exert pro- or anti-fibrogenic 
effects on hepatic stellate cells, thereby potentially regulating liver fibrosis 
progression. 
Specific aims: 
1. To examine whether peripheral blood mononuclear cells from patients 
with CHB can produce soluble mediators that are capable of activating 
HSC. 
2. To investigate whether NK cells from patients with CHB are able to 
induce apoptosis of activated HSC thereby exerting an anti-fibrogenic 
effect. 
3. To examine the anti-apoptotic phenotype of HSC contributing to their 
escape from TRAIL mediated killing.  
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2. Materials and Methods 
 
Patients and healthy controls 
Local ethical boards at Camden Primary Care Trust, University College 
Hospital, Royal London Hospital and Royal Free Hospital Trust approved this 
study. All participants of the study have given written, informed consent. All 
sample and data storage complies with the requirements of Data Protection 
Act 1998 and Human Tissue Act 2004. Peripheral blood was obtained from 
patients infected with CHB attending clinics at Mortimer Market Centre 
(Bloomsbury, London), University College London Hospital NHS Foundation 
Trust (Bloomsbury, London), Royal London Hospital, Barts Health NHS Trust 
(Whitechapel, London) and Royal Free London NHS Foundation Trust 
(Hampstead, London). All HBV infected patients were anti-HCV and anti-HIV 
antibody negative. The patients were stratified on the basis of their disease 
status: viral load (determined by real-time PCR), liver inflammation indicated 
by serum levels of alanine transaminase (ALT) and degree of fibrosis 
determined by Ishak stage and/or ELF test (Ishak score: 1-2 mild fibrosis, 3-4 
moderate fibrosis; ELF test: 0-7.7 no/mild fibrosis, 7.7-9.8 moderate to severe 
fibrosis). For the isolation of primary human HSC, liver tissue was obtained 
from healthy margins of non-HBV metastatic livers. The clinical details of the 
patients and the healthy controls that participated in this study are given in 
subsequent Results chapters.  
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Isolation of peripheral blood mononuclear cells 
Up to 50ml of venous blood was collected from all consented donors in 10ml 
BD Vaccutainer® containing EDTA or sodium heparin and processed 
immediately. The peripheral blood mononuclear cells (PBMC) were isolated 
from whole blood using Ficoll-plaque Plus (GE Healthcare, Buckinghamshire, 
UK) density gradient centrifugation. In a 50ml falcon tube, 20ml of whole 
blood was carefully layered on top of 15ml of Ficoll-Plaque Plus and 
centrifuged at 2200 rpm at 20°C for 22 minutes without brakes. The PBMC 
were carefully aspirated from the interface using 2 ml Pasteur pipettes and 
diluted 1:1 with RPMI 1640 (Invitrogen™, California, USA) and washed at 
1800 rpm at 20°C for 15 minutes. The PBMC pellet was re-suspended in 
RPMI 1640. The cells were diluted 1:9 in trypan blue (Sigma-Aldrich, St Louis, 
USA) and were counted using Neubauer counting chamber under a light 
microscope. The number of cells was determined using the following formula: 
 
Number of cells/ml = number of cells counted x dilution factor x 104  
 
The cells were washed and re-suspended in foetal bovine serum (FBS) 
(Invitrogen™, California, USA) with 10% DMSO (Sigma-Aldrich, St Louis, 
USA) at a concentration of 107 cells/ml and transferred into cryovials 
(Corning, New York, USA). Cryovials were frozen at -80°C in Mr Frosty® 
(Fisher Scientific, Waltham, USA) for up to 24 hrs and then transferred to gas-
phase nitrogen storage tanks.  
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Isolation of primary human hepatic stellate cells 
Healthy margins of metastatic liver tissue were collected from consented 
patients during surgery. The tissue was washed in PBS and transferred to a 
petri plate (Sarstedt, Numbrecht, Germany) containing a PF3 buffer made up 
of Hank’s balanced salt solution (HBSS) (Invitrogen™, California, USA) with 
calcium and magnesium, 0.01% collagenase IV and 0.001% DNAse I. The 
tissue was then passed through tissue press (2mm diameter holes) and was 
collected into a 50ml falcon tube (BD Falcon, Oxford, UK) containing 10 ml of 
the PF3 buffer and incubated at 37°C water bath for 20 minutes with 
occasional shaking. The homogenate was filtered through a 70 µm cell 
strainer (BD Falcon, Oxford, UK) into a new falcon tube using the back of a 
10ml plunger and centrifuged at 500 rpm for 2 minutes at 4°C to get rid of the 
hepatocytes. The supernatant was transferred in to a new falcon tube and 
centrifuged at 1500rpm for 10 minutes at 4°C. the pellet comprising of non-
parenchymal liver cels was re-suspended in PF4 buffer made up of HBSS 
without calcium and magnesium containing 0.001% DNAse I and 0.25% BSA.  
The pellet was re-suspended in 10 ml of 17% Optiprep® (density gradient 
diluted in PF4) (Sigma-Aldrich, St Louis, USA). 10 ml of 11.5% of Optiprep® 
was carefully layered on top of it. Additional 4ml of PF4 was layered on top of 
it and centrifuged at 2700 rpm for 17 minutes at 20°C without any breaks. The 
hepatic stellate cell fraction on top of the 11.5% optiprep layer was aspirated 
using a 2ml Pasteur pipette.  
 77 
17%
11.5%
HSC
KC
 
An equal volume of PF4 was added to it and centrifuged at 1500 rpm for 10 
minutes. The pellet was re-suspended in SteCM media (ScienCell Research 
Laboratories, California, USA) and counted as described previously. The cells 
were plated at a density of 5 x 104 cells/cm2 in appropriate sized tissue culture 
flasks (NUNC, Waltham, USA). It is noteworthy that at this stage, freshly 
isolated HSC need to be cultured in the tissue culture flasks instead of tissue 
culture plates. It was observed while optimising this protocol that freshly 
isolated HSC plated on tissue culture plates did not proliferate or grow very 
well on plates; as a result they could not be expanded and frozen for future 
use.  Plausible reasons for this could be the difference in the plastic of the 
tissue culture flask and tissue culture plates, secondly the surface area 
available for cells to grow is much less than in a flask which may influence 
their growth and proliferative potential.  The cells were left for 24 hours to 
attach and were then washed with media and fresh media was added. The 
quiescent hepatic stellate cells started differentiating into an activated state in 
around 7-10 days post culture. The cells were then passaged twice before 
freezing them down using FBS and 10% DMSO as previously described.  
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Isolation of intrahepatic lymphocytes 
In a petri-plate (Sarstedt, Numbrecht, Germany), liver tissue was suspended 
in RPMI 1640 (Sigma Aldrich) and using mechanical force, macerated using 
back of a 10 ml syringe plunger. The cell suspension was then passed 
through 70mm cell strainer (BD Biosciences) several times and then 
centrifuged at 1800 rpm for 15 minutes to get rid of cell debris. The pellet was 
resuspended in RPMI 1640 (Sigma Aldrich) supplemented with 10% foetal 
bovine serum (Invitrogen™, California, USA)) for counting. The cells were 
then used for subsequent experiments.  
 
Isolation of NK cells using magnetic beads 
NK cells were isolated from PBMC by negative selection using CD3 magnetic 
beads and then by positive selection using CD56 magnetic beads (Miltenyi 
Biotech, Bergisch Gladbach, Germany) or by using NK cell isolation kit 
(Miltenyi Biotech, Bergisch Gladbach, Germany) according to the 
manufacturers instructions. The purity of NK cells was checked using 
flowcytometry by gating on CD56+ and CD3- cells. The purity of NK cells 
obtained was always greater than 95%. No difference was found in the quality 
or purity of NK cells when either positive or negative selection was used. It is 
noteworthy that in some assays positive selection may activate the cells as 
the magnetic microbeads directly bind to the NK cells. However, this was not 
the case in assays done in this thesis. In the majority of experiments negative 
selection was performed using the NK cell isolation kit as it is faster and takes 
half the time compared to positive isolation.  
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Culturing LX2 cell line 
LX2 is an immortalized HSC cell line isolated in Professor Scott Friedman’s 
lab. This cell line was used to optimise and perform experiments. LX2 cell line 
expresses most markers of activation of HSC, such as high levels of αSMA, 
Collagen 1, vimentin etc (Xu et al., 2005). Even though this is an activated cell 
line, it has been well established in our lab (Rosenberg lab) and others that 
LX2 cells further up-regulate activation markers in response to stimulation.  
LX2 cells were defrosted and cultured in tissue culture flasks in media 
comprising of DMEM (Invitrogen™, California, USA) supplemented with 10% 
FBS (Invitrogen™, California, USA). When cells reached 80% confluence, 
they were passaged and plated in 48-well or 24-well plates in 300µl and 500µl 
of DMEM+10%FBS respectively for subsequent experiments.  
Experiments using a transwell system 
Cryopreserved PBMC were thawed and counted. The cells were re-
suspended in RPMI 1640 supplemented with 10% FBS, 100U/ml 
penicillin/streptomycin (Invitrogen™, California, USA), MEM essential amino 
acids (Invitrogen™, California, USA), MEM non-essential amino acids 
(Invitrogen™, California, USA), HEPES (Invitrogen™, California, USA), β-
mercaptoethanol (Sigma-Aldrich) and sodium pyruvate (CRPMI, Invitrogen™, 
California, USA). The cells were plated in 96 U-bottomed plates at 30 x 105 
cells/well in 200µl volume with medium only (negative control), 1µM HBV 
overlapping (OLP) peptide which is a pool of 15mer peptides overlapping by 
10 residues spanning 24 peptides of the core of HBV (genotype D, JPT), or 
0.5µM PepMix CEF Pool (32 peptides from CMV, EBV, Influenza virus, JPT 
as a positive control) with rIL-2 (Roche) supplement (20U/ml). Half the media 
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was replaced with fresh CRPMI supplemented with rIL-2 on day 3 of culture. 
Two parallel plates were setup for each experiment. 
 
 
The PBMC were restimulated with relevant peptides and cultured on transwell 
membranes (0.3µm) on day 9 of culture with LX2 cells (plated on 24-well 
transwell plates, Beckton Dickinson, New Jersey, USA 24 hours prior). 16 
hours post culture in the transwell system, supernatant from one of the plates 
was stored in -20°C freezer for future Real time PCR experiments. 24 hours 
after transwell system culture, LX2 cells from the second plate were harvested 
and stained (surface and intracellularly) for markers of activation. The cells 
were acquired on BDTM LSR II flow cytometer  (Beckton Dickinson) and 
analysed using FlowJo (Treestar). 
 
Real time PCR to examine the activation of LX2  
Stored supernatant from the transwell experiment were applied to LX2 cells 
(plated on 48 well plate 24 hour prior) for 16 hours. The LX2 were harvested, 
lysed and their RNA was extracted using the TaqMan® Gene Expression 
Cells-To-CTTM kit (Applied Biosystems, Paisley, UK) according to 
manufacturer’s instructions. The lysates were converted to cDNA using 
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reverse transcription according to manufacturer’s instructions. For running the 
Real time PCR, the gene expression assays used were αSMA and Pro-
Collagen I (ACTA2, COL1, Applied Biosystems Paisley, UK). The house-
keeping gene used was GAPDH (GAPDH, Applied Biosystems Paisley, UK). 
All the gene expression assays were labeled with FAM. The PCR cocktail was 
added on to 384-well PCR plates to which the cDNA was added in triplicates. 
The PCR was run on Applied Biosystems 7900 HT machine. The data were 
analysed using -2ΔΔCT method as described Livak et al. (Livak and 
Schmittgen, 2001). 
 
Apoptosis assay 
Cryopreserved primary HSC were thawed and cultured in T-25 tissue culture 
flask (NUNC, Waltham, USA) for 4 days at 37ºC with 5% CO2. The primary 
HSC were then detached using 0.05% Trypsin/EDTA (Invitrogen™, California, 
USA) and plated on 48 well plates (Corning, New York, USA).  
 
Isolated NK cells and primary HSC were co-cultured at an E:T ratio of 10:1 for 
5 hours in SteCM. After co-incubation, the primary HSC were harvested and 
their apoptosis was studied by intracellularly staining for active caspase-3 
using active caspase-3 apoptosis kit (BD Bioscience, Oxford, UK) according 
to manufacturer’s instructions. The data were collected on BDTM LSR II flow 
cytometer  (Beckton Dickinson, New Jersey, USA) and analysed using FlowJo 
(Treestar, Oregon, USA). The positive control for apoptosis experiments was 
500ng/ml of SuperKiller TRAIL (Enzo Lifesciences, Exeter, UK) which is a 
trimeric stable form of recombinant TRAIL and induces apoptosis of cells via 
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the Caspase 3 pathway.  
 
Blocking experiment 
TRAIL-R3 (MAB-630, R & D Systems, Minneapolis, USA) and TRAIL-R4 
(MAB-633, R & D Systems, Minneapolis, USA) neutralising antibodies were 
used to block these receptors on primary HSCs. The antibodies were added 
at a concentration of 5 µg/ml for 30 minutes to HSC cultures. The neutralising 
antibodies were washed off using PBS prior to setting up apoptosis assays. 
 
Real time PCR for baseline mRNA levels of αSMA and TRAIL-receptors 
on LX2 and primary HSC 
LX2 and primary HSCs were lysed and their RNA was extracted using the 
TaqMan® Gene Expression Cells-To-CTTM kit (Applied Biosystems Paisley, 
UK) according to manufacture’s instructions. The lysates were converted to 
cDNA using reverse transcription according to manufacturer’s instructions. 
For running the Real time PCR, the gene expression assays used were 
αSMA, TRAIL-R1, TRAIL-R2, TRAIL-R3 and TRAIL-R4  (Applied Biosystems 
Paisley, UK). The house-keeping gene used was GAPDH (GAPDH, Applied 
Biosystems Paisley, UK). All the gene expression assays were labeled with 
FAM. The PCR cocktail was added on to 96-well PCR plates to which the 
cDNA was added in triplicates. The PCR was run on Applied Biosystems 
7900 HT machine. The data were analysed using -2ΔΔCT method as described 
Livak et al. (Livak and Schmittgen, 2001). 
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Flow cytometry 
All stains for flow cytometry analysis were performed on single cell 
suspensions in 96 U-bottomed plates (Sarstedt, Numbrecht, Germany) at 4ºC. 
 
Surface staining of PBMC/pHSC/LX2 
Following cell culture, cells were washed in 1x PBS (Invitrogen™, California, 
USA) and centrifuged at 1600rpm for 6 minutes. The supernatant was 
discarded and the pellets of cell were re-suspended by gentle vortexing. The 
cells were stained with Live/Dead® Cell viability stain (Invitrogen™, California, 
USA) and the relevant anti-human antibodies in 1x PBS for 30 minutes at 4ºC 
in the dark. Appropriate isotype controls were used where necessary. Post 
incubation the cells were washed and fixed with 150 µl/well of BDTM Cytofix. 
Cells were transferred to 500 µl polystyrene tubes for acquisition. Data was 
acquired on BDTM LSR II flow cytometer  (Beckton Dickinson, New Jersey, 
USA) and analysed using FlowJo (Treestar Oregon, USA). 
 
Surface staining of intrahepatic cells isolated from liver explants and 
biopsies 
Cells were washed in 1x PBS (Invitrogen™, California, USA) and centrifuged 
at 1600rpm for 6 minutes. The supernatant was discarded and the pellets of 
cell were re-suspended by gentle vortexing. FcR blocking reagent (Miltenyi) 
was added to the cells to avoid non-specific binding of antibodies at a 
concentration of 1:5 for 10 minutes. Live/Dead® Cell viability stain 
(Invitrogen™, California, USA) and the relevant anti-human antibodies in 1x 
PBS were then added to the cells without washing for 30 minutes at 4ºC in the 
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dark. Appropriate isotype controls were used where necessary. Post 
incubation the cells were washed and fixed with 150 µl/well of BDTM Cytofix 
(Beckton Dickinson, Oxford, UK). Cells were transferred to 500 µl polystyrene 
tubes for acquisition. Data was acquired on BDTM LSR II flow cytometer  
(Beckton Dickinson, New Jersey, USA)  and analysed using FlowJo (Treestar 
Oregon, USA). 
 
Intracellular staining of PBMC/pHSC/LX2 
Cells were surface stained as described above, following which they were 
washed and re-suspended in BDTM Cytofix-Cytoperm (Beckton Dickinson, 
Oxford, UK) for 20 minutes at 4ºC in the dark. After permeabilisation and 
fixation the cells were stained intracellularly using the relevant anti-human 
antibodies in 0.1% saponin for 30 minutes at 4ºC in the dark. Appropriate 
isotype controls were used where necessary. After staining the cells were 
washed and re-suspended in 150 µl/well of BDTM Cytofix (Beckton Dickinson, 
Oxford, UK). Data was acquired on BDTM LSR II flow cytometer  (Beckton 
Dickinson, New Jersey, USA) and analysed using FlowJo (Treestar).  
The antibodies used for both extra- and intra-cellular staining are listed below 
in table 3. 
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Marker Fluorochrome IgG Manufacturer 
Live/Dead® stain Blue  Invitrogen 
CD3 PE Cy7 IgG1κ eBiosciences 
TRAIL PE IgG1 eBiosciences 
CD56 ECD IgG1 Beckman Coulter 
NKG2A Alexa Fluor 700 IgG2A R&D Systems 
NKp46 BD v450 IgG1κ BD Biosystems 
HLA DR BD v500 IgG2A BD Biosystems 
NKp30 APC IgG1 Miltenyi 
CD16 APC Cy7 IgG1 BD Biosystems 
Caspase 3 PE IgG BD Biosystems 
TRAIL-R1 PE IgG1 R&D Systems 
TRAIL-R2 PE IgG2B R&D Systems 
TRAIL-R3 PE IgG1 R&D Systems 
TRAIL-R4 PE IgG1 R&D Systems 
αSMA PE IgG2A R & D Systems 
CD19 APC Cy7 IgG1 Biolegend 
CD68 FITC IgG1 eBiosciences 
Cytokertain FITC IgG1 eBiosciences 
CD14 BD v500 IgG1 BD Biosystems 
CCL2 FITC IgG2B R & D Systems 
ICAM1 Pacific Blue IgG1κ Biolegend 
PDGFRβ APC IgG1κ Biolegend 
αSMA PE IgG2A R & D Systems 
Table 2-1: List of antibodies for flow cytometry 
 Directly conjugated anti-human flow cytometry antibodies extra- and intra-
cellular antigens with respective isotypes. 
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Transducing HSC using lentiviral vectors with short hairpin  
 
The lentivector pSIN-GFP was digested with EcoRI and BamHI, and the 
promoter of the gene encoding phosphoglycerate kinase (PGK) was amplified 
by polymerase chain reaction (PCR) for introduction of EcoRI-BamHI 
restriction sites. Then, the SFFV promoter from the plasmid pSIN-GFP was 
replaced with the promoter of the gene encoding PGK, cloned by blunt-end 
ligation, to generate the plasmid pSIN-PGK-GFP. A second cassette 
containing the U6 promoter was cloned in this backbone downstream the 
cPPT sequence between ClaI-EcoRI restriction sites. A BamHI site was 
introduced downstream of the U6 promoter to clone the short hairpin RNA 
(shRNA) of interest between BamHI and EcoRI restriction sites. The U6-
shRNA cassette was placed upstream the PGK promoter and GFP. All 
constructs were engineered by standard cloning techniques. 
The following shRNA sequences were used: 
shTR2: 
CTCACTGGAATGACCTCCTTTCTCGAGAAAGGAGGTCATTCCAGTGAG 
shTR4: 
GATGGTCAAGGTCAGTAATTGTTCAAGAGACAATTACTGACCTTGACCATCTT
TTTTACGCGT 
shCTR: 
CCTAAGGTTAAGTCGCCCTCGTTCAAGAGACGAGGGCGACTTAACCTTA
GG 
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Knockdown progress was observed by monitoring GFP expression using 
fluorescence microscopy. Knockdown lentiviruses were produced using a 
packaging cell line (293T-cells) and transfected with p8.91 (encoding 
structural proteins, gag, pol, rev, tat), pMDG (encoding VSVg env) and 
transfer vectors pSIREN shCTR or pSIREN shTR2. This work was done in 
collaboration with Itziar Otano (postdoc, Maini Lab). 
 
The shCTR and shTR2 carrying lentivirus were transduced into HSC plated in 
a 24 well plate in 500µl volume of SteCM at an MOI (multiplicity of infection) 
of 40 for upto three days. Transduction was checked microscopically to look 
for GFP+ cells. Transduction and knockdown was confirmed using FACS. The 
cells were then used for subsequent experiments. 
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3. PBMC from CHB patients produce soluble mediators that activate 
stellate cells  
 
Background: 
Liver fibrosis is a common consequence of CHB. As mentioned in detail 
previously, HSC activated by changes in the liver milieu are the main cellular 
source of hepatic fibrosis. HSC were first described by Kupffer in the 19th 
century and their presence was confirmed by Rothe a decade later (Friedman, 
2008a). The past thirty years have seen vast advances in the field of HSC 
biology and liver fibrosis. Most of the current knowledge of HSC is based on 
experiments done using animal models. Liver fibrosis can be induced in 
rodent models using either chemical mediated liver injury (e.g. CCl4) or biliary 
fibrosis induced by bile duct ligation. Several animal cell lines have been set 
up to overcome the need to isolate HSC from animal models of liver fibrosis 
and facilitate in vitro assays (Gutierrez-Ruiz and Gomez-Quiroz, 2007). It is 
however, essential to validate the findings of animal studies in human HSC to 
determine their relevance in human disease. The limitation of using human 
HSC is the infrequent availability of ‘healthy’ human liver tissue, along with the 
unpredictable yield, purity and the variation in behavior of cells isolated from 
each donor. Immortalised human HSC lines have been used for the past 
decade to overcome these issues.  
 
The most commonly used human HSC line is the LX2 cell line that has 
retained some key features of activated primary HSC (Xu et al., 2005). LX2 
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were created by Scott Friedman’s group using primary human HSC from one 
donor and transfecting them with the pRSV-Tag plasmid that encodes the 
SV40 large T antigen under the control of rous sarcoma virus promoter. SV40 
large T antigen has the capacity to inhibit G1 cell cycle growth arrest, 
rendering cells immortal (Ali and DeCaprio, 2001). These cells were then 
cultured in low serum media to further separate them from primary HSC that 
thrive on serum growth factors. Low (1%) and normal (10%) serum 
supplemented cultures were sequentially repeated to obtain the LX2 cell line, 
which has the ability to sustain itself and proliferate, even in low serum media, 
for up to fifty passages (Xu et al., 2005). LX2 have been shown to express 
typical markers of activated HSC such as αSMA, vimentin, PDGF-Rβ, ICAM-1 
etc. In contrast to primary activated HSC, LX2 express GFAP and lack the 
expression of TIMP-1 (Xu et al., 2005).  
 
 As has been described in detail in Chapter 1, some cells of the immune 
system have been shown to play a pro-fibrogenic role whilst others have been 
attributed to have an anti-fibrotic function. Cells of the immune system that 
induce or perpetuate fibrosis include platelets, NKT cells, CD4 T cells, CD8 T 
cells, ILC, macrophages and DC. They do so by producing various pro-
fibrogenic chemokines, cytokines and growth factors such as IL-13, IL-8, IL-4, 
IL-17, TNF-α, TGF-β and PDGF.  In CHB, due to prolonged and persistent 
antigen exposure, the cells of the immune system have an altered phenotype 
and function as has been described by various groups in the past two 
decades. Whether immune cells in CHB have the capacity to produce soluble 
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mediators that contribute to CHB-associated liver fibrosis has never been 
studied before and is the main focus of this chapter.  
 
Studies conducted by our group in HCV have demonstrated that peripheral 
mononuclear immune cells from patients with chronic hepatitis C produce 
soluble factors that activate HSC and their propensity to do so was associated 
with the rate of progression of fibrosis in these patients. Work done in the 
Rosenberg group by Fowell et al. demonstrated that PBMC from HCV 
infected patients with fast progressing fibrosis, on stimulation with HCV 
proteins (Core, NS3, NS4), are able to activate LX2 significantly more than 
those from HCV infected patients with slow progressing fibrosis (as shown in 
below in fig 3.1) or healthy controls (data not shown) (Fowell, 2008). I 
contributed to this work by performing RT PCR for markers of activation on 
LX2. 
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Figure 3-1: Effect of soluble mediators produced by PBMC from HCV 
infected patients on activation of LX2.  
PBMC from HCV infected patients with fast and slow progressing fibrosis 
were stimulated with HCV proteins (Core, NS3 and NS4). The supernatant 
from the culture was collected 5 days post culture and applied to LX2 cells for 
24 hours. The mRNA from LX2 was extracted and analysed for markers of 
activation using RT PCR.  PBMC from HCV infected patients with fast 
progressing fibrosis were able to activate LX2 significantly more than from 
patients with slow progressing fibrosis. (p=0.0005, one-way ANOVA) 
 
Lopes et al. from the Maini group performed gene array experiments using 
virus-specific CD8+ T cells from CHB patients and compared them with CD8+ 
T cells from patients who had resolved HBV (Lopes et al., 2008). They 
observed the upregulation of multiple pro-fibrogenic genes listed below (Table 
3.1). 
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Table 3-1: Upregulation of fibrogeinc genes in virus-specific CD8+ T cells 
from CHB patients. Fold change and significance (d score) of genes in virus-
specific CD8+ T cells from chronic HBV infected patients over resolved HBV 
infected patients. 
 
These data from our group suggest that, as in chronic HCV infection, in CHB, 
some immune cells may exert a pro-fibrotic role. Results of the gene array 
study suggests that virus-specific CD8+ T cells in CHB may play a crucial role 
in fibrosis.  This has never been studied in the context of CHB and was the 
main aim of this chapter. 
 
 93 
 
3.1 Patient cohort 
Local and national research ethics committees at Camden Primary Care 
Trust, University College Hospital, Royal London Hospital and Royal Free 
Hospital Trust approved this study. All participants of the study have given 
written, informed consent. All sample and data storage complies with the 
requirements of Data Protection Act 1998 and Human Tissue Act 2004. 
Peripheral blood was obtained from patients infected with CHB attending 
clinics at Mortimer Market Centre (Bloomsbury, London), University College 
London Hospital NHS Foundation Trust (Bloomsbury, London), Royal London 
Hospital, Barts Health NHS Trust (Whitechapel, London) and Royal Free 
London NHS Foundation Trust (Hampstead, London). All HBV infected 
patients were anti-HCV and anti-HIV antibody negative. Patients were 
stratified on the basis of their disease status: viral load (determined by real-
time PCR), liver inflammation indicated by serum levels of alanine 
transaminase (ALT) and degree of fibrosis determined by Ishak stage and/or 
ELF test (Ishak score: 1-2 mild fibrosis, 3-4 moderate fibrosis, 5-6 cirrhosis; 
ELF test: ≤7.7 no/mild fibrosis, 7.7-9.8 moderate to severe fibrosis, >9.8 
cirrhosis). 
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Table 3.2: 
 
Patient 
ID 
HBeAg 
status 
Fibrosis 
status 
Viral load 
(IU/ml) 
ALT 
(IU/L) 
Gender Age 
(years) 
Treatment 
Pt01 + Moderate 
(Biopsy) 
700,000,000 66 M 71 Untreated 
Pt02 + Mild 
(biopsy) 
80,275.14 36 F 33 Untreated 
Pt03 + Normal 
(ultrasound) 
51,406,000	  
 
330	  
 
F 23 Untreated 
Pt04 - Mild 
(Biopsy) 
31,344 
 
37 
 
F 
 
25 Untreated 
Pt05 
 
- Not done 720 41 M 26 Untreated 
Pt06 + Moderate 
(Biopsy) 
100,000,000 87 F 32 Untreated 
Pt07 
 
- Mild (ELF) 849 43 M 39 Untreated 
Pt08 
 
- Mild (ELF) 31 15 F 34 Untreated 
Pt09 
 
- Not done 137 11 F 49 Untreated 
Pt10 - Moderate 
(ELF) 
66 15 F 54 Untreated 
Pt11 
 
+ Mild (ELF) 7,022,700 108 F 27 Untreated 
Pt12 - Moderate 
(Biopsy) 
48,021 54 F 68 Untreated 
Pt13 
 
- Mild (ELF) 80 31 F 22 Untreated 
Pt14 - Moderate 
(Biopsy) 
6583 27 F 41 Untreated 
Pt15 - Cirrhotic 
(Biopsy) 
Not detected 200 M 70 Untreated 
Pt16 + Cirrhotic 
(Biopsy) 
1,990,429 44 F 62 Untreated 
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Pt17	  
 
- Mild  
(Biopsy) 
828,773	  
 
281	  
 
F 37 Untreated 
Pt18	   + Mild  
(Biopsy) 
1,545,586	   37	   Not 
known 
49 Untreated 
Pt19	   - Mild  
(Biopsy) 
421	   58	   M 46 Untreated 
Pt20	   Not 
done 
Moderate 
(ELF) 
48	   48	   M 37 Untreated 
Pt21	   + Moderate 
(ELF) 
104,891	   22	   F 25 Untreated 
Pt22	   - None 
(Biopsy) 
1092	   53	   F 37 Untreated 
Pt23	   - Normal 
(Biopsy) 
41,728	   95	   M 41 Untreated 
Pt24	    Normal 
(fibroscan 
3.6) 
11,000	   33	   M 41 Untreated 
Pt25	  
	  
- Not done 1119	   29	   M 45 Untreated 
Pt26	  
	  
- Not done 4,400	   59	   M 46 Untreated 
Pt27	  
	  
- Not done Not	  detected	   17	   F 61 Untreated 
Pt28	   - Moderate 
(Biopsy) 
1150	   114	   Not 
known 
49 Untreated 
Pt29	   - Moderate 
(Biopsy) 
142,919	   48	   Not 
known 
32 Untreated 
Pt30	  
	  
- Not done Not	  detected	   11	   F 35 Untreated 
Pt31	   + Mild  
(Biopsy) 
249,497,143	   38	   F 30 Untreated 
Pt32	   + Mild  
(Biopsy) 
1,115,000,000	  
	  
78	   M 30 Untreated  
Pt33	   - Moderate 
(Biopsy) 
24	   26	   M 37 Untreated 
Pt34	   - Normal 7678	   68	   M 50 Untreated 
 96 
(Biopsy) 
Pt35	  
	  
- Not done Not	  detected	   normal	   Not 
known 
 Untreated 
Pt36	  
	  
- Not done Not	  detected	   normal	   M 50 Untreated 
Pt37	  
	  
+ Not done 2,000,000	   230	   F 42 Untreated 
 
Table 3-2: CHB patient cohort detail information.  
 
Details of CHB patients used in the study. First column is the patient study 
code, second column shows the HBeAg status of the patient, third column 
denotes the fibrosis stage of the patient, fourth column is the HBV DNA (viral 
load) of the patients (IU/ml), fifth column gives alanine aminotransferase 
(ALT) levels of the patient in IU/L, sixth column indicates the gender of the 
patient (Female=F, Male=M), seventh column indicates the age of the patient 
at the time of sample collection in year and the eighth column indicates the 
treatment status of the patient at the time of sample collection, 
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The details of normal healthy donors that consented and participated in this 
study are as follows. 
 
Table 3.3: 
Donor ID Gender Age 
HD01 M 37 
HD02 F 31 
HD03 F 25 
HD04 F 38 
HD05 F 39 
HD06 F 26 
HD07 M 21 
HD08 M 38 
HD09 F 31 
HD10 M 30 
 
Table 3-3: Healthy donor detailed information.  
The first column gives the study code of the healthy donors, second column 
gives details of gender of the participant and the third column gives details of 
the age at the time of sampling of each participant. 
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Based on the background data described, we set out to investigate whether 
PBMC from patients with CHB can produce soluble factors driving a pro-
fibrogenic reaction in stellate cells. To this end, we performed experiments 
using a transwell system. We cultured PBMC from CHB patients for 9 days, 
with and without stimulation, with HBV peptides before transferring to the 
upper well of transwell chambers, and LX2 were cultured in the lower 
chamber twenty four hours prior. Twenty four hours after culture in the 
transwell system with PBMC in the upper chamber, the activation status of 
LX2 cells in the lower chamber was examined at protein level (CCL2, ICAM1) 
using flow cytometry. In addition, the PBMC supernatants were collected and 
applied to a fresh batch of LX2 for 16hrs and the levels of activation markers 
(αSMA and Pro-collagen I) of the LX2, relative to un-stimulated LX2, were 
measured at an mRNA level using real-time PCR. GAPDH was the house-
keeping gene used for RT PCR assays. 
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3.2 Activation of stellate cells at mRNA levels by soluble mediators 
produced by PBMC of CHB patient  
 
As mentioned above, PBMC from CHB patients and healthy volunteers were 
cultured with LX2 in a transwell system for 24 hours. The supernatant from 
this system was collected and applied to a fresh batch of LX2, cultured in 48-
well tissue culture plates at a density of 5,000 cells/cm2 for 16 hours. The LX2 
were then harvested and their RNA extracted and converted to cDNA. The 
levels of αSMA and Pro-collagen I were then determined using Real-time 
PCR as has been described in further detail in Materials and Methods section 
of this thesis. Figure 3.2a illustrates the experimental setup. We found a 
statistically significant increase in the mRNA levels of αSMA in LX2 that were 
cultured in supernatants from CHB patient PBMC compared to healthy PBMC 
(Fig 3.2b). We found a similar trend in Pro-collagen I mRNA levels (Fig 3.2c), 
however this was not statistically significant. This suggests that PBMC from 
CHB patients are in a pro-fibrogenic state and are able to produce soluble 
mediators that can activate stellate cells compared to PBMC from healthy 
controls. 
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Figure 3-2: Activation of stellate cells at mRNA levels by soluble 
mediators produced by PBMC of CHB patients.  
a) Diagram of experimental setup. PBMC from CHB patients and healthy 
donors were cultured for 9 days and transferred to the top chamber of the 
transwell system, LX2 were grown in the bottom panel of the transwell system 
for 24 hours. The supernatant was collected and applied to fresh LX2 grown 
in a separate plate for 16 hours. These LX2 were then harvested and their 
mRNA was extracted using Taqman Cell-to-CT kit. Real time PCR was 
performed to look for the mRNA expression of αSMA and Pro-Collagen I. b) 
Cumulative data showing the fold change in mRNA levels of αSMA in LX2 
cultured with supernatants from PBMC of healthy donors and CHB patients 
over baseline levels normalised to GAPDH. Significantly higher up-regulation 
of αSMA in LX2, cultured with PBMC from CHB patients compared to healthy 
donors (p=0.0457, Mann-Whitney U-test) c) Cumulative data showing the fold 
change in mRNA levels of Pro-Collagen I in LX2 cultured with supernatants 
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from PBMC of healthy donors and CHB patients over baseline levels 
normalized to GAPDH (p=0.6033, Mann-Whitney U-test). 
3.3 Clinical parameters of CHB patients do not influence their capacity 
to produce fibrogenic soluble mediators that activate stellate cells at 
mRNA level  
 
We found a difference between activation of LX2 subjected to supernatants 
from CHB patients compared to healthy controls, however, there was a 
spread observed in the potential of PBMC from CHB patients to activate HSC. 
To understand this better, CHB patients were stratified on the basis of clinical 
parameters. The CHB patients were divided on the basis of their fibrosis stage 
(Ishak score cut off 2, ELF test cut off 7.7), viral load (cut off 2,000 IU/ml) and 
the levels of ALT (cut off 50 IU/L). There was no significant difference 
observed in the levels of αSMA in patients with varying levels of fibrosis, viral 
load or ALT (Figure 3.3a).  
 
The same analysis was performed for Pro-collagen I and no significant 
differences were found in any of the clinical parameters (Figure 3.3b).  
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 Figure 3-3: Clinical parameters of CHB patients do not reflect on their 
capacity to produce soluble mediators to activate LX2.  
RT PCR performed on LX2 incubated with supernatants from PBMC cultures 
of healthy donors and CHB patients to examine the levels of αSMA and Pro-
collagen I. CHB patients are divided on the basis of their fibrosis stage, viral 
load (VL) and ALT levels. a) no statistical difference was found when CHB 
patients were divided on the basis of fibrosis stage (p=0.1509, Kruskal Wallis 
ANOVA), viral load (p=0.1269, Kruskal Wallis ANOVA) and ALT levels 
(p=0.1266, Kruskal Wallis ANOVA) and their potential to upregulate αSMA at 
mRNA levels was examined. b) no statistical difference found when CHB 
patients were divided on the basis of fibrosis stage (p=0.9006, Kruskal Wallis 
ANOVA), viral load (p=0.8172, Kruskal Wallis ANOVA) and ALT levels 
(p=0.4830, Kruskal Wallis ANOVA) and their potential to upregulate Pro-
collagen I at mRNA levels was examined. 
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3.4 Optimisation of the characterisation of HSC using flow cytometry 
 
Typically, as a read out in studies conducted using LX2 and/or primary HSC 
(animal or human), markers of activation are either examined at mRNA level 
using RT PCR or at protein level using western blots or microscopy 
associated techniques such as immunofluorescence, immunohistochemistry 
and immunocytochemistry. These are all very widely used, validated 
techniques however they are unable to provide a qualitative and quantitative 
assessment of the expression of various markers on each cell. To address 
this we developed the characterisation of LX2 using flow cytometry (FACS). It 
is worth noting that stellate cells are comparatively large in size, along with 
being auto-fluorescent when quiescent, making them difficult to study using 
FACS. For this reason, LX2 were cultured and stained for markers of 
activation to determine if FACS can be used as an assay to quantify HSC 
activation. The markers that were chosen were αSMA, a marker expressed by 
HSC when they become myofibroblastic; ICAM1, an adhesion molecule 
expressed on activated HSC; CCL2, also known as monocyte chemo-
attractant protein-1 (MCP-1), a chemokine produced by HSC to facilitate the 
migration lymphocytes to the site of injury; and PDGFβ receptor, up-regulated 
on activated HSC to promote their proliferation. Plots in Figure 3.4 
demonstrate baseline levels of activation of LX2 determined by the expression 
of these markers compared to their respective antibody isotypes using FACS. 
The plots show the frequency of expression of these markers at baseline and 
their mean fluorescence intensity against isotype controls.  
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Figure 3-4: Characterisation of LX2 cells using FACS. 
LX2 were stained for Dead cell marker and markers of activation: αSMA, 
ICAM1, CCL2 and PDGFRβ along with respective isotypes. The cells were 
acquired using flow cytometry on BD LSR2 and analysed using Flowjo 
software.  a) Gating strategy of HSC showing forward scatter/side scatter 
(FSC/SSC) gates and Live/Dead gates. b) Representative plots and 
histograms showing percentage expression and MFI respectively of 
activation markers on HSC against matched isotype controls. 
 
 105 
3.5 Activation of stellate cells at protein level by soluble mediators 
produced by PBMC from CHB patient  
 To investigate the activation of stellate cells at protein level, multi-colour flow 
cytometry was used as a read out. αSMA, PDGFRβ, CCL2 and ICAM1 were 
stained for, as markers of activation as has been described in the previous 
sub-section. However, it was found that the staining for αSMA and PDGFRβ 
was inconsistent between experiments and we are trying to optimise this. For 
this reason, these data were excluded from current data analysis. In the 
following data, levels of chemo-attractant CCL2 and adhesion molecule 
ICAM1 were studied as markers of activation.  
 
To investigate the potential of PBMC from CHB patients and healthy donors to 
produce soluble mediators that can activate HSC at protein level, PBMC from 
CHB patients and healthy donors were cultured for 9 days. They were then 
transferred to the top chamber (permeable membrane) of the transwell 
system. The LX2 were plated on the bottom chamber of the transwell system 
24 hours prior to culture with PBMC. This transwell culture was incubated for 
24 hours and LX2 were harvested to stain for markers of activation (ICAM1 
and CCL2) and were acquired for flow cytometry using the BD LSR2. The 
data was analysed using FlowJo software. A diagram of the experimental 
design is illustrated in figure 3.5. 
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Figure 3-5: Experimental design.  
LX2 were plated at the bottom and PBMC were plated in the top chamber of 
the Transwell system for 24 hours. At the end of incubation, LX2 were 
harvested using Trypsin/EDTA and were stained for markers of activation 
(ICAM1 and CCL2) and analysed using flow cytometry.  
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As seen in the representative plot in Figure 3.6a, the levels of CCL2 and 
ICAM1 on LX2 were increased more than two-fold, when they were cultured 
with PBMC from CHB patients compared to LX2 alone as opposed to 
minimal/no difference between LX2 cultured with healthy PBMC versus LX2 
alone. In the cumulative data shown in Figure 3.6b, there was a trend towards 
increased levels of CCL2 and ICAM1 in LX2, cultured in a transwell system 
with PBMC, from CHB patients compared to PBMC from healthy, however 
this was not statistically significant. This is similar to the trends observed at 
mRNA level (Figure 3.2) when the levels of αSMA and Pro-collagen I were 
examined, suggesting that PBMC from CHB patients produce soluble 
mediators that have a variable capacity to activate hepatic stellate cells at 
mRNA and protein levels. 
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 Figure 3-6: PBMC from CHB patients have a variable capacity to 
activate HSC by producing soluble mediators.  
Fold change over baseline of activation of LX2 upon culture with PBMC from 
healthy donors and PBMC from CHB patients in a transwell system. LX2 were 
stained for respective markers and flow cytometry was used analyse data. a) 
No statistical difference was found when CHB patients were divided on the 
basis of fibrosis stage (p=0.3507, Kruskal Wallis ANOVA), viral load 
(p=0.9192, Kruskal Wallis ANOVA) and ALT levels (p=0.4323, Kruskal Wallis 
ANOVA) and their potential to upregulate CCL2 at protein levels was 
examined. b) no statistical difference found when CHB patients were divided 
on the basis of fibrosis stage (p=0.6174, Kruskal Wallis ANOVA), viral load 
(p=0.6661, Kruskal Wallis ANOVA) and ALT levels (p=0.7235, Kruskal Wallis 
ANOVA) and their potential to upregulate ICAM1 at protein levels was 
observed. 
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3.6 Clinical stratification of CHB patients do not influence their capacity 
to produce fibrogenic soluble mediators that activate stellate cells at 
protein level 
 
CHB patients were then segregated on the basis of clinical parameters. They 
were divided on the basis of their fibrosis stage (Ishak score cut off 2, ELF 
test cut off 7.7), viral load (cut off 2000 IU/ml) and the levels of ALT (cut off 50 
IU/L). Even though a trend towards the increased levels of CCL2 and ICAM1 
in LX2, cultured in a transwell system with PBMC from CHB patients 
compared to healthy was observed; no statistical difference was found in the 
levels of activation marker in LX2 between CHB patients with varying degree 
of fibrosis, viral load and ALT (Figure 3.7). This was consistent with the trends 
observed when levels of activation at mRNA level were studied after 
stratifying the CHB patients on the basis of their clinical parameters (Figure 
3.3). 
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Figure 3-7: Clinical parameters of CHB patients do not reflect on their 
capacity to produce soluble mediators to activate LX2 at protein level.  
 
Fold change over baseline of activation of LX2 upon culture with PBMC from 
healthy donors and CHB patient PBMC, in a transwell system. LX2 were 
stained for respective markers and flow cytometry was used for analysis. a) 
No statistical difference was found when CHB patient were divided on the 
basis of fibrosis stage (p=0.3507, Kruskal Wallis ANOVA), viral load 
(p=0.9192, Kruskal Wallis ANOVA) and ALT levels (p=0.4323, Kruskal Wallis 
ANOVA) and their potential to upregulate CCL2 at protein levels was 
examined. b) no statistical difference was found when CHB patients were 
divided on the basis of fibrosis stage (p=0.6174, Kruskal Wallis ANOVA), viral 
load (p=0.6661, Kruskal Wallis ANOVA) and ALT levels (p=0.7235, Kruskal 
Wallis ANOVA) and their potential to upregulate ICAM1 at protein levels was 
observed.
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3.7 Investigating potential soluble mediators that may be produced by 
CHB patient PBMC that activate HSC  
 
As has been described earlier, gene array studies done by our group have 
demonstrated that virus-specific CD8+ T cells from CHB patients upregulate 
certain pro-fibrogenic genes compared to CD8+ T cells from patients with 
resolved HBV. Table 3.1 enlists these genes along with their fold change 
increase. Connective tissue growth factor (CTGF) and insulin-like growth 
factor binding protein 3 (IGFBP3) had the highest fold change in gene 
expression on virus specific CD8+ T cells from CHB patients compared to 
patients with resolution of HBV.  
 
CTGF is a monomeric protein that comprises 349 residues (Bradham et al., 
1991). It has been shown to be upregulated by TGF-β, hypoxia and high 
levels of glucose (de Winter et al., 2008; Gressner et al., 2007; Phanish et al., 
2005). CTGF has been shown to be found in cytosolic space in mesangial 
cells, however mostly CTGF is secreted and can be found in extracellular 
spaces and the micro-environment of cells. It can be detected in plasma, 
serum and urine (Gressner and Gressner, 2008; Kubota et al., 2004; 
Roestenberg et al., 2006). Several studies have implicated the role of CTGF 
in cell proliferation, migration, matrix production and cellular adhesion in 
various cells in the body (de Winter et al., 2008; Safadi et al., 2003; Secker 
and Daniels, 2008; Twigg et al., 2002; Weston et al., 2003).  
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Insulin-like growth factors (IGF) have been reported to play a role in cell 
growth, differentiation and metabolism. In the circulation, they are usually 
bound to Insulin-like growth factor binding proteins (IGFBP) that facilitate the 
attachment of IGF to their receptors and also increase their half life (Ruan and 
Ying, 2010). High expression of IGFBP3 has been associated with pulmonary 
fibrosis and cystic fibrosis (Canale-Zambrano and Haston, 2011; Pilewski et 
al., 2005). Their role in liver fibrosis remains to be investigated. 
 
While performing experiments using PBMC from CHB patients and culturing 
them with LX2 in a transwell system, supernatant from some of the assays 
were frozen. The supernatants were thawed and ELISA performed to 
determine the levels of CTGF and IGFBP3 in the supernatants. Commercially 
bought ELISA kits were used. As can be seen in Figure 3.8 below, the PBMC 
from CHB patients produce CTGF in general. In this cohort the levels of 
CTGF produced are not influenced by the disease status of the patient (Figure 
3.9). It is noteworthy that the cohort is small and this experimental assay 
needs to be performed on a larger cohort to have a better understanding of 
the role of CTGF production by PBMC of CHB patients, and to examine if their 
clinical parameters influence their production of  CTGF.  ELISA was also 
performed for IGFBP3, however the optical densities for all the levels were 
below levels of detection (data not shown) suggesting that this protein is not 
secreted by PBMC from CHB patients in culture. Alternatively, ELISA as an 
assay is not sensitive enough to detect the levels of any secreted IGFBP3. 
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Figure 3-8: Levels of CTGF produced by PBMC from CHB patients 
produced in culture.  
ELISA was performed on supernatant collected from PBMC cultured with LX2 
in a transwell system using a commercially available kit following 
manufacturers instructions. This graph shows levels of CTGF (pg/ml) detected 
in the supernatant of PBMC culture of each patient. Each individual bar 
represents one patient.  
 
 Figure 3-9: Clinical parameters of CHB patients do not correlate with 
their capacity to produce CTGF.  
CHB patients from figure 2.10 were segregated on the basis of their fibrosis 
stage, VL and ALT as described previously. No statistically significant 
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difference was found when CHB were compared on the basis of their fibrosis 
stage (p=0.1667, Mann Whitney U-test) or on the basis of their viral load (VL) 
and ALT (p=0.5714, Mann Whitney U-test).  
 
3.8 Activation of HSC by PBMC from CHB patients is not mediated by 
HBV peptides  
 
To determine whether the capacity of PBMC from CHB patients to activate 
HSC was antigen specific, PBMC from CHB patients were stimulated with 
immunodominant HBV overlapping peptides (pool of 15mer peptides 
overlapping by 10 residues spanning 24 peptides of the core of HBV) on day 
zero of culture and were re-stimulated with the peptides on day 9, when they 
were added to the top chamber, of the transwell system.   
 
It was observed that PBMC from CHB patients on stimulation with HBV 
overlapping peptides did not have an enhanced effect on the activation of LX2 
in a transwell culture system at mRNA level as shown in Figure 3.10.  
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 Figure 3-10: HBV peptide stimulation of PBMC from HBV infected 
patients has no effect on their fibrotic potential at mRNA level.  
PBMC from CHB patients (n=29) did not augment their pro-fibrotic effect on 
stimulation with HBV overlapping peptides as there is no difference seen in 
the mRNA levels of αSMA (p=0.7621, Wilcoxon paired test) and the mRNA 
levels of pro-collagen I (p=0.8797, Wilcoxon paired test) activation of LX2. 
The mRNA levels are calculated as a fold change of baseline normalized to 
GAPDH.  
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Next we wanted to examine if this lack of further activation of LX2, after 
transwell system culture, with PBMC from CHB patients stimulated with HBV 
overlapping peptides was also translated to protein level. For this PBMC from 
CHB patients were stimulated with immunodominant HBV overlapping 
peptides on day zero of culture and were re-stimulated with the peptides on 
day 9, when they were added to the top chamber of the transwell system. The 
LX2 plated at the bottom chamber of the transwell system were harvested 24 
hours later and were stained for CCL2 and ICAM1 as markers of activation. 
The data were analysed using flow cytometry.  
 
It was observed that PBMC from CHB patients on stimulation with HBV 
overlapping peptides did not have an enhanced effect on the activation of LX2 
in a transwell culture system at protein level as well as shown in Figure 3.11.  
 
The HBV overlapping peptides are able to stimulate both CD4+ and CD8+ T 
cell responses.  This suggests that a non virus-specific cell type is producing 
the fibrogenic soluble mediators. An alternative interpretation is that the 
response elicited by this strategy in these patients was insufficient to stimulate 
HSC above what is seen without in vitro re-stimulation. These possibilities are 
discussed further in the conclusion of the chapter. 
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Figure 3-11: HBV peptide stimulation of PBMC from HBV infected 
patients has no effect on their fibrotic potential at protein level.  
PBMC from CHB patients (n=25) did not augment their pro-fibrotic effect on 
stimulation with HBV overlapping peptides as there is no difference seen in 
the protein levels of CCL2 (p=0.5360, Wilcoxon paired test) and protein levels 
of ICAM1 (p=0.0.1194, Wilcoxon paired test) as markers of activation of LX2. 
The CCL2 and ICAM1 levels are shown as percentage expression of each 
respective marker.  
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Conclusion 
 
In this chapter the potential of PBMC from CHB patients to produce soluble 
mediators that may activate HSC was investigated. This was done using 
PBMC from CHB patients and healthy controls and culturing them in a 
transwell system with a well-established human HSC cell from Scott 
Friedman’s group called the LX2. The readouts were both at mRNA levels 
and protein level. 
 
LX2 is an activated HSC line, however, as has been previously described, bu 
our group and others, that LX2 can be further activated.  
 
It was observed that PBMC from CHB patients can significantly upregulate 
mRNA levels of αSMA and show a trend towards the upregulation of pro-
collagen I. As a spread was observed in the potential of LX2 to be activated 
by PBMC from CHB patients, the CHB were then segregated on the basis of 
their fibrosis stage, viral load and ALT levels. No significant differences were 
detected.  
 
This effect was also studied at protein level and cumulatively a trend was 
observed in the potential of PBMC of CHB patients to activate HSC, however 
this was not statistically significant. In line with observations made at mRNA 
level, dividing patients on the basis of clinical parameters did not show any 
significant differences in their potential to activate HSC. 
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This could reflect that the clinical parameters used in this study to stratify the 
patients for analysis do not correlate with their potential to activate HSC. It 
would be interesting to classify patients on their disease stage as has been 
described by the European Association of Study of the Liver (EASL) 
(described in detail in chapter 1). However, for this clinical data from the 
patients would have to be collected at sequential time points to determine 
their disease progression. These clinical data are not available to us at this 
point.  
 
To further investigate previous published data from the group by Lopes et al. 
in the context of this project, we wanted to try and identify some potential 
soluble mediators produced by PBMC of CHB patients that could be activating 
HSC. CTGF and IGFBP3 were selected to be investigated, as the genes of 
these two proteins were highly upregulated on virus-specific CD8+ T cells. 
ELISA were performed on the supernatants of PBMC cultures for CTGF and 
IGFBP3 (Lopes et al., 2008). CTGF was found to be produced by PBMC of all 
donors and this was not dependent on their CHB clinical stratification. IGFBP3 
was not detected in the supernatant of healthy donors or patient PBMC. This 
suggests that some other soluble mediators may play a role in activating 
HSC.  
 
To determine whether this activation was an effect of virus-specific cells, the 
PBMC from CHB patients were stimulated with immunodominant HBV 
overlapping peptide that stimulate both CD4+ and CD8+ T cell responses. 
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However, no differences were found in the HSC activation capacity of 
unstimulated and peptide stimulated PBMC. These data imply that a non-virus 
specific cell type is producing the soluble mediators that are further activating 
LX2.  
 
The findings of this chapter are discussed in further detail in the discussion 
chapter.  
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4. Assessing the potential of NK cells from patients with CHB to kill 
hepatic stellate cells 
 
Background 
 
As has been described in the previous chapter, most of the published human 
in vitro studies using HSC have been conducted using a human HSC cell line 
– LX2. This is due in part to lack of availability of human liver tissue to extract 
primary human HSC and also because the a standardized cell line provides a 
constant and reproducible tissue for research. Fortunately, during the course 
of this study, this lab had the opportunity of access liver tissue from healthy 
margins of liver tissue following resections for hepatic metastases.  These 
healthy margins have been used to optimise the isolation of primary HSC. 
Making full use of this rare opportunity, the major experiments of the next two 
chapters were done using primary human HSC. LX2 were used to optimise, 
compare and characterize assays. Being one of the few labs in the world to 
have access to human healthy liver tissue and use primary human HSC, the 
various assays used in this these chapters had to be carefully optimised and 
corrected to account for inter-donor variability. The details of this have been 
discussed in the next section.  
 
The crucial role of the HSC in the liver injury response and fibrogenesis has 
been discussed in greater detail in the Introduction section. In acute liver 
injury HSC become activated and accumulate at the site of injury (Iredale et 
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al., 1998; Mathew et al., 1994). Upon activation, HSC acquire a more 
myofibroblast-like αSMA-positive phenotype and start to proliferate, which has 
been attributed to being central to the entire fibrotic process (Pinzani and 
Rombouts, 2004). Activated HSC express collagen I and III (Friedman, 2008b; 
Friedman et al., 1985). HSC have been shown to also express MMPs such as 
MMP-1, MMP-2 and MMP-14 that can degrade collagenous matrix (Aimes 
and Quigley, 1995; Milani et al., 1994; Ohuchi et al., 1997). It has been 
demonstrated in animal models and human studies that progression of 
fibrosis is associated with reduced interstitial collagenase activity of MMPs 
and this has been attributed to the production of TIMP-1 and TIMP-2 by HSC 
(Arthur, 2000; Iredale, 2001). When activated, HSC enter the growth cycle 
(Friedman, 2008a) which leads to an overall increase in the number of 
activated HSC that actively produce collagenous matrix and simultaneously 
prevent its degradation by expressing TIMPs, as is seen in chronic livery 
injury.  Resolution of fibrosis has been observed in both acute and chronic 
fibrosis once the underlying condition/disease is successfully cleared or 
treated (Dufour et al., 1997; Dufour et al., 1998; Hammel et al., 2001; Mathew 
et al., 1994; Vukobrat-Bijedic et al., 2014). Resolution is associated with 
reduction of ECM and restoration of the liver architecture to a normal to near-
normal state. For this, reduction in the number of activated HSC is essential. 
This is possible by three ways: reversion to a quiescence-like state, direct 
apoptosis and senescence-led apoptosis (Bataller and Brenner, 2005). Of 
these, apoptosis of activated HSC is the most widely researched and has 
been demonstrated to be the most effective and plausible mechanism of 
resolving fibrosis. Studies looking at the role of other cells contributing to their 
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apoptosis have revealed that, of the resident liver cells, KC stimulated with 
LPS can induce apoptosis of HSC in a caspase 9-mediated manner in vitro 
(Fischer et al., 2002).  In addition, the crucial HSC apoptosis-triggering 
function of NK cells has come to light in several studies in the past decade 
(Gur et al., 2012; Radaeva et al., 2006).  
 
NK cells belong to the innate arm of the immune system. They play a crucial 
role in acute infection, forming an initial defense against the pathogen. In 
chronic infections, they can have dysregulated effector function. NK cells can 
be activated on stimulation with cytokines such as type I IFNs, IL-12, IL-18, IL-
15 and IL-8 and a downregulation of inhibitory signals (Nguyen et al., 2002; 
Rehermann, 2013). However, in CHB they are not just responsible for antiviral 
activity but have an important regulatory function throughout the chronic 
phase of disease (Rehermann, 2013). NK cells are enriched in the liver at the 
site of HBV viral replication (Doherty et al., 1999; Dunn et al., 2007). In CHB, 
NK cells can kill viral infected hepatocytes and contribute to viral clearance 
while causing liver damage (Dunn et al., 2007). They have also been shown 
to contribute to viral persistence by deleting virus-specific CD8+ T cells in 
CHB via the TRAIL pathway (Peppa et al., 2013). These studies demonstrate 
varying roles of NK cells in CHB.  
 
NK cells have higher expression of activatory receptors NKp46, NKp30 and 
NKG2C in CHB compared to chronic HCV infected patients (Nattermann et 
al., 2006). They also have elevated expression of the death ligand TRAIL 
especially in patients with high ALT compared to healthy controls (Dunn et al., 
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2009; Peppa et al., 2013). TRAIL is preferentially expressed on the CD56bright 
subset of NK cells that mediate non-antigen specific death via this pathway. 
The percentage of CD56bright NK cells is higher in the intrahepatic 
compartment compared to the periphery (Bonorino et al., 2009). During flares 
of CHB, it has been demonstrated that the IFN-α induced in this phase drives 
the expression of TRAIL on NK cells (Dunn et al., 2007). It has also been 
observed that CHB patients on pegylated IFN-α therapy have an increased 
expression of TRAIL on their NK cells (Micco et al., 2013). 
 
Death ligand TRAIL has the capacity to bind to four membrane bound 
receptors: TRAIL R1 (DR4), TRAIL R2 (DR5, Killer, TRICK), TRAIL R3 
(DcR1, LIT, TRID) and TRAIL R4 (DcR2, TRUNDD) and one soluble receptor, 
osteoprotegrin (OPG) (Lalaoui et al., 2011). TRAIL can induce apoptosis by 
binding to TRAIL-R1 and TRAIL-R2 on target cells. TRAIL-R1 and 2 both 
have an intracellular death domain (DD), which is essential for downstream 
signaling leading to apoptosis (Feinstein et al., 1995).  
 
On binding with trimeric TRAIL, TRAIL-R1 and R2 induce the recruitment of 
FADD (Fas-associated death domain protein) with their respective DD, which 
leads to the recruitment of pro-caspase-8 and -10, resulting in the formation of 
DISC (death-inducing signaling complex). Within the DISC, caspase-8 and -
10 undergo downstream catalytic cleavage in the cytosol triggering the 
caspase cascade which leads to caspase-3 mediated apoptosis (Bodmer et 
al., 2000; Kischkel et al., 1995; Kischkel et al., 2001).  
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The anti-fibrotic role of NK cells has been documented in several animal 
models over the past decade. Work done by the Friedman group, was the first 
to demonstrate that HSC can undergo TRAIL-mediated death using 
recombinant TRAIL (Taimr et al., 2003). In 2006, two important independent 
murine studies were the first to demonstrate the role of NK cells in HSC 
killing, and this was attributed to the TRAIL and the NKG2D pathway (Melhem 
et al., 2006; Radaeva et al., 2006). In the past few years, studies have moved 
on to primary human HSC and the Natterman group have demonstrated in in 
vitro cultures, the anti-fibrotic role of NK cells of HCV patients through TRAIL, 
NKG2D and Fas dependent killing of HSC (Glassner et al., 2013; Glassner et 
al., 2012). Collaborative work between the Safadi and Mandelboim groups 
has also shown that NK cells can kill HSC via the NKp46 pathway; they were 
the first to demonstrate expression of the unknown ligand of NKp46 on HSC 
using fusion proteins (Gur et al., 2012). However, the anti-fibrotic role of NK 
cells has never been investigated in the context of CHB.  Keeping in mind the 
altered phenotype of NK cells in CHB, the main aim of this chapter is to 
investigate if NK cells from CHB have the ability to kill primary human HSC.  
 
 
4.1 Optimising extraction and culture of primary human HSC  
 
For the majority of the assays in this chapter and the next chapter, primary 
human HSC have been used. As has been mentioned previously, many of the 
studies related to human HSC are conducted using LX2 cell line. In our group, 
we had access to healthy margins of metastatic liver resections. These 
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resections were used to isolate primary human HSC that were expanded and 
stored for subsequent use in experiments. A detailed methodology of the 
extraction process has been described previously in the Materials and 
Methods section. Briefly, the liver resection is mechanically cut into small 
pieces (approximately 2mm) and digested using 0.1% collagenase type IV 
and 0.001% DNase I for 20 minutes. The homogenate is then passed through 
70 µm cell strainer and centrifuged at a low speed (500rpm) to discard 
hepatocytes. The homogenate is washed twice and carefully layered in a 
double density gradient (17% bottom and 11.5% top) and centrifuged. A HSC 
rich layer is found at the top of the 11.5% gradient. The cells are collected, 
washed, counted and plated in tissue culture flasks to be expanded. It was 
observed during optimisation stages, that if the freshly isolated HSC were 
cultured in tissue culture plates (48-well or 24-well), they did not grow and 
proliferate. This could be because the plastic used in tissue culture plates 
differs from tissue culture flasks or because in plates the cells have restricted 
space to grow compared to a flask and this might effect their growth cycle. 
Approximately 7-10 days post culture in a tissue culture flask, HSC 
differentiate into myofibroblast like activated HSC.  
 
To determine that the HSC isolated and grown, were purely HSC, their mRNA 
was extracted to run a RT PCR for levels of αSMA as is traditionally done 
(Figure 4.1a). Microscopically, the grown and cultured HSC cultured showed a 
characteristic ‘star-like’ myofibroblast phenotype (Figure 4.1b). The HSC were 
used between passage 2 and passage 5. Each batch of HSC was used at the 
same passage and days of culture for each individual experiment.  
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It is note worthy that all the liver resections used in this study were from 
patients undergoing liver surgery for removal of metastases. These patients 
might have undergone treatment against metastasis such as chemotherapy.  
The influence of an individual’s disease and/or treatment on their isolated 
HSC remains unknown. Whether this has affected the results presented in 
this chapter and the next chapter needs to be investigated further. It would be 
interesting to compare HSC isolated from the livers of non-cancerous 
patients, potentially from cadavers. However, this was not possible during the 
course of this study due to lack of ethics for obtaining such tissue. Also 
access to clinical data of these patients is necessary to determine if the 
differences in HSC of different donors was attributable to their prior treatment. 
We do not have access to this information at the moment, but this would be 
interesting to look at in the future.  
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Figure 4-1: Baseline levels of αSMA and morphology HSC.   
a) mRNA was extracted at the passage when primary HSC cells were used 
for experiments and was quantified using RT PCR to examine the levels of 
αSMA. mRNA levels of αSMA in different batches of HSC obtained from six 
different donors in red dots. mRNA levels of αSMA in LX2 cell line depicted in 
blue dot. b) Representative picture taken from light microscope of primary 
human HSC in culture at 10x magnification demonstrating their myofibroblast 
morphology.  
0.00
0.05
0.10
0.15
0.20
0.25
2-
∆C
T  o
f t
ar
ge
t g
en
e
 n
or
m
al
is
ed
 to
 G
AP
D
H
αSMA
a) b)
 
 129 
4.2 Optimising read outs for apoptosis of HSC using flow cytometry 
Classically, staining with Annexin V and 7-aminoactinomycin D (7-AAD) are 
used to quantify the degree of apoptosis in cells. Annexin V labeled with 
fluorescent probes can bind to phosphatidylserine and be detected using   
flow cytometry or fluorescent microscopy. In a normal healthy cell, 
phosphatidylserine is present on the cytoplasmic side of the cellular 
membrane and when the cell becomes apoptotic it is translocated to the outer 
part of the membrane where it can be detected using Annexin V. 7-AAD is a 
fluorescent molecule that can stain for nucleic acids and is therefore used for 
detection of dead cells with a permeabilised nucleus. This method of detection 
is very effective in determining dead or dying cells, however, it does not 
indicate whether the cell died via apoptosis, necrosis or necroptosis. In this 
study, we were interested in focusing on apoptosis of HSC; for this reason, we 
wanted the detection to be more focused towards staining of specific makers 
of apoptosis and so it was chosen to stain for caspases. A comparison was 
done between the traditional method of staining for Annexin V and 7-AAD with 
staining for pan-caspases and 7-AAD. To stain for pan-caspases, 
commercially available kit called Fluorescent labeled inhibitor of caspases 
(FLICA®) was used. These optimisations were done on both LX2 and primary 
human HSC. LX2 and primary human HSC were stained for apoptosis and 
death using AnnexinV/7-AAD and pan-caspase FLICA/7-AAD to optimise the 
read-out for apoptosis. As demonstrated in Figure 4.2 below, HSC being 
highly auto-fluorescent interfered with the fluorochromes of these markers, 
leading to improper staining detection. As can be seen in the plots, with both 
the staining in LX2 as well as primary HSC, a diagonal streak of population 
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can be observed. In such situations it is difficult to separate auto-fluorescence 
from real positive staining. Even though upon treatment with a positive control 
to induce death (camptothecin), there is an increment in the expression levels 
of respective markers, it is not a clear staining, requiring approximation in the 
gating strategy from which accurate data cannot be deduced.  
 
 
Figure 4-2: Apoptosis read out comparison of HSC.  
LX2 (top panel) and primary HSC (pHSC)  (bottom panel) and treated with 
camptothecin (8µg/ml) for 5 hours. LX2 and pHSC were then harvested and 
stained for either Annexin V and 7AAD or for FLICA (pan-caspase) and 7AAD 
and analysed using flow cytometry. Percentage expression of each marker is 
shown in each quadrant gate in the untreated condition and camptothecin 
treated condition.  
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Moving forward from this, to establish staining with a marker labeled with a 
fluorochrome that did not interfere or contribute to auto fluorescence. For this 
we stained LX2 and primary HSC with cleaved caspase 3 and Live/Dead cell 
viability stain. Cleaved caspase 3 was chosen because caspase 3 is the final 
caspase to be cleaved in the caspase cascade leading to apoptosis and 
therefore reflects the cells’ commitment to undergo apoptosis. As 
demonstrated in Figure 4.3 below, successful staining for apoptosis was 
observed without any hindrance due to auto-fluorescence.  
 
 
Figure 4-3: Apoptosis read out. 
LX2 and primary HSC (pHSC) were treated with camptothecin (8µg/ml) for 5 
hours. LX2 and pHSC were then harvested and stained for dead cell marker 
and cleaved caspase 3 and analysed using flow cytometry.   FACS plots 
demonstrating a reliable readout of apoptosis on HSC.  Percentage 
expression of each marker is shown in each quadrant gate in untreated 
condition and camptothecin treated condition.  
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In these optimization experiments, LX2 and primary HSC were both used to 
set up an effective readout for apoptosis. The results demonstrated that 
primary HSC can be used as reliable targets to study apoptosis and therefore, 
for the remaining project, primary cells were used to study the potential of 
HSC to undergo apoptosis.  
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4.3 Correcting for inter-donor variability of HSC to undergo apoptosis 
Having established an effective readout for apoptosis of HSC, the next step 
was to optimise and setup the apoptosis assay. In this thesis, for all the 
assays primary human HSC have been studied. These primary human HSC 
have been isolated from healthy margins of metastatic liver tissue obtained 
from consented donors at the Royal Free Hospital. They were isolated from 
the liver tissue using enzymatic and mechanical digestion and then using 
three density gradients to obtain HSC. These HSC were then grown in tissue 
culture flasks and were spontaneously activated and expanded (for details, 
see Methods chapter). Aliquots of these were frozen in liquid nitrogen for 
long-term storage. The HSC were used in experiments between passage 2 
and passage 5. In these assays, SuperKiller TRAIL was used as a positive 
control for apoptosis. SuperKiller TRAIL is a stable trimer of TRAIL that can 
induce apoptosis of target cells in a TRAIL-mediated manner. Before 
performing the experiments, to determine if there was variability in the degree 
of apoptosis in HSC from different HSC donors; HSC from two different 
donors were treated with positive control in the same experiment. As 
expected, inter-donor variability was observed in the potential of HSC from 
different donors to undergo apoptosis illustrated in Figure 4.4 below. To 
address this, the degree of apoptosis was determined by normalizing to that 
of the positive control in each experiment.  For example, if the frequency of 
baseline apoptosis is 1 and that induced by positive control is 50, then 
positive control normalized baseline degree of apoptosis would be 1/50 x 
100= 2%; assuming that the positive control reflects the maximum potential of 
the cells to undergo apoptosis is each individual experiment.  
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Figure 4-4: Variability in apoptosis potential of primary HSC from 
different donors. 
FACs plots showing % expression of cleaved caspase 3 on primary human 
HSC (pHSC) from two different donors (pHSC1 and pHSC2) at baseline 
and on treatment with SuperKiller TRAIL (500ng/ml) for 5 hours. 
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4.4 Patient Cohort 
Local and national ethical boards at Camden Primary Care Trust, University 
College Hospital, Royal London Hospital and Royal Free Hospital Trust 
approved this study. All participants of the study have given written, informed 
consent. All sample and data storage complies with the requirements of Data 
Protection Act 1998 and Human Tissue Act 2004. Peripheral blood was 
obtained from patients infected with CHB attending clinics at Mortimer Market 
Centre (Bloomsbury, London), University College London Hospital NHS 
Foundation Trust (Bloomsbury, London), Royal London Hospital, Barts Health 
NHS Trust (Whitechapel, London) and Royal Free London NHS Foundation 
Trust (Hampstead, London). All HBV infected patients were anti-HCV and 
anti-HIV antibody negative. The patients were stratified on the basis of their 
disease status: viral load (determined by real-time PCR), liver inflammation 
indicated by serum levels of alanine transaminase (ALT) and degree of 
fibrosis determined by Ishak stage and/or ELF test (Ishak score: 1-2 mild 
fibrosis, 3-4 moderate fibrosis, 5-6 cirrhosis; ELF test: ≤7.7 no/mild fibrosis, 
7.7-9.8 moderate to severe fibrosis, >9.8 cirrhosis). 
 
Clinical  details of CHB patients along with their study codes are detailed in 
Table 4.1 below.
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Pt ID Fibrosis HBeAg Viral Load 
(IU/ml) 
ALT 
(IU/L) 
Gender Age 
(yrs) 
Treatment 
Pt001 Moderate 
(ELF) 
- <2000 Not 
done 
M 19 Untreated 
Pt002 Moderate 
(ELF) 
- 10,853 10 M 32 Untreated 
Pt003 Not done - <2000 Not 
done 
M 34 Untreated 
Pt004 Cirrhosis 
(Biopsy) 
- 29 Not 
done 
M 49 Untreated 
Pt005 Moderate 
(ELF) 
- Not done Not 
done 
 36 Untreated 
Pt006 Cirrhosis 
(Biopsy) 
- 172 57 M 53 Untreated 
Pt007 Moderate 
(Biopsy) 
- 1,535 53 F 57 Untreated 
Pt008 Moderate 
(Biopsy) 
- 10,107 20 M 46 Untreated 
Pt009 Cirrhotic 
(Biopsy) 
- Not 
detected 
200 F 70 Untreated 
Pt010 Mild 
(ELF) 
- Not 
detected 
22 F 29 Untreated 
Pt011 Severe 
(ELF) 
- 110,000 53 M 44 Untreated 
Pt012 Not done - Not 
detected 
134 M 28 Untreated 
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Pt013 Moderate 
(ELF) 
- 6,100 93 M 30 Untreated 
Pt014 Moderate 
(ELF) 
- Not 
detected 
84  19 Untreated 
Pt015 Severe 
(ELF) 
+ 27,000,000 748 M 35 Untreated 
Pt016 Not done 
 
- 13,000 186 M 33 Untreated 
Pt017 Moderate 
(Biopsy) 
- 1,150 114  48 Untreated 
Pt018 Moderate 
(ELF) 
+ 73,164,142 172 F 25 Untreated 
Pt019 Not done - 110 
 
18 F 60 Untreated 
Pt020 Mild 
(ELF) 
- 16,000 47 F 35 Untreated 
Pt021 Mild 
(ELF) 
- 1,800 18 F 28 Untreated 
Pt022 Moderate 
(ELF) 
Not 
done 
Not 
detected 
27 M 33 Untreated 
Pt023 Moderate 
(ELF) 
Not 
done 
Not 
detected 
24 F 27 Untreated 
Pt024 Moderate 
(ELF) 
- 7,066 26 F 40 Untreated 
Pt025 Mild 
(ELF) 
- 421 58 M 36 Untreated 
Pt026 Severe + 32,000 160 M 59 Untreated 
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(Biopsy) 
Pt027 Not done 
 
- 13,000 186 M 33 Untreated 
Pt028 Moderate 
(ELF) 
- 1,127,317 189 F 52 Untreated 
Pt029 None 
(Biopsy) 
- 347 25 F 43 Untreated 
Pt030 Moderate 
(Biopsy) 
- 1150 114  48 Untreated 
Pt031 Not done - 2,832 41 F 
 
33 Untreated 
Pt032 Not done + 100,000,000 233 M 32 Untreated 
 
Pt033 Not done - 9,400 25 F 60 Untreated 
 
Pt034 Not done  430 21 F 
 
56 Untreated 
Pt035 Cirrhotic 
(Biopsy) 
- Not 
detected 
51 M 36 Untreated 
Pt036 Not done - 2,200 24 F 45 
 
Untreated 
Pt037 Not done - 1,500 19 F 31 
 
Untreated 
Pt038 Not done - Not done 19 F 34 
 
Untreated 
Pt039 
 
Not done + 14,911,605 74 M 33 Untreated 
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Pt040 Not done - Not done Not 
done 
F 27 Untreated 
Pt041 
 
Not done - 1,100 22 F 41 Untreated 
Pt042 Not done - Not 
detected 
22 M 36 Untreated 
Pt043 
 
Not done - 180 20 F 22 Untreated 
Pt044 
 
Not done - 220 41 F 36 Untreated 
Pt045 
 
Not done - 1000 34 M 40 Untreated 
Pt046 Not done - Not 
detected 
86 M  Untreated 
Pt047 Not done - Not 
detected 
Not 
done 
M 29 Untreated 
Pt048 Not done + 2000 Not 
done 
M 30 Untreated 
Pt049 Not done + Not done Not 
done 
 38 Untreated 
Pt050 None 
(Biopsy) 
- 4850 26 F 35 Untreated 
Pt051 Not done - Not 
detected 
39 M 41 Untreated 
Pt052 Mild 
(Biopsy) 
- 5440 47 M 44 Untreated 
Pt053 Mild - 33,500 19 F 42 Untreated 
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(Biopsy) 
Pt054 Not done - 2,700 25 M 43 Untreated 
        
 
Table 4-1: Details of CHB patients whose PBMC were used in this study.  
 
First column is the patient sample code, second column is the fibrosis score of 
patients, third column gives the HBeAg status of the patient, fourth column is 
the HBV DNA  (viral load) of the patients (IU/ml), fifth column gives alanine 
aminotransferase (ALT) levels of the patient in IU/L, sixth column indicates the 
gender of the patient (Female=F, Male=M), seventh column indicates the age 
of the patient at the time of sample collection in years and the eighth column 
indicates the treatment status of the patients.  
 
Table 4.2 below gives the details of the healthy donors that consented and 
participated in this study. 
Pt Id 
 
Gender Age 
HD001 
 
M 31 
HD002 
 
F 26 
HD003 
 
M 29 
HD004 
 
F 34 
HD005 
 
M 25 
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HD006 
 
F 36 
HD007 
 
M 23 
HD008 F 38 
 
HD009 M 31 
 
HD010 F 44 
 
HD011 F 32 
 
HD012 F 22 
 
HD013 F 32 
 
HD014 F 32 
 
HD015 M 35 
 
HD016 M 32 
 
HD017 F 33 
 
HD018 M 27 
 
HD019 M 24 
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HD020 F 26 
 
 
Table 4-2: Details of healthy donors whose PBMC were used in this 
study.  
First column gives the sample code, second column gives the gender of the 
participant (F=female, M=male) and the third column gives the age of the 
participant in years at the time when sample was collected. 
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4.5 Developing an assay to study the role of NK cells in HSC apoptosis  
 
Having normalized the read-out for apoptosis of HSC, the experimental 
design was created. The HSC plated on 48-well tissue culture plates were co-
cultured with NK cells from CHB patients or healthy donors. Post co-culture, 
the apoptosis of HSC was determined by staining them for cleaved caspase-3 
and analysed using flow cytometry. NK cells were purified from whole PBMC 
using a magnetic bead NK cell isolation kit. As can be seen in Figure 4.5 
below, very clean purities of NK cells were obtained, determined by staining 
for CD56+ CD3- cells and analysed using flow cytometry.  
 
 
Figure 4-5: NK cell purity post magnetic bead isolation. 
FACS plot demonstrating the levels of purity post magnetic bead isolation of 
NK cells by gating on CD56+ CD3- cell population. Doublets and dead cells 
have been excluded in previous gates.  
 
 
NK cells isolated from PBMC of CHB patients and healthy donors were co-
cultured with already plated primary HSC for five hours as illustrated in figure 
4.6 below.  
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Figure 4-6: Experimental design. 
Experimental design to study NK cell-HSC interaction and examine the 
apoptosis-inducing potential of NK cells against HSC. Primary human HSC 
were plated 24 hours prior to setting up co-culture experiments at a density of 
10,000 cells per well. NK cells were purified from whole PBMC using a 
magnetic bead NK cell isolation kit and left in culture overnight. NK cells and 
HSC were co-cultured for 5 hours. At the end of co-culture, HSC were 
harvested using Trypsin/EDTA and stained for Dead cell marker and cleaved 
caspase 3 to study apoptosis. The data was analysed using flow cytometry. 
Superkiller TRAIL (500ng/ml) was used as a positive control for apoptosis.  
 
4.6 NK cells have a variable and limited potential to kill HSC 
Having optimised and established the conditions to effectively measure 
apoptosis of HSC, the co-culture experiments were carried out measuring 
apoptosis of HSC at baseline, with a positive control and in co-culture with NK 
cells purified from PBMC of a cohort of 18 healthy and 59 CHB donors. As 
demonstrated in Figure 4.7a below, NK cells from some donors were able to 
induce a degree of apoptosis of HSC. Figure 4.7b shows the cumulative data 
of induction of apoptosis in HSC by NK cells of CHB patients and healthy 
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individuals. These data have been normalized to apoptosis induced by the 
positive control (SuperKiller TRAIL, 500ng/ml) in each individual experiment. 
This is done by assuming that the positive control reflects the maximum 
(100%) potential of the HSC to undergo apoptosis is each individual 
experiment, the cleaved caspase 3 levels of HSC at baseline and post co-
culture with NK cells are calculated in relation to positive control. As can be 
seen in Figure 4.7, NK cells from CHB patients can significantly induce 
apoptosis of HSC. However for the whole cohort, this is not significantly 
higher than that induced by NK cells from the cohort of healthy individuals. A 
large spread in the killing potential of NK cells of CHB patients and healthy 
donors can be observed. 
 
NK cells from some healthy donors and CHB patients have a better potential 
to induce apoptosis compared to others. NK cells from the majority of the 
donors are unable to induce effective apoptosis of HSC.  These data indicate 
that NK cells have a variable and limited potential to induce apoptosis of HSC. 
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Figure 4-7: NK cells have a variable capacity to trigger apoptosis in HSC. 
Human primary HSC were co-cultured with NK cells from healthy donors and 
CHB patients for 5 hours. Treatment of HSC with Superkiller TRAIL 
(500ng/ml) for the same duration as the co-culture was used as the positive 
control. a) Representative FACS plot demonstrating the capacity of NK cells 
from a healthy donor and patient with CHB, compared to SuperKiller TRAIL, 
to induce cleaved caspase 3 expression in HSC. b) Summary graph showing 
% of cleaved caspase 3 normalised to positive control in primary HSC (pHSC) 
alone, after co-culture with NK cells from healthy donors and after co-culture 
with NK cells from CHB patients. (p=0.0504, Kruskal-Wallis ANOVA).  
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4.7 Capacity of NK cells to kill HSC varies according to patient CHB 
disease status 
 
To address this variable potential of NK cells to kill HSC, the CHB patients 
were stratified on the basis of their HBeAg status, viral load, ALT and fibrosis 
stage. As previously mentioned in the Introduction section of this thesis, the 
various parameters that determine disease status may influence the fibrosis 
status of patients. The patients were stratified on the basis of their disease 
status: viral load (determined by real-time PCR), liver inflammation indicated 
by serum levels of alanine transaminase (ALT) and degree of fibrosis 
determined by Ishak stage (ranked by a histopathologist as part of routine 
clinical diagnosis) and/or ELF test (Ishak score: 1-2 mild fibrosis, 3-4 
moderate fibrosis; ELF test: 0-7.7 no/mild fibrosis, 7.7-9.8 moderate to severe 
fibrosis). To understand this more finely, a table showing the various stages of 
each patient is given in Table 3.1 and following that is the stratified data 
showing the influence of the disease status on the ability of NK cells to induce 
apoptosis of HSC in Figure 4.8. 
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The cumulative results of CHB disease stratification are illustrated below in 
Figure 4.8. 
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Figure 4-8: Stratification of CHB patients and their potential to kill HSC. 
Human primary HSC were co-cultured with NK cells from CHB patients for 5 
hours. Treatment of HSC with Superkiller TRAIL (500ng/ml) for the same 
duration as the co-culture was used as the positive control. % of cleaved 
caspase 3+ primary human HSC (pHSC) post co-culture normalized to 
positive control. Cumulative plots showing capacity of NK cells of CHB 
patients to kill HSC, dividing patients on the basis of HBeAg (p=0.0695, 
Kruskal-Wallis ANOVA), HBV viral load (p=0.1935, Kruskal-Wallis ANOVA), 
ALT (p=0.1266, Kruskal-Wallis ANOVA) and stage of fibrosis (p=0.0635, 
Kruskal-Wallis ANOVA). 
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These data indicate that the HBeAg status, viral load, ALT levels and fibrosis 
stage of the patients does not influence the killing potential of their NK cells 
statistically. However, patients with ALT > 40 have a trend towards an 
enhanced potential of their NK cells to kill HSC. Previous work has 
demonstrated that NK cells of CHB patients with elevated levels of ALT have 
high levels of TRAIL expression (Dunn et al., 2007; Peppa et al., 2010). NK 
cells of CHB patients with moderate to severe fibrosis also exhibit a trend 
towards improved capacity to kill HSC however this is not statistically 
significant compared to NK cells of patients with no or mild fibrosis.  
 
Next we wanted to investigate whether the gender of the patients influenced 
the capacity of their NK cells to induce apoptosis of HSC. For this, the 
patients from the cumulative graph in Figure 4.7 were divided on the basis of 
their gender. As can be seen in Figure 4.9 below, the gender of the patients 
had no significant effect on the potential of their NK cells to induce apoptosis 
of HSC.  
 
Furthermore, we also wanted to examine if the age of the patients had an 
impact on the apoptosis inducing capability of NK cells. To study this, the age 
of the CHB patient at the time of sampling was correlated with their potential 
to trigger apoptosis of HSC. Figure 4.10 demonstrates that in the current 
cohort, no statistical correlation exists between these factors.  
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Figure 4-9: Segregation of CHB patients on the basis of gender and their 
capacity to kill HSC. 
Human primary HSC were co-cultured with NK cells from CHB patients for 5 
hours. Treatment of HSC with Superkiller TRAIL (500ng/ml) for the same 
duration as the co-culture was used as the positive control. % of cleaved 
caspase 3+ primary human HSC (pHSC) post co-culture is normalized to 
positive control. Cumulative graph showing the capacity of NK cells of female 
CHB patients and male CHB patients to induce apoptosis of HSC. No 
statistical difference was found between the two (p=0.1205, Mann-Whitney U 
test).  
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Figure 4-10: No correlation between age of CHB patients and their 
capacity to induce apoptosis of HSC.  
Human primary HSC were co-cultured with NK cells from CHB patients for 5 
hours. Treatment of HSC with Superkiller TRAIL (500ng/ml) for the same 
duration as the co-culture was used as the positive control. % of cleaved 
caspase 3+ primary human HSC (pHSC) post co-culture is normalized to 
positive control. Correlation graph showing the age of CHB patients in years 
(x axis) against their capacity to induce apoptosis of HSC (y axis). No 
statistical significance found. 
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4.8 Effects of antiviral treatment on NK cell potential to kill HSC 
 
Next we wanted to examine the effect of anti-viral treatment in patients with 
CHB on their NK cells to determine if this influenced their potential to kill HSC. 
The patient cohort used for this analysis and their clinical details are enlisted 
in Table 4.3 below. As can be seen in the cumulative plot below (Figure 4.11), 
NK cells of patients on NUC therapy were unable to induce apoptosis of HSC. 
However, there was no statistical difference between the potential of NK cells 
from untreated CHB patients and that of CHB patients on NUC therapy. It is 
worth noting that the cohort size of CHB patients on treatment is much smaller 
compared to untreated patients. These findings are in line with previously 
published data from our group showing that NK cells of CHB patients on NUC 
treatment are less activated and express less TRAIL compared to those of 
untreated patients (Peppa et al., 2010). Phenotyping NK cells for activation 
and TRAIL expression from patients used in these experiments 
complemented previously published data. Plausibly due to their less activated 
phenotype, these NK cells from CHB patients on NUCs are unable to trigger 
apoptosis of HSC. 
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Pt Id HBeAg Viral 
load 
(IU/ml) 
ALT 
(IU/ml) 
Treatment Fibrosis 
status 
Age 
(yrs) 
Pt1 
 
+ 29,786 61 Lam+Adv Mild 48 
Pt2 - Not 
detected 
17 Adv Moderate 64 
Pt3 
 
- 16,000 47 Adv Mild 40 
Pt4 +  Not 
detected 
42 Lam+Adv Moderate 59 
Pt5 + Not 
detected 
36 Ten Not done 62 
Pt6 
 
- 60 x106 126 Lam Not done 79 
Pt7 
 
+ 179 38 Ten Not done 31 
Pt8 - Not 
detected 
18 Ten Not done 48 
Pt9 - Not 
detected 
18 Ten Not done 52 
 
Table 4-3: Details of CHB patients on NUC therapy whose PBMC were 
used in this study.  
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Figure 4-11: NK cells from CHB patients on NUCs do not show any 
difference in their capacity to induce apoptosis of HSC compared to 
baseline apoptosis of HSC. 
Graph showing cumulative data of % of  cleaved caspase 3 levels normalized 
to positive control (SuperKiller TRAIL 500ng/ml) on primary HSC (pHSC) after 
co-culture with NK cells from healthy donors, untreated (UT) CHB patients 
and CHB patients on NUCs using flow cytometry. (p=0.1052, Kruskal-Wallis 
ANOVA). 
 
Following on from this, we wanted to examine if activating NK cells influenced 
their potential to kill HSC.  
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4.9 NK cells activated with IFNα have an augmented potential to kill HSC 
NK cells can be activated in the presence of cytokines such as IFN-α as 
mentioned before. Previous work from our group and others has 
demonstrated that NK cells are activated on in vitro and in vivo treatment with 
IFN-α (Micco et al., 2013; Walzer et al., 2005). IFN-α has also been 
demonstrated to have a direct anti-fibrotic effect by reducing the proliferative 
potential of HSC in in vitro experiments with LX2 in a dose dependent manner 
(Ogawa et al., 2009), however, this needs to be investigated in further detail. 
In this study, to examine whether activated NK cells had an enhanced 
potential to induce apoptosis of stellate cells, purified NK cells were activated 
in vitro with recombinant IFN-α (rIFN-α) (105 U/ml) overnight and washed 
before being co-cultured with HSC to determine apoptosis of HSC, as 
described in Materials and Methods. This working concentration of rIFN-α was 
chosen as it has been previously described that this is the approximate 
concentration of IFN-α found in the circulation of CHB patients on peg-IFN-α 
therapy (Dunn et al., 2007). We observed that upon activation with IFN-α, NK 
cells had an improved capacity to kill HSC as illustrated in representative 
FACS plot in Figure 3.12a. The cumulative graphs of these data in Figure 
3.12b show a significant increase in the killing capacity of NK cells activated 
by IFN-α over untreated NK cells. This enhanced capacity of NK cells to kill 
HSC was observed both in NK cells from CHB patients and healthy donors, 
which implies that this is not a CHB specific effect and IFN-α activated NK 
cells in general exhibited a better anti-fibrotic capacity to kill HSC.   
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Figure 4-12: Effect of activated NK cells on HSC apoptosis. 
NK cells from healthy donors and CHB patients were left untreated or were 
treated with rIFNα (105 U/ml) overnight and co-cultured with primary human 
HSC (pHSC) for 5 hours. % expression of cleaved caspase 3+ HSC was 
determined using flow cytometry.  a) Representative FACS plot showing 
improved capacity of NK cells treated with IFNα to kill HSC and b) cumulative 
plots of impact of IFN-a on the capacity of NK cells from healthy donors 
(p=0.0115, Wilcoxon paired test) and CHB patients (p=0.0152, Wilcoxon 
paired test) to kill HSC.  
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These data demonstrated that IFN-α increased the potential of NK cells to kill 
HSC. These data led us to probe the pathway through which NK cells could 
be killing HSC.  
4.10 Examining whether peripheral NK cells reflect the intra-hepatic NK 
cells in the context of their interaction with HSC 
 
As has been described in the Introduction section, NK cells in the liver 
comprise around 40% of the lymphocyte population compared to 8-15% in the 
periphery (Cooper et al., 2001). They are not only more concentrated in the 
liver but also phenotypically different, in that the liver contains a greater 
proportion of CD56bright NK cells compared to the periphery. We have 
previously shown that intrahapetic NK cells are more activated and express 
higher levels of TRAIL than those in the circulation (Dunn et al., 2007). This 
phenotype of liver NK cells has interesting parallels with recent high profile 
publications revealing a separate lineage of liver-resident NK cells in murine 
models with a different transcriptional profile and high levels of TRAIL 
expression (Daussy et al., 2014; Peng et al., 2013). It would be important 
therefore to examine the interaction between liver NK cells and HSC, since 
this may represent a unique physiological function for liver-lineage NK cells. 
Some preliminary experiments were conducted using intrahepatic 
lymphocytes (IHL) extracted from surplus biopsy tissue from CHB patients 
and perfusates from livers of healthy organ donors. As illustrated in Figure 
4.13, IHL from CHB patients in one case showed a better potential to kill HSC 
compared to IHL from healthy individuals. It is noteworthy that these are very 
preliminary results and were obtained from only two samples from both 
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healthy and CHB patients. It is impossible to conclude anything from these 
few samples, however, it would be interesting to investigate the apoptosis 
inducing potential of liver NK cells from CHB patients compared to their 
circulating counterparts and compared to intrahepatic NK cells from healthy 
controls.  
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Figure 4-13: HSC apoptosis induced by IHL from healthy and CHB 
donors. 
Cleaved caspase 3 levels of primary HSC (pHSC) when co-cultured with intra-
hepatic lymphocytes (IHL) isolated from healthy donor livers and liver biopsies 
from CHB with and without in vitro treatment with IFN-α. These data were 
collected using flow cytometry. 
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4.11 IFN-α upregulates expression levels of TRAIL on NK cells 
To investigate the pathway through which NK cells trigger apoptosis in HSC 
that was augmented by IFN-α, both treated (with rIFN-α) and untreated NK 
cells were phenotyped from all patients and healthy donors. This was done at 
the time of co-culture. Out of all NK markers that were stained for, the death 
ligand TRAIL was the only marker that was significantly upregulated on NK 
cells on in vitro treatment with IFN-α. The summary data for this are shown in 
Figure 4.14. These data suggested that the mechanism through which NK 
cells treated with rIFN-α have an improved capacity to kill HSC is the TRAIL 
pathway.  
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Figure 4-14: Effect of in vitro rIFN-α stimulation on NK cells. 
NK cells from healthy donors and CHB patients were either left untreated 
treated with rIFNα (105 U/ml) overnight and stained for the specified markers. 
No statistical significance was observed on NK cells of healthy donors and/or 
CHB patients post in vitro treatment with rIFNα in the expression levels of 
HLA DR (p=0.7354, p=0.1495 Wilcoxon paired test) , NKG2A (p=0.6848, 
p=0.5163 Wilcoxon paired test), NKG2D (p=0.1677, p=0.1698 Wilcoxon 
paired test), NKp46 (p=0.1619, p=1.000 Wilcoxon paired test) and NKp30 
(p=0.4961, Wilcoxon paired test) on NK cells from healthy donors and CHB 
patients. Statistically significant differences were found in the levels of TRAIL 
(p=0.0134, p<0.0001 Wilcoxon paired test) on NK cells from healthy donors 
and CHB patients. 
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TRAIL is a death ligand belonging to the tumor necrosis family superfamily, 
which can induce apoptosis of target cells expressing the relevant TRAIL- 
receptor. Significant upregulation of TRAIL on NK cells irrespective of the 
disease status, and not any other NK cell activatory receptor, suggested that 
TRAIL might be the dominant pathway via which NK cells exhibited improved 
potential to induce apoptosis of HSC upon in vitro pre-treatment and 
activation with rIFN-α.  
 
4.12 HSC undergo TRAIL mediated apoptosis 
As a proof of principle to test whether TRAIL was an effective mechanism 
through which HSC could undergo apoptosis, a lentiviral system was used to 
knock-down the expression of TRAIL-R2 on HSC. TRAIL can interact with 
TRAIL-R1 and TRAIL-R2 to induce apoptosis. HSC have been previously 
shown to express TRAIL-R2 (Taimr et al., 2003). In collaboration with Itziar 
Otano in the group, short hairpin (sh) RNA delivered by lentiviral vectors were 
developed to knock-down the expression of TRAIL-R2 on HSC (Otano, I 
unpublished). LX2 were used for this setup. Using this system, the expression 
of TRAIL-R2 was effectively knocked down from LX2 using shTRAIL-R2 
compared to control sh (sh CTR) as illustrated in Figure 4.15 below. 
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Figure 4-15: Knock-down of TRAIL-R2 on HSC using lentiviral vectors. 
LX2 were transduced using lentivirus containing control short hairpin  (sh 
CTR) or short hairpin against TRAIL-R2 (sh TRAIL-R2) at an MOI of 40. The 
plasmids containing short hairpin also had GFP to determine effective 
transduction of cells. Diagramatic illustration (top panel) and FACS plot 
showing effective transduction of LX2 using a lentiviral vector to deliver 
shCTR and shTRAIL-R2 by looking at the expression of GFP and the levels of 
TRAIL-R2.  
 
Next, to determine if knocking down TRAIL-R2 influenced apoptosis of HSC, 
LX2 were treated with Superkiller TRAIL and as shown in Figure 4.16, the 
majority of untransduced LX2 and those transduced with shCTR underwent 
apoptosis in a TRAIL-dependent manner. However, LX2 lacking TRAIL-R2 
owing to knock-down of the receptor were protected from TRAIL mediated 
killing.  
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Figure 4-16: Rescue of TRAIL mediated apoptosis of HSC by knocking 
down TRAIL-R2. 
LX2 transduced using lentivirus containing control short hairpin  (sh CTR) or 
short hairpin against TRAIL-R2 (sh TRAIL-R2) at an MOI of 40. The plasmids 
containing short hairpin also had GFP to determine effective transduction of 
cells. Un-transduced and transduced LX2 were treated with SuperKiller TRAIL 
(500ng/ml) for five hours and their degree of apoptosis was examined by 
staining for cleaved caspase 3 and analysed using flow cytometry. FACS 
plots showing levels of cleaved caspase 3 on untreated un-transduced HSC, 
HSC transduced with sh CTR and HSC transduced with sh TRAIL R-2 (top 
panel). Bottom panel showing cleaved caspase 3 levels of un-transduced 
HSC, HSC transduced with sh CTR and HSC transduced with sh TRAIL R-2 
upon treatment with SuperKiller TRAIL.  
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These data indicate that high levels of TRAIL can induce apoptosis of HSC. 
However, it is noteworthy that even with very high levels of TRAIL, as in this 
experiment, around 40% of HSC were not susceptible to apoptosis. This 
suggests that there could be other underlying mechanisms that allow HSC to 
escape apoptosis.  
 
4.13 Blocking TRAIL on NK cells has no effect on their potential to kill 
HSC 
To investigate the role of TRAIL in relation to NK cell killing of HSC, TRAIL 
was blocked on NK cells using neutralising antibodies against TRAIL before 
co-culturing them with HSC. We found that blocking TRAIL was able to 
reduce NK cell killing in some patients but not in others, such that it had no 
overall effect on the killing potential of NK cells from the whole cohort. These 
data have been summarized in Figure 4.14. As can be seen in Figure 4.17a, 
TRAIL blockade did reduce the NK cell-mediated induction of cleaved 
caspase 3 on HSC in some cases while in other cases TRAIL blockade 
induced HSC apoptosis. The cumulative data for this are shown in Figure 
4.17b. 
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Figure 4-17: TRAIL blockade overall does not influence the apoptosis 
inducing potential of NK cells on HSC. 
TRAIL was blocked on NK cells from CHB patients using neutralising antibodies 
against TRAIL (1µg/ml) prior to co-culture with primary human HSC. Above data 
depicts the potential of these NK cells to induce apoptosis in primary HSC 
normalized to positive control. a) Data from individual patients showing the effect 
of NK cells killing HSC before (white bar) and after TRAIL blockade (red bar). b) 
Cumulative plot showing no overall difference in the effect of blocking TRAIL on 
NK cells before co-culturing them with HSC (p=0.9306, Wilcoxon paired test) and 
their potential to trigger apoptosis of HSC. 
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Next we wanted to examine the effect of clinical status of CHB patients on the 
potential of their NK cells to kill HSC post blocking TRAIL on their surface. For 
this, the CHB patients from Figure 4.17 were segregated on the basis of their 
HBeAg, viral load, ALT levels and stage of fibrosis (determined using IIshak 
fibrosis stage or ELF test). Figure 4.18 demonstrates that in this cohort, the 
clinical parameters of the patients studied, do not influence the capacity of NK 
cells (post TRAIL blockade) to trigger apoptosis of HSC.  
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Figure 4-18: Stratification of CHB patients and the capacity of their NK 
cells to kill HSC post TRAIL blockade. 
TRAIL was blocked on NK cells from CHB patients using neutralising 
antibodies against TRAIL (1µg/ml) prior to co-culture with primary human 
HSC. Above data depicts the potential of these NK cells to induce 
apoptosis in primary HSC normalized to positive control. No statistically 
significant difference was found in the capacity of untreated NK cells from 
CHB patients and TRAIL neutralised NK cells from the same CHB patients;  
HBeAg negative  (p=0.5879, Wilcoxon paired test), HBeAg positive 
(p=0.5000, Wilcoxon paired test), low viral load (VL) (<2000IU/ml) 
(p=0.2500, Wilcoxon paired test), high viral load (>2000IU/ml) (p=0.3008, 
Wilcoxon paired test), low ALT (<40IU/L) (p=0.1055, Wilcoxon paired test), 
high ALT (>40IU/L) (p=0.2500, Wilcoxon paired test), no/mild fibrosis 
(p=1.000, Wilcoxon paired test) and moderate/severe fibrosis (p=0.9375, 
Wilcoxon paired test) to kill HSC. 
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Furthermore, on analysis of expression levels of TRAIL on NK cells with their 
capacity to induce apoptosis in HSCs, it was found that there was no 
correlation between these two factors as demonstrated by the correlation 
graph in Figure 4.19. This suggested that even though TRAIL-TRAIL receptor 
interaction can impact on the apoptosis of HSC, this is not solely dependent 
on levels of TRAIL on NK cells. The expression of TRAIL-receptors on HSC 
may be influencing this interaction.  
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Figure 4-19: No correlation between levels of TRAIL on NK cells and 
their capacity to induce apoptosis of HSC. 
Levels of surface expression of TRAIL on NK cells (CD56+) determined 
using flow cytometry (y axis) are correlated with their potential to trigger 
apoptosis of HSC studied as % of cleaved caspase 3 normalized to 
positive control (x axis). No statistical correlation is found between the two.  
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To further examine whether the level of TRAIL expressed on NK cells was 
insufficient to trigger apoptosis of HSC or whether there was a potential role of 
the expression of TRAIL receptors in the capacity of HSC to undergo TRAIL-
mediated apoptosis, the degree of apoptosis of HSC was investigated after 
treating them with recombinant stabilized TRAIL ligand, SuperKiller TRAIL at 
high levels (500ng/ml). It was observed that even with such high levels of 
TRAIL, HSC were unable to undergo complete or high levels of apoptosis 
(Figure 4.20). These data imply that in this system, potentially the expression 
of TRAIL receptors (on the surface of HSC) may regulate or influence the 
capacity of HSC to undergo TRAIL-mediated apoptosis.  
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Figure 4-20: Capacity of HSC to undergo TRAIL-mediated apoptosis 
using recombinant TRAIL 
 
HSC were treated with 500ng/ml of SuperKiller TRAIL for five hours. HSC 
were then stained for cleaved caspase 3 and were analysed using flow 
cytometry. Graph depicts (n=28) significant increase in % of expression 
levels of cleaved caspase 3 post treatment with SuperKiller TRAIL in HSC 
compared to untreated HSC (p<0.0001, Wilcoxon paired test). However, 
complete or high levels of apoptosis of HSC was not achieved. 
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Conclusion 
In this chapter the in vitro experimental work has demonstrated that NK cells 
from CHB patients have a variable capacity to induce apoptosis of primary 
human HSC. NK cells from some healthy controls induced apoptosis of HSC, 
however, NK cells of CHB patients overall have a greater propensity to kill 
HSC. We postulate that this may be attributable to higher levels of activation 
and of death inducing ligands that can mediate caspase-3 mediated apoptosis 
on NK cells from patients with active HBV infection. This concurs with the 
published data showing higher levels of death inducing ligand TRAIL on NK 
cells of CHB patients compared to healthy controls (Dunn et al., 2007; Maini 
and Peppa, 2013; Rehermann, 2013).  
 
It was observed that the NK cells of CHB patients had a variable capacity to 
kill HSC. For this, the patients were stratified based upon their disease status 
and it was observed that patients with high ALT showed a trend towards 
improved killing potential of HSC. This could possibly be due to increased 
activation and higher levels of TRAIL on the surface of NK cells of these 
patients (Dunn et al., 2007). It was also observed that NK cells from CHB 
patients with moderate to sever fibrosis had a trend towards better killing 
potential of HSC. There are two possible explanations for this paradoxical 
finding: firstly, that fibrosis progresses in these patients despite the anti-
fibrogenic activity of NK cells, which may nevertheless be limiting it to some 
degree. Secondly, HSC of these patients may escape NK mediated death in 
vivo by mechanisms not fully captured by the in vitro assays.  
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CHB patients were also segregated on the basis of their gender and it was 
found that there was no statistical difference between NK cells of female or 
male CHB patients and their capacity to trigger apoptosis of primary human 
HSC. Next, we wanted to examine whether the age of the patients influenced 
the capacity of their NK cells to kill. No correlation was found between the age 
of the patients and their potential to kill HSC suggesting that age of CHB 
patients does not alter the function of their NK cells within the range of ages 
tested. However, it would be interesting to investigate whether the duration of 
HBV infection has an effect on the function of NK cells of patients. This data is 
not available for this cohort at the moment. 
 
As previous studies have described the activation of NK cells when subjected 
to IFN-α, this study was taken further by activating NK cells of CHB patients 
and healthy individuals with rIFN-α to examine if activated NK cells have an 
enhanced ability to kill HSC. It was observed that irrespective of the donor 
status (CHB or healthy), rIFN-α activated NK cells were able to kill HSC 
better. Phenotyping the NK cells with and without activation with rIFN-α 
revealed that TRAIL was the only ligand being upregulated with this cytokine, 
suggesting that this enhanced capacity of NK cells to kill HSC may be 
mediated via the TRAIL death-inducing pathway.  
 
To investigate whether these findings of NK cells isolated from PBMCs of 
CHB patients translate to the functionality of intrahepatic NK cells, preliminary 
experiments were carried out by isolating intrahepatic lymphocytes (IHL) from 
surplus tissue of liver biopsy specimens from CHB patients and IHL obtained 
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from liver perfusates of healthy liver donors. The n number for these 
preliminary experiments is very low to deduce any conclusion. However, this 
would be interesting to study in detail in the future as intrahepatic NK cells 
have a higher expression of TRAIL on their surface compared to NK cells in 
the periphery (Dunn et al., 2007). Also, recent publications have described a 
separate lineage of resident liver NK cells in mice and it would be important to 
study their role in this context (Daussy et al., 2014; Peng et al., 2013). 
 
In this study, even though NK cells were able to trigger apoptosis of HSC 
which was further augmented by pre-treatment with rIFN-α; complete 
apoptosis of HSC was never attained, even with very high in vitro levels of 
TRAIL with the positive control (SuperKiller TRAIL).  
 
In addition, although in vitro upregulation of TRAIL on NK cells did improve 
their capacity to kill HSC, blocking TRAIL on NK cells had no overall effect on 
their killing potential.  
 
These findings prompted the question: do HSC have an anti-apoptotic 
mechanism switched on that limits their capacity to undergo TRAIL-mediated 
apoptosis? 
 
In the next chapter we therefore examined the potential anti-apoptotic 
phenotype of HSC.  
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5. Investigating the role of TRAIL receptors in regulating apoptosis 
susceptibility of stellate cells 
 
Background 
Upon activation, the HSC becomes phenotypically myofibroblastic as a result 
of changes at gene expression level. Activated HSCs have a pro-survival 
phenotype that is associated with production of survival factors such as 
TGFβ, IGF-1, activation of NFκB and long-term changes in IκB proteins and 
Rel-like factors (Elsharkawy et al., 2005; Elsharkawy et al., 1999). Along with 
the pro-survival signals, activated HSCs have also been shown to have active 
anti-apoptotic signaling. An elegant study done using rodent and human HSC 
has shown that activated HSC overexpress Bcl-2, which makes them resistant 
to a variety of pro-apoptotic stimuli (Novo et al., 2006). In the same study, it 
was demonstrated that silencing of Bcl-2 in HSC rendered them apoptotic. 
However, TRAIL mediated apoptosis was not studied in this report. It is worth 
noting that Bcl-2 is part of the intrinsic apoptotic pathway, whereas TRAIL-
induced death is a part of the extrinsic apoptotic pathway. However there are 
reports that the extrinsic apoptotic pathway does cross over and initiate the 
intrinsic apoptotic pathway and therefore can also be regulated in this manner 
(Falschlehner et al., 2007; Gogvadze and Orrenius, 2006). These pathways 
have been described in more detail in the Introduction. 
 
Based on previous murine studies, the TRAIL mediated apoptotic pathway 
seems to be one of the dominant routes by which NK cells kill HSC. In the 
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previous chapter it has been demonstrated that TRAIL was the only marker to 
be significantly upregulated on NK cells treated with IFN-α in vitro, but we 
were unable to demonstrate that the baseline or IFN-α enhanced killing of 
HSC was TRAIL-dependent. This prompted us to examine the expression of 
receptors of TRAIL on HSCs to investigate the regulation of apoptosis through 
this pathway. We hypothesized blocking TRAIL may not reproducibly block 
apoptosis because it would prevent engagement of this ligand with both 
death-inducing and inhibitory receptors. 
 
The death ligand TRAIL has been previously described to bind to TRAIL-R1, 
TRAIL-R2, TRAIL-R3, TRAIL-R4 and OPG (Walczak, 2013). TRAIL can 
induce apoptosis by binding to TRAIL-R1 and TRAIL-R2 on target cells. 
TRAIL-R1 and 2 both have an intracellular death domain (DD), which is 
needed for downstream apoptosis-inducing signaling. TRAIL-R1 and -R2 
were both discovered in 1997 and they share 58% sequence homology (Pan 
et al., 1997a; Pan et al., 1997b; Screaton et al., 1997; Walczak et al., 1997).  
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Figure 5-1: Schematic role of TRAIL receptors. 
The cartoon illustrates the structures of the different TRAIL receptors and their 
downstream signaling. TRAIL-R1 and -R2 have transmembrane death 
domains; on binding to TRAIL, TRAIL-R1 and -R2 initiate downstream 
caspase cascade to cleave caspase 3 and induce apoptosis. TRAIL-R3 
completely lacks the transmembrane death domain and TRAIL-R4 has a 
truncated transmembrane death domain.  
 
However, if TRAIL binds to TRAIL-R3 or -R4 there is no downstream signaling 
leading to caspase-mediated apoptosis as these two receptors lack the intra-
cellular death domain (Lalaoui et al., 2011). TRAIL-R3 and -R4 share high 
homology of their extracellular domain with TRAIL-R1 and -R2 (Falschlehner 
et al., 2007). TRAIL-R3 is held on to the membrane via its glycosyl-
phosphatidylinositol tail (GPI) whereas TRAIL-R4 is anchored on to the 
surface of the cell through a transmembrane domain that includes a truncated 
DD that is unable to recruit the adaptor protein FADD (Lalaoui et al., 2011; 
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Meng et al., 2000). Most studies demonstrating the apoptosis preventing 
function of TRAIL-R3 have done so by over-expressing TRAIL-R3 on TRAIL-
sensitive cells, however, their decoy role in a physiological setting still remains 
to be established (Falschlehner et al., 2007; Merino et al., 2006; Toscano et 
al., 2008).  Like TRAIL-R3, TRAIL-R4 is unable to induce apoptosis, however, 
unlike TRAIL-R3, TRAIL-R4 has a cytosolic death domain which is truncated. 
Similar to TRAIL-R3, most of the studies showing the apoptosis-inhibitory role 
of TRAIL-R4 have been carried out in overexpression systems.  
 
Another molecule that can inhibit downstream TRAIL-mediated apoptosis is 
cellular FLICE-like inhibitory protein (c-FLIP). c-FLIP is an anti-apoptotic 
protein that can be recruited at the site of DISC and regulate the activation of 
caspase-8. cFLIP is known to exist in three isoforms dependent on their 
amino acid lengths: cFLIPL, cFLIPR and cFLIPS  (Safa, 2012). cFLIP can be 
transcriptionally activated by changes in the microenvironment such as growth 
factors, cytokines, interleukins and chemotherapeutic agents (Safa et al., 
2008). This molecule has homeostatic functions in normal tissue and has 
been reported to play a crucial role in T cell proliferation and embryonic 
development of certain organs (Yeh et al., 2000; Zhang et al., 2008). 
However, abnormal expression of this anti-apoptotic protein has been found in 
several diseases such as rheumatoid arthritis, cancer, Alzheimer’s disease 
and multiple sclerosis (Safa, 2012). Animal model studies have demonstrated 
that suppressing the expression of cFLIP sensitizes cancer cells to death 
ligand mediated apoptosis and chemotherapy (Day et al., 2008).  
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Work looking at the expression of death inducing receptors on stellate cells 
has successfully shown that primary human HSC and LX2 (human HSC line) 
express high levels of apoptosis-inducing receptor TRAIL-R2 (Glassner et al., 
2012; Taimr et al., 2003). However, there is only one published report of the 
expression of the apoptosis inhibitory receptors TRAIL-R3 and TRAIL-R4 on 
LX2 at mRNA level (Taimr et al., 2003). In this chapter we have investigated 
whether these receptors were also expressed at protein level on HSC and if 
they contributed to their anti-apoptotic phenotype. We have also examined if 
the expression of TRAIL receptors on HSC influences their interaction with NK 
cells, inhibiting/promoting TRAIL-mediated apoptosis.  
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5.1 Expression of TRAIL receptors of primary HSC 
In every individual experiment, HSC were phenotyped for the expression of all 
the TRAIL receptors. As can be seen in Figure 5.2a and 5.2b, primary HSC 
express low levels of TRAIL -R1 and TRAIL-R3 at mRNA levels, however 
TRAIL-R1 is not translated at protein level; this is possibly due to post-
translational modifications as described in tumor studies (Lin et al., 2010) 
whereas TRAIL-R3 is expressed at protein level. TRAIL-R2 and TRAIL-R4 are 
both highly expressed on primary HSC at mRNA and protein level.  
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Figure 5-2: Expression of TRAIL receptors on primary human HSC. 
a) mRNA levels of TRAIL-R1 (TR-1), -R2 (TR-2), -R3 (TR-3) and -R4 (TR-
4) on primary human HSC from six donors (red) and LX2 (blue) b) 
Expression of TRAIL-R 1-4 , -R2, -R3 and -R4 at protein level using flow 
cytometry on primary human HSC.  
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5.2 Expression of TRAIL-receptors ex vivo on freshly isolated HSC 
From these initial studies, it was unclear whether the pattern of TRAIL 
receptor expression was being modulated by in vitro culture of stellate cells. 
The expression of TRAIL-R4 and TRAIL-R3 on HSC was therefore next 
examined ex vivo on freshly isolated HSC. For this, sufficient primary HSC 
were obtained from six liver resections to stain these cells directly ex vivo, 
without the need for in vitro expansion. The gating strategy for these has been 
illustrated in Figure 4.3a; we excluded all other possible cell populations 
(Figure 4.3a legend) from the HSC fraction of the cell isolation method. To 
also exclude potential stem cells, CD45+ cells were gated out from HSC 
donor 6 and this exclusion will be included in future phenotyping. Figure 4.3b 
shows the expression of these receptors ex vivo on HSC from six different 
liver donors. These data reveal that HSC express apoptosis inducing receptor 
TRAIL-R2 and apoptosis inhibiting receptor TRAIL-R3 and TRAIL-R4 in vivo 
and this expression is not an artifact of culturing these cells. Expression levels 
ex vivo showed considerable variability between different donor livers as also 
noted after in vitro culture, explored further in section 5.4. 
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Figure 5-3: Ex vivo expression of TRAIL receptors on freshly isolated 
human HSC.  
a) gating strategy of HSC ex vivo. Bigger cells were gated in the FSC-SSC 
gate, followed by excluding dead cells and B cells (CD19+); in the next gate 
monocytic lineages, macrophages, KC and LSEC were excluded by gating 
out CD14+, Cytokeratin+, CD68+ cells, CD146; next T cells, Tregs, NK cells, 
NKT cells and MAIT cells were excluded by gating out CD3+ and CD56+ 
cells; by excluding other cells we are left with HSC b) histograms showing % 
expression of TRAIL receptors on freshly isolated primary HSC from five 
different donors (blue) against matched isotype control (grey). 
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5.3 Functionality of inhibitory/regulatory receptor TRAIL-R3 
 
 TRAIL-R3 is an apoptosis inhibitory receptor for TRAIL. This receptor 
completely lacks the intracellular death domain. Overexpression experiments 
have demonstrated that TRAIL-R3 acts as a decoy receptor by sequestering 
exogenous TRAIL in the lipid rafts of target cells and via this mechanism they 
plausibly prevent the formation of DISC (Merino et al., 2006). To determine 
whether the expression of TRAIL-R3 on primary human HSC influenced their 
ability to undergo TRAIL mediated apoptosis, functional experiments were 
performed by blocking TRAIL-R3 on primary HSC and examining whether this 
affected their ability to undergo TRAIL mediated apoptosis. For this, primary 
HSC were treated with neutralising antibodies against TRAIL-R3 before the 
addition of SuperKiller TRAIL for five hours; the levels of cleaved caspase 3 
were then stained and acquired using flow cytometry. As can be seen in the 
Figure 5.4 below, blocking TRAIL-R3 on primary HSC did improve their 
capacity to undergo TRAIL mediated apoptosis. 
 
Figure 5-4: Effect of TRAIL-R3 blockade on primary HSC and their 
susceptibility to apoptosis. 
FACS plots showing cleaved caspase 3 levels of primary HSC untreated, 
treated with SuperKillerTRAIL (500ng/ml) and treated with SuperKiller TRAIL 
after blocking TRAIL-R3 using blocking antibody (5µg/ml) on HSC. 
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This is the first demonstration of a decoy role of TRAIL-R3 in primary human 
cells. However, it is noteworthy that these experiments need to be performed 
on HSC from more donors and determine if this is a consistent reproducible 
effect.  
 
5.4 Functionality of inhibitory/regulatory receptor TRAIL-R4  
 
Expression of high levels of TRAIL-R4 on HSC was particularly interesting 
because unlike inhibitory receptor TRAIL-R3 that lacks an intracellular death 
domain, TRAIL-R4 has a truncated trans-membrane intra-cellular death 
domain. Studies done by overexpressing this receptor have reported that 
TRAIL-R4 can activate NFκB which can further upregulate anti-apoptotic 
genes and might actively contribute to protecting TRAIL-sensitive cells from 
apoptosis (Degli-Esposti et al., 1997). Other studies have also demonstrated 
that TRAIL-R4 can interact with TRAIL-R2 in a ligand dependent and 
independent manner and inhibit downstream caspase signaling via TRAIL-R2 
(Clancy et al., 2005; Merino et al., 2006). TRAIL-R4 interaction with TRAIL, 
along with inhibiting the caspase cascade, may also promote cell proliferation 
by indirectly activating the PI3/Akt pathway (Lalaoui et al., 2011). To 
investigate whether the expression of TRAIL-R4 on HSC influenced their 
TRAIL mediated apoptosis potential, HSC were stained for TRAIL-R4 from 
five different donors and checked for their levels using flowcytometry. These 
HSC were treated with Superkiller TRAIL for 5 hours and the levels of active 
caspase-3 induced were compared using flow cytometry. Figure 5.5a shows 
the expression of TRAIL-R4 on HSC from all five donors. Figure 5.5b 
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demonstrates the levels of caspase-3 on these cells over baseline when 
treated with Superkiller TRAIL. Figure 5.5c shows striking negative correlation 
between the levels of TRAIL-R4 on HSC and their potential to undergo 
TRAIL-mediated apoptosis, implying that the higher the level of TRAIL-R4, the 
lower is their susceptibility to undergo TRAIL-mediated apoptosis. 
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Figure 5-5: Functional effect of expression of TRAIL-R4 on HSC. 
a) % Expression of TRAIL-R4 on HSC from 5 different donors using flow 
cytometry. b) Potential of these HSC to undergo TRAIL-mediated 
apoptosis. c) Correlation between expression of TRAIL-R4 on HSC and 
their capacity to undergo TRAIL-mediated apoptosis.  
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We then investigated whether the levels of TRAIL-R2 expression on primary 
HSC regulated the capacity of HSC to undergo TRAIL-mediated apoptosis, as 
was observed with TRAIL-R4 in figure 5.5. Figure 5.6 shows that no 
correlation was found. These data imply that even though TRAIL mediated-
apoptosis of HSC occurs through TRAIL-R2, expression levels of this receptor 
are not the limiting factor that determines the capacity of HSC to undergo 
TRAIL-mediated apoptosis.  
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Figure 5-6: No correlation between expression levels of TRAIL-R2 on 
HSC and their potential to undergo apoptosis. 
% expression of TRAIL-R2 on primary HSC from five donors analysed 
using flow cytometry (x axis) and the capacity of these HSC to undergo 
TRAIL mediated apoptosis (SuperKiller TRAIL, 500ng/ml) assessed by % 
of cleaved caspase 3 using flow cytometry (y axis) plotted in a correlation 
graph. No Correlation between expression of TRAIL-R2 on primary HSC 
and their capacity to undergo TRAIL-mediated apoptosis was observed..  
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Furthermore, the effect of blocking TRAIL-R4 was examined on these HSCs. 
For this, purified monoclonal antibody was used to block TRAIL-R4 on HSC 
and it was found that blocking TRAIL-R4 did increase the induction of 
apoptosis in HSC in some cases and not in others  (Figure 5.7). It is 
noteworthy that three primary human HSC lines out five responded to TRAIL-
R4 blocking, enhancing their potential to undergo TRAIL mediated apoptosis. 
The response to blockade did not correlate with baseline levels of TRAIL-R4 
expression (Figure 5.5a) on these primary HSC.  
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Figure 5-7: Effect of blocking TRAIL-R4 on HSC and their capacity to 
undergo TRAIL-mediated apoptosis 
TRAIL-R4 was blocked on primary HSC using neutralising antibody (5µg/ml)  
before adding SuperKiller TRAIL (500ng/ml) to assess their capacity to 
undergo TRAIL mediated apoptosis. Flow cytometry analysis of % cleaved 
caspase 3 is used as a readout. Graph showing cleaved caspase 3 levels on 
untreated primary HSC, treated with SuperKiller TRAIL with or without pre-
treatment with a monoclonal antibody to block TRAIL-R4 or an isotype 
control for blocking. 
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This once again underscored the inter-donor variability and suggested HSC 
from different individuals have differential dependence on the different TRAIL 
receptors to regulate apoptosis. This could also represent the affinity with 
which the blocking antibody binds to each separate primary HSC line. To 
overcome any non-specific binding or low affinity binding of blocking antibody 
against TRAIL-R4, we developed a system using short hairpin against TRAIL-
R4 (shTRAIL-R4) delivered using a lentiviral vector to knock-down the 
expression of TRAIL-R4 in HSC. This work was done in collaboration with 
Itziar Otano (Postdoc, Maini group). As a proof of principle this was first 
optimised using LX2. As can be seen in Figure 5.8, LX2 were effectively 
transduced with lentivirus (GFP+). TRAIL-R4 expression was knocked-down 
in LX2 transduced with lentivirus containing shTRAIL-R4 compared to those 
transduced with lentivirus containing a control short hairpin.  
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Figure 5-8: TRAIL-R4 knock-down of HSC. 
Using lentivirus to deliver short hairpin against TRAIL-R4 to knock it down. 
Diagramatic illustration and FACS plot showing expression of TRAIL-R4 
against levels of transduction (GFP+) in untransduced LX2 or LX2 transduced 
with short hairpins against TRAIL-R4 or control. 
 
Next, to examine whether knock-down of TRAIL-R4 on the surface of LX2 
made them more susceptible to TRAIL mediated killing, untransduced LX2, 
LX2 transduced with control lentivirus (ctrLV), LX2 transduced with lentivirus 
containing shTRAIL-R4 (shTR4) and LX2 with TRAIl-R4 neutralised using 
blocking antibody (aTR4) were treated with SuperKiller TRAIL (500 ng/ml) for 
five hours and their levels of cleaved caspase 3 were analysed using flow 
cytometry (Figure 5.9). This experiment was done with three technical 
replicates for each condition. It was observed that LX2 transduced with 
shTRAIL-R4 and LX2 treated with blocking antibody against TRAIL-R4 both 
had an improved potential to undergo TRAIL-mediated apoptosis compared to 
apoptosis in untransduced LX2 and LX2 transduced with control lentivirus. 
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This is however, a preliminary experiment done on LX2, we would like to 
repeat this in primary human HSC  from different donors. It is noteworthy that 
unlike primary HSC, LX2 do not express TRAIL-R3, therefore antibody 
blockade or knocking down TRAIL-R3 using lentivirus was not possible in this 
cell line.  
 
It is worth noting that there was considerable amount of caspase 3+ LX2 at 
baseline with TRAIL-R4 blocking using neutralising antibody. These data 
could suggest that the TRAIL-R4 monoclonal antibody could be partially 
stimulatory or that HSC are dependent on tonic survival signals from TRAIL-
R4 even in absence of ligand.  
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 Figure 5-9: Using lentiviral vectors to knock-down expression of TRAIL-R4 
on HSC and their susceptibility to undergo TRAIL mediated apoptosis.  
Representative FACS plots showing % expression of cleaved caspase 3 on 
untreated and Superkiller TRAIL (500ng/ml) treated untransduced LX2, LX2 
transduced with control lentivirus (ctrLV), LX2 transduced with lentivirus 
containing shTRAIL-R4 (shTR4) and LX2 neutralised with TRAIL-R4 using 
blocking antibody (aTR4) (5µg/ml). Cumulative graph showing technical 
replicates of this experiment. 
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Having demonstrated that expression of TRAIL-R3 and TRAIL-R4 could 
modulate the susceptibility of primary HSC to apoptosis induction by an 
artificial form of TRAIL-ligand, our next aim was to investigate if this was also 
the case for NK cells endogenously expressing TRAIL.  
 
5.5 Functional effect of expression of TRAIL-R3 and -R4 on HSC on their 
susceptibility to NK cell mediated death 
 
To investigate this, TRAIL-R3, TRAIL-R4 or both were neutralised on HSC, 
which were then co-cultured with NK cells with or without in vitro recombinant 
IFN-α treatment (to upregulate their TRAIL expression). Figure 5.10a 
illustrates the experimental design of this assay. As can be seen in Figure 
4.10b, blocking TRAIL-R4 on primary HSC using neutralising antibody 
significantly increased the susceptibility of HSC to undergo TRAIL-mediated 
apoptosis by NK cells. On some of the patients from Figure 5.10b, TRAIL-R3 
was also neutralized on primary HSC. Data represented in Figure 5.10c 
depicts the improved susceptibility of primary HSC to undergo apoptosis upon 
co-culture with NK cells from CHB patients after blocking TRAIL-R3 and 
TRAIL-R3+TRAIL-R4 on the surface of primary HSC.  
 
Figure 5.11 shows the caspase 3 levels of primary HSC upon co-culture with 
NK cells from individual CHB patients and the levels of caspase 3 after 
blocking TRAIL-R3 or TRAIL-R4 or both on primary HSC. The data shows 
that blocking TRAIL-R3,-R4 or both does make HSC more susceptible to NK 
cell mediated killing in some cases while it has no effect in other cases. These 
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differences are consistent with human data examining in vitro blockade of 
molecules such as PD-1, CTLA-4 etc. owing to the heterogeneity in patient 
cells.  
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Figure 5-10: Effect of NK-HSC co-culture post neutralising TRAIL-R3 
and -R4 and combination on HSC. 
NK cells were co-cultured with HSC after TRAIL-R3 and TRAIL-R4 surface 
expression was blocked on HSC using neutraling antibodies (5µg/ml); their 
capacity to undergo apoptosis was determined by staining for caspase 3 and 
analysed using flow cytometry. Graphs represent levels of caspase 3 
normalised to positive control (SuperKiller TRAIL). a) diagrammatic 
representation of experimental design. b) Significant difference was found in 
the capacity of HSC to undergo NK-mediated apoptosis after blocking 
TRAIL-R4 (0.0226, Wilcoxon-paired test) c) significant difference was found 
in apoptosis of HSC upon blocking TRAIL-R3 and combination blockade of 
TRAIL-R3 and –R4 and co-culture with NK cells (0.0153, Friedman test one-
way ANOVA).   
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 Figure 5-11: Individual patient data for effect of NK-HSC co-culture post 
neutralising TRAIL-R3 and -R4 and combination on HSC.  
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NK cells were co-cultured with HSC after TRAIL-R3 and TRAIL-R4 surface 
expression was blocked on HSC using neutralising antibodies (5µg/ml); their 
capacity to undergo apoptosis was determined by staining for caspase 3 and 
analysed using flow cytometry. Graphs represent levels of caspase 3 
normalised to positive control (SuperKiller TRAIL). White bars represent 
apoptosis of primary human HSC post co-culture with each CHB patients. 
Blue, red and green bars show apoptosis of primary human HSC after TRAIL-
R3 blockade, TRAIL-R4 blockade, TRAIL-R3,4 blockade using respective 
neutralising antibodies post co-culture with each CHB patients.    
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Next, experiments were done to examine whether HSC, when their inhibitory 
TRAIL receptors were blocked, had an increase in susceptibility to undergo 
apoptosis when co-cultured with NK cells that were pre-activated using rIFN-α 
(to upregulate their levels of TRAIL expression). As can be seen in Figure 
5.12b, blocking TRAIL-R4 on HSC showed a significant increase in their 
susceptibility to TRAIL-mediated killing by NK cells activated with IFN-α 
compared to untreated NK cells. It was found that (Figure 5.12a, c) blocking 
TRAIL-R3, the combination of TRAIL-R3 and-R4 on HSC showed a non-
significant trend to make them more susceptible to TRAIL-mediated killing by 
NK cells activated with IFN-α compared to untreated NK cells from CHB 
patients. 
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Figure 5-12: Effect of NK (untreated and rIFN-α treated)-HSC co-
culture post neutralising TRAIL-R3 and -R4 and combination on HSC. 
 
NK cells were co-cultured with HSC after TRAIL-R3 and TRAIL-R4 surface 
expression was blocked on HSC using neutralising antibodies (5µg/ml); 
their capacity to undergo apoptosis was determined by staining for caspase 
3 and analysed using flow cytometry. Graphs represent levels of caspase 3 
normalised to positive control (SuperKiller TRAIL). a) NK cells of CHB 
patients treated with rIFN-α in vitro have a non-significant trend of improved 
capacity to kill primary HSC (post neutralising TRAIL-R3) (p=0.3426, 
Wilcoxon paired test). b) NK cells of CHB patients treated with rIFN-α in 
vitro have a significant improved capacity to kill primary HSC (post 
neutralising TRAIL-R4) (p<0.0001, Wilcoxon paired test). c) NK cells of 
CHB patients treated with rIFN-α in vitro have a non-significant trend of 
improved capacity to kill primary HSC (post neutralising TRAIL-R3 and –
R4) (p=0.6159, Wilcoxon paired test) 
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These data indicate that upon upregulating TRAIL levels on NK cells after pre-
treating them with IFN-α and co-culturing them with HSC that have TRAIL-R3, 
-R4 or the combination blockade, NK cells did show a significant improvement 
in their potential to kill HSC. It is noteworthy that in some cases blocking 
TRAIL-R3 and/or -R4 greatly improved the killing potential of activated NK 
cells while in other cases blocking these receptors did not affect the killing 
potential of NK cells. It is worth noting that the primary HSC lines used for 
these experiments were the ones that responded to TRAIL-R4 blockade from 
Figure 5.7 (pHSC2,3,4). It is also worth noting that unlike LX2 (figure 5.9), 
primary HSC did not increase their baseline apoptosis on treatment with 
TRAIL-R4 neutralising antibody, this could suggest that in LX2, blocking 
TRAIL-R4 could have a ligand independent effect that drives their apoptosis 
and is enhanced on ligand engagement.  
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5.6 Other potential mechanisms that may suppress TRAIL mediated 
apoptosis of HSC 
As described in the Introduction section of this thesis, apoptosis is a very 
organized and regulated mechanism of programmed cellular death that can 
occur in two ways: via the intrinsic pathway, also known as the mitochondrion-
initiated pathway; and via the extrinsic or cell surface death receptor pathway 
(Elmore, 2007; Gogvadze and Orrenius, 2006). TRAIL – TRAIL receptor 
interactions fall under the extrinsic apoptotic pathway. In this pathway, other 
than interaction with TRAIL-R3 and TRAIL-R4, there is another downstream 
molecule that can inhibit apoptosis referred to as the cellular FLICE-like 
inhibitory protein (c-FLIP). c-FLIP is an anti-apoptotic protein that can be 
recruited at the site of DISC and regulate the activation of caspase-8 as 
illustrated in the Figure 5.13  below.  
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Figure 5-13: cFLIP blocks downstream TRAIL-mediated apoptosis. 
Schematic diagram of cFLIP preventing downstream caspase mediated 
apoptosis by engaging with DISC.  
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Expression of cFLIP in primary human HSC was examined using flow 
cytometry and it was revealed that HSC express high levels of cFLIP as 
shown in Figure 5.14. 
 
 
Figure 5-14: High expression of cFLIP in primary human HSC. 
Histogram of FACS staining of cFLIP on primary HSC in red against matched 
isotype control in grey. 
 
Expression of cFLIP is another potential mechanism to protect HSC from 
TRAIL mediated apoptosis and facilitate fibrosis. However, there is a need to 
check this finding with technical and biological (other primary HSC donors) 
replicates and their functional role needs to be investigated further. cFLIP 
could be a potential reason why no augmentation on NK cell-mediated 
apoptosis in seen in HSC after blocking inhibitory TRAIL-R3 and TRAIL-R4.  
 
Along with the anti-apoptotic role of TRAIL-R3 and TRAIL-R4 as described in 
this thesis, high expression of cFLIP and Bcl-2 on HSC may be plausible 
complementary mechanisms that allow escape of HSC from TRAIL-mediated 
apoptosis.  
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Conclusion 
In this chapter it has been demonstrated that primary human HSC express 
high levels of apoptosis-inducing TRAIL-R2 along with apoptosis-inhibitory 
TRAIL-R3 and regulatory TRAIL-R4.  
 
Further investigation revealed that expression of TRAIL-R4 inversely 
correlated with induction of TRAIL-mediated apoptosis on HSC, implying that 
TRAIL-R4 plays a dominant role in regulating TRAIL-mediated apoptosis in 
these cells, irrespective of their expression of other TRAIL receptors. These 
data suggest that in patients with fibrosis, the expression of TRAIL-R4 on their 
activated HSC could determine the potential for resolution of fibrosis. This is 
the first report of a direct correlation between expression of TRAIL-R4 on a 
primary cell type and its potential to undergo apoptosis. However, this needs 
to be investigated further in in vivo models.  
 
The functional role of expression of these receptors was examined by co-
culturing them with NK cells from CHB patients with and without pre-activation 
with rIFN-α. It was observed that blocking these receptors did not significantly 
enhance the capacity of NK cells to kill HSC. This could possibly be due to the 
affinity with which the blocking antibodies bind to HSC. Another system has 
been setup to overcome any drawbacks of using neutralising antibody. A 
lentiviral system was developed to deliver short hairpin against TRAIL-R4 to 
knock-down its expression in HSC. Data in this chapter show successful 
transduction of LX2 with these and an augmentation in their capacity to 
undergo TRAIL mediated apoptosis. In the future, this system will be used in 
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primary human HSC from different donors to determine whether knock-down 
of TRAIL-R4 makes primary HSC as susceptible to TRAIL mediated apoptosis 
as LX2. 
 
The influence of expression levels of TRAIL-receptors on their capacity to 
undergo TRAIL-mediated apoptosis as described in this chapter brings to light 
the fact that correcting for apoptosis based on TRAIL as a positive control is 
probably not ideal for looking at variability attributable to these receptors. In 
the future, we would like to re-analyse data without correcting against the 
positive control and instead analysing according to status of primary HSC in 
terms of balance of different TRAIL receptors. 
 
The outcome and the future perspective of this study is discussed further in 
the Discussion section of this thesis.  
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Figure 6-15: Potential downstream signaling of TRAIL-R4. 
 
Cartoon showing the different TRAIL receptors and their downstream 
signaling interactions. TRAIL-R4 has a truncated transmembrane death 
domain. Two publications have overexpressed TRAIL-R4 on cell lines and 
demonstrated that TRAIL-R4 has the capacity for downstream activation of 
the NFκB and PI3/Akt pathways leading to cell survival and proliferation 
(Degli-Esposti et al., 1997; Lalaoui et al., 2011). The mechanism through 
which this downstream mechanism is initiated remains to be investigated.  
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6. Conclusion and Discussion 
Summary and Discussion of work presented 
Chronic infection with HBV can lead to cirrhosis and/or HCC, which are the 
causes of mortality in this disease. Liver cirrhosis is the end stage of fibrosis, 
which is the culmination of scar tissue formation over an extended period of 
time, as a result of persistent liver injury. In CHB, the rate at which fibrosis 
develops differs from patient to patient but population studies suggest that the 
incidence of cirrhosis in patients with CHB followed in clinics is 2-3% per year 
(Cabibbo et al., 2012; Di Marco et al., 1999; Fattovich et al., 1991) and the 
incidence of decompensated cirrhosis is 0.5 per 1000 person-years 
(McMahon et al., 2001). Currently, there are no drugs licensed for the 
treatment of liver fibrosis, though many are under investigation. Since HBV is 
a non-cytopathic virus, the damage caused to the liver by this infection is a 
result of the immune responses it triggers. In this thesis, we have examined 
the role of immune responses in driving HBV-related liver fibrosis.  
 
In chapter 2 of this study, it was shown for the first time, with primary samples 
from patients infected with CHB, that peripheral blood mononuclear cells from 
these patients produce soluble mediators that can activate HSC (LX2) at an 
mRNA and protein level. There is a possibility of more than one cell type 
contributing to this observation. 
 
Previous work in our group by Lopes et al. showed an upregulation of various 
pro-fibrogenic genes, such as, connective tissue growth factor (CTGF), 
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fibroblast growth factor (FGF), insulin-like growth factor binding protein 3 
(IGFbp-3) (Lopes et al., 2008) in virus-specific CD8+ T cells from patients with 
persistent compared to resolved HBV infection. ELISA were performed with 
supernatants from these PBMC cultures for CTGF and IGFBP-3. No 
expression of IGFBP-3 at protein level was found. Expression of CTGF was 
observed, however this was not conclusive and could not be correlated with 
disease status. This could be because the experimental timing may have 
been wrong to detect the release of these factors. The cells might need longer 
than 24 hours to secrete fibrotic factors. Another explanation for this might be 
that the impact of these fibrotic factors from HBV-specific CD8+ T cells is 
swamped by a stronger effect from some other constituent of PBMC or that 
HBV-specific CD8+ T cells do not produce pro-fibogenic factors detectable at 
protein level 
 
Studies performed by Fowell et al. in the Rosenberg group, have investigated 
the role of PBMC from HCV infected patients in liver fibrogenesis (Fowell, 
2008). It was found that on stimulation with HCV proteins, PBMC from HCV 
infected patients with fast progressing fibrosis are able to produce soluble 
factors that can activate HSC (LX2 in this case) at mRNA level (αSMA and 
Pro-collagen I) more than PBMC from HCV infected patients with slow 
progressing fibrosis and healthy controls. Since they used HCV proteins in 
their experimental design to stimulate the PBMC from HCV infected patients, 
it is possibly the CD4+ T cells in the system that were responding to the 
protein stimulation. They observed that HCV proteins alone did not have an 
effect of enhancing LX2 activation and concluded that the effects observed 
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were mediated by a PBMC fraction but did not refine whether or not this effect 
was attributable to innate or adaptive immune responses. 
 
Other groups working on regulatory T cell (Treg) have shown that in HBV 
infection, the balance between T helper 17 cells and Tregs is able to influence 
the progression of liver fibrosis by activating HSC (Li et al., 2012).  
 
NKT cells and especially MAIT cells are additional possible candidates for the 
cells responsible for driving the activation of LX2 in our study. NKT cells are 
known to drive fibrosis directly in the liver in a CXCR6 dependent manner and 
by secreting pro-fibrotic cytokines in HBV transgenic mice models and also 
indirectly by stimulating other immune cells in the liver to produce pro-
inflammatory cytokines (Gao et al., 2009; Jin et al., 2011; Swain, 2010; Wehr 
et al., 2013). MAIT cells have been shown to be abundant in the human liver. 
On stimulation they produce pro-fibrogenic cytokines such as IL17A and 
TNFα (Dusseaux et al., 2011; Tang et al., 2013; Walker et al., 2012). 
 
Macrophages have an important pro-fibrogenic role (Duffield et al., 2005; 
Imamura et al., 2005; Meng et al., 2012; Negash et al., 2013). Studies in HCV 
have implicated their pro-fibrogenic role via IL1β (Negash et al., 2013; 
Shrivastava et al., 2013). It would be especially interesting to study the role of 
intra-hepatic macrophages and Kupffer cells from CHB livers in activating 
HSC.  
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Even though the PBMC from CHB patients were able to significantly activate 
HSC more than PBMC from healthy controls, there was a large spread of pro-
fibrotic responses amongst the patient cohort. The CHB patients were 
stratified into various disease stages to dissect their fibrotic potential better. 
We compared them on their degree of fibrosis determined by Ishak stage 
and/or ELF scores. It is worth noting that we did not have many patients with 
severe or advanced fibrosis and therefore we have separated them into those 
with an Ishak fibrosis stage below 2 and ELF score below 7.7 as mild/no 
fibrosis and those with an Ishak fibrosis stage between the range of 2-4 and 
ELF score between the range of 7.7 – 9.8 as having moderate fibrosis. We did 
not see any differences in the potential of their PBMC to activate HSC. We 
need to test the fibrotic potential of PBMC of CHB patients with severe fibrosis 
or cirrhosis to study this stratification better.  
 
The viral load and HBeAg status (data not shown) of the patients were also 
compared and these comparisons did not show any differences in pro-fibrotic 
potential of PBMC according to viral load and HBeAg status.  
 
However, in this study it was observed that patients with increasing liver 
inflammation, measured by ALT, show a trend towards greater stellate cell 
activation. This was seen consistently, both at mRNA and protein levels with 
all the four markers of activation. This could possibly be because, during 
inflammation the immune cells are activated further. This could result in them 
producing more pro-fibrogenic soluble mediators to activate stellate cells to 
initiate the wound-healing mechanism. Our preliminary findings showing more 
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association with ALT than fibrosis score, raises the possibility that the PBMC 
pro-fibrogenic effect may be more relevant in initiating fibrosis than in 
perpetuating it once it is established. Further investigation of this would 
require longitudinal follow-up studies with much larger cohorts of patients. 
 
In chapter 3 of this thesis, the anti-fibrotic potential of NK cells in the context 
of CHB was investigated. Data accumulating over the past decade point to a 
number of different roles for NK cells in CHB, in line with their capacity to 
exert both antiviral (Dunn et al., 2007; Vivier et al., 2011) and 
immunoregulatory functions (Martin-Fontecha et al., 2004; Morandi et al., 
2006; Peppa et al., 2013; Rehermann, 2013).  This study is the first to 
examine their role in CHB associated fibrosis.  
 
2006 was a milestone year in the area of NK cell-HSC interactions. Two key 
independent studies reported for the first time the anti-fibrotic role of NK cells 
by demonstrating that they could kill activated HSC in animal models of CCl4-
induced fibrosis (Melhem et al., 2006; Radaeva et al., 2006). In 2012, this 
interaction was studied for the first time using primary human HSC and NK 
cells from HCV patients (Glassner et al., 2012).  
 
This thesis has examined the NK cell-HSC interactions for the first time in the 
setting of CHB and has shown that in vitro, NK cells from CHB patients have 
the capacity to trigger apoptosis of HSC. However there is considerable 
variation in their potential to induce apoptosis and in the majority of cases the 
extent of apoptosis of HSC demonstrable in vitro is limited, in line with the 
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progressive fibrosis seen in many of these patients. This varied potential of 
NK cells from CHB patients to kill HSC is possibly due to the altered 
phenotype of NK cells in CHB (Maini and Peppa, 2013; Rehermann, 2013). 
Also since this is a cross-sectional study, the time-point or the stage of the 
disease at which the patients are bled for this study may influence their 
capacity to induce apoptosis of HSC. Alternatively, these variations in the 
potential of NK cells of patients to trigger apoptosis of HSC could be a 
manifestation of inter-individual variation in host responses that may partially 
account for variation in disease progression. To examine this further the CHB 
patients enrolled in this study were stratified on the basis of HBV viral load, 
HBeAg status, degree of fibrosis and ALT levels. This division did not lead to 
a conclusive finding however, patients with high ALT or more fibrosis showed 
a trend towards a higher potential to kill HSC. This could suggest that during 
flares of liver inflammation characteristic of certain stages of chronic infection, 
NK cells become transiently activated and kill activated HSC. It was also 
observed that CHB patients taking oral anti-viral NUCs were unable to induce 
apoptosis of HSC, congruent with the observation that treatment with NUCs 
reduces the activation status of NK cells (Peppa et al., 2010), which in turn 
may have an impact on their anti-fibrotic activity.  
 
To examine this further, NK cells were activated in vitro using recombinant 
IFN-α, a type-I IFN that has been previously described to activate NK cells 
(Bryceson et al., 2006; Caligiuri, 2008; Nguyen et al., 2002). This study 
revealed that IFN-α activated NK cells had an improved potential to trigger 
apoptosis of HSC; examining the changes in various NK cell markers 
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implicated upregulation of TRAIL in this augmentation. The fact that NK cells 
from patients with high ALT and those with augmented TRAIL expression had 
an improved potential to kill HSC is in line with previously published data that 
demonstrated that NK cells from CHB patients with high ALT have higher 
expression of TRAIL (Dunn et al., 2007; Peppa et al., 2010). The levels of 
TRAIL on NK cells have been shown to be further upregulated in CHB 
patients on peg-IFNα therapy (Micco et al., 2013). In HCV, it has been shown 
that patients treated with peg-IFNα therapy have a slower rate of progression 
of fibrosis (Vukobrat-Bijedic et al., 2014). The same effect has been observed 
in CHB (Papatheodoridis et al., 2005). However, it remains to be established if 
this is due to activation of NK cells. It has been demonstrated in in vitro 
experiments using LX2 that IFNα can directly negatively influence the 
proliferative potential of HSC (Ogawa et al., 2009). This thesis has focused of 
the effect of in vitro treatment of NK cells with IFN-α and their interaction with 
HSC. Several roles of the TRAIL pathway in NK cells from CHB patients have 
already been researched. It has been demonstrated that in CHB, NK cells can 
interact with infected hepatocytes via the TRAIL pathway to induce their 
apoptosis and play an anti-viral role while contributing to liver damage (Dunn 
et al., 2007). TRAIL-expressing NK cells also have the capacity to kill virus-
specific CD8 T cells via the TRAIL pathway and thus may contribute to viral 
persistence (Peppa et al., 2013). 
 
The finding that NK cells were able to kill stellate cells even in patients with 
increased levels of CHB-related liver fibrosis suggests that they are unable to 
prevent progressive fibrosis, even though they may still be constraining it to 
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some degree. It is also worth noting that during liver injury, activated HSC 
produce high levels of TGF-β compared to quiescent HSC (Jeong et al., 
2011). TGF-β and other immunosuppressive cytokines such as IL-10 have 
been shown to dampen the effector function of NK cells; this could be another 
factor responsible for the varied potential of NK cell to kill in CHB (Dasgupta 
et al., 2005; Peppa et al., 2010; Yu et al., 2006). In murine studies, it has been 
demonstrated that TGF-β produced by HSC does influence anti-fibrotic 
activity of NK cells (Jeong et al., 2011). Another explanation could be that the 
variation in NK cell function is attributable to differential expression of 
inhibitory KIRs on NK cells of CHB patients that has not been studied in detail 
yet. The balance between activating and inhibitory KIRs on NK cells have 
been shown to influence their ability to kill HSC in HCV and murine fibrosis 
models (Muhanna et al., 2011).  
 
Having established the role of the TRAIL pathway in NK cell mediated 
apoptosis of HSC, we further investigated NK cell - HSC interactions via the 
TRAIL pathway to further probe the role of this pathway in liver fibrosis. We 
demonstrated that even though in vitro augmentation of TRAIL on NK cells did 
improve their potential to kill HSC, complete apoptosis of HSC was never 
achieved even after the addition of high dose of SuperKiller TRAIL (positive 
control). Additionally, TRAIL expression on NK cells did not correlate with their 
ability to induce apoptosis of HSC and TRAIL blockade did not abrogate NK 
cell killing of HSC.  
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To understand this better, we further investigated the phenotype of HSC that 
may allow them to escape TRAIL and NK cell-mediated apoptosis. As has 
been explained in previous sections, TRAIL can interact with TRAIL-R1 and 
TRAIL-R2 to induce apoptosis and with TRAIL-R3 and TRAIL-R4 to suppress 
apoptosis. It has been previously described that both primary and cell line 
(LX2) HSC express high levels of TRAIL-R2 (Glassner et al., 2012; Taimr et 
al., 2003). However, the protein expression of TRAIL-R3 and -R4 on primary 
human HSC has been demonstrated for the first time in this thesis. 
Expression of TRAIL-R3 and TRAIL-R4 has been demonstrated in several 
tumor cells such as osteosarcoma cells, colon cancer cells, acute myeloid 
leukemia cells, breast cancer cells and other primary cells such as 
hepatocytes in HCV, CD8 T cells, colon epithelia, HUVECs at protein level 
directly ex vivo (Bouralexis et al., 2003; Brost et al., 2010; Brost et al., 2014; 
Clancy et al., 2005; Riccioni et al., 2005; Secchiero et al., 2003; Toscano et 
al., 2008). However to date, the studies that have investigated a functional 
role for TRAIL-R3 and TRAIL-R4 have done so using cell lines that have been 
manipulated to overexpress these receptors (Clancy et al., 2005; Davidovich 
et al., 2004; Merino et al., 2006; Sheridan et al., 1997; Walczak, 2013; Zhu et 
al., 2011). The ‘decoy’ role of these receptors has been demonstrated in 
several such overexpression studies showing that interaction of TRAIL with 
these receptors prevents apoptosis (Bouralexis et al., 2003; Davidovich et al., 
2004; Falschlehner et al., 2007; Merino et al., 2006). Overexpression 
experiments have also revealed the potential role of TRAIL-R4 in promoting 
cell survival and proliferation (Degli-Esposti et al., 1997; Lalaoui et al., 2011). 
Studies have also demonstrated that TRAIL-R4 can interact with TRAIL-R2 in 
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a ligand dependent as well as independent manner to protect the cell from 
TRAIL-mediated apoptosis (Clancy et al., 2005; Merino et al., 2006).  To our 
knowledge, our work constitutes the first report of the functional apoptosis-
inhibitory role of TRAIL-R3 and TRAIL-R4 on primary human cells. This study 
has demonstrated that blocking these receptors on HSC makes them more 
susceptible to NK cell-mediated apoptosis, further underscoring the crucial 
role of these receptors in protecting activated HSC from undergoing 
apoptosis. We have thereby demonstrated that this ‘decoy’ effect has a 
physiological role in primary human cells against NK cells analysed directly ex 
vivo from patients with CHB.  
 
We have shown that the expression level of TRAIL-R4 on HSC has a clear 
negative correlation with their potential to undergo TRAIL mediated apoptosis. 
Blocking TRAIL-R4 on HSC and co-culturing them with NK cells activated with 
IFN-α further increased their susceptibility to undergo apoptosis. This was 
also observed while blocking TRAIL-R3 in some of the cases.  
 
A possible explanation for the effect of TRAIL-R4 blockade is that interaction 
between TRAIL and TRAIL-R4 could result in signaling via the truncated 
trans-membrane domain of TRAIL-R4, promoting cell-survival and 
proliferation via the NFκB and PI3/Akt pathway (Degli-Esposti et al., 1997; 
Lalaoui et al., 2011). Blocking this regulatory receptor not only allows TRAIL 
to preferentially bind to other receptors but also inhibits the survival pathway; 
as a result when TRAIL engages with TRAIL-R2 there is no 
competitive/regulatory mechanism to check the initiation of the caspase 
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cascade. However, when TRAIL-R3, is blocked, (which completely lacks the 
intracellular death domain and is known to work by competition (Merino et al., 
2006)), TRAIL can still engage with apoptosis-inducing TRAIL-R2 and pro-
survival TRAIL-R4, which might therefore be less effective at enhancing NK 
mediated killing. These downstream pathways have not been studied in HSC, 
however these are plausible mechanisms by which TRAIL-R4 may protect 
HSC from TRAIL-mediated apoptosis and promote HSC proliferation and 
survival has illustrated in Figure 6.1. 
 
Results from this thesis suggest that NK cells from CHB patients could play a 
regulatory role in liver fibrosis (Figure 6.2). Depending on the interaction of 
TRAIL expressed on NK cell with the TRAIL receptors expressed on HSC, 
there could be three plausible fates of HSC. The TRAIL-TRAIL-R2 interaction 
could lead to apoptosis of HSC, therefore having an anti-fibrotic effect. TRAIL 
on NK cells could also interact with TRAIL-R3 and -R4 and prevent apoptosis 
of HSC and thus have a pro-fibrotic effect. The third possibility that remains to 
be explored further is that TRAIL on NK cells could interact with TRAIL-R4 on 
HSC and promote the proliferation and survival of HSC via Akt and NFκB 
signaling, again having a pro-fibrotic role.  
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The balance between these different outcomes, dictated by NK TRAIL 
expression and primary HSC TRAIL receptor expression, may be an 
important determinant of liver fibrosis progression. 
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Figure 6-1: Potential outcomes of NK cell-HSC interaction by TRAIL- TRAIL 
receptor pathway. 
Diagram representing 3 putative effects of TRAIL engagement with TRAIL-
receptors on HSC. If TRAIL on NK cell interacts with TRAIL-R2 on HSC, it can 
promote apoptosis of HSC and play an anti-fibrotic role (top panel). TRAIL could 
interact with TRAIL-R3 and -R4 to allow HSC to escape apoptosis and therefore 
have a pro-fibrotic role (middle panel). TRAIL on NK cells might also interact with 
TRAIL-R4 on HSC to promote HSC proliferation and in turn have a pro-fibrotic 
role (bottom panel).  
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The unanswered questions arising from this thesis and the future and 
translational potential of this thesis are discussed further in the next section.  
 
Questions and future directions 
This thesis has contributed to the field of study of the regulatory role of NK 
cells in CHB as well as the area of the apoptosis-resistant nature of HSC that 
promotes fibrosis. The findings of the two results chapters have generated 
some interesting questions which merit further study. These are: 
 
• Which mononuclear cell is responsible for activating HSC and does  
this have a pro-fibrogenic effect? 
• Are PBMC from CHB patients able to activate primary human HSC? 
• Is the anti-fibrotic effect of peg-IFNα therapy in CHB mediated through 
NK-HSC interactions? 
• Besides TRAIL, are there other NK-HSC cells interactions that might 
promote/inhibit fibrosis? 
• Does TRAIL-TRAIL-R4 interaction influence the proliferation of HSC? 
 
Although this is not an exhaustive list, answering these questions will help to 
enhance the understanding of these cells and the mechanisms through which 
they might be implicated in liver fibrosis. This will allow us to understand and 
identify pathways and molecules that might represent therapeutic targets for 
the treatment of CHB associated liver fibrosis. The tenable answers to these 
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questions have been discussed with some preliminary data (where available) 
below. 
 
Which mononuclear cell is responsible for activating HSC and is this a 
pro-fibrogenic effect translated on to primary human HSC? 
 
 In chapter two of this thesis, it was demonstrated that PBMC from CHB 
patients have a capacity to activate HSC (LX2) at mRNA and protein levels by 
secreting soluble mediators. Next, it would be interesting to identify which 
cell(s) is responsible for the production of these soluble mediators. This can 
be done by using magnetic bead purification or antibody labeled cellular 
sorting to isolate individual cells that comprise the PBMC population such as 
CD4+ T cells, CD8+ T cells, NK cells, T regs, B cells, NKT cells, 
macrophages and dendritic cells and culture them with HSC in a transwell 
system and then study the activation of HSC, post transwell based co-culture. 
It is likely that more than one cell type is playing a role in activating HSC. The 
interaction of different cell types with each other could also be contributing to 
their production of HSC-activating molecules.  Once the cell types are 
identified it would be easier to narrow down and identify the secreted 
compound by the cell that is playing an activatory role towards HSC.  
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Are PBMC from CHB patients able to activate primary human HSC? 
 
These findings from the study in this thesis have been shown in LX2, an 
immortalized HSC cell line. While LX2 form a good constant in the 
experimental setup which has PMBC from different participants as the 
variable, in the future it would be interesting to apply this experimental set up 
to primary human HSC to determine whether these findings are also observed 
in a more physiological setting.   
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Is the anti-fibrotic effect of peg-IFNα therapy in CHB mediated through 
NK-HSC interactions? 
In vitro activation of NK cells can increase their potential to kill HSC. It would 
be interesting to investigate the capacity of NK cells isolated from patients on 
peg-IFNα therapy to induce apoptosis. It has been previously published that 
NK cells of patients on peg-IFNα therapy have increased levels of TRAIL 
expression on their surface along with improved effector function (Micco et al., 
2013). This has not been investigated in this study but would be the next step 
and would be interesting to explore in the future. It has been reported that 
HCV patients on peg-IFNα therapy have a slower rate of progression of 
fibrosis and NK cells have been shown to play a role in this (Glassner et al., 
2012; Vukobrat-Bijedic et al., 2014). In CHB as well, it has been demonstrated 
that patients who respond to peg-IFNα therapy have a slower rate of 
progression of fibrosis (Papatheodoridis et al., 2005). The role of NK cells of 
these CHB patients on peg-IFNα therapy in the context of reduced rate of 
progression of fibrosis would be the next step of investigation. For this, PBMC 
from CHB patients would be isolated at time-points prior to treatment and 
during treatment with peg-IFNα therapy. NK cells isolated from these PBMCs 
would then be co-cultured with HSC to determine changes in their capacity to 
induce apoptosis. At the time points at which the patients are bled for the 
study, their fibrosis status could also be checked using a non-invasive 
biomarker test (ELF test) to correlate the fibrosis stage in the patient with the 
potential of their NK cells to mediate apoptosis.  
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Besides TRAIL, could NK cells-HSC interact via other pathways that 
might promote/regress fibrosis? 
In the past decade, several murine studies have investigated the various 
mechanisms through which NK cells can kill HSC. It has been demonstrated 
that both murine and human HSC express some of the ligands for NKG2D, 
including ULBP-2 and MICA/B. NKG2D is highly expressed on NK cells of 
healthy individuals, and this high expression is maintained on NK cells of CHB 
patients (Maini and Peppa, 2013). In HCV studies and animal studies it has 
been shown that this pathway contributes to NK cell mediated killing of HSC 
(Glassner et al., 2012; Radaeva et al., 2006). Along with the NKG2D pathway, 
the role of the Fas-FasL pathway has also been elucidated. HSC express Fas 
and can interact with FasL on NK cells to undergo apoptosis (Glassner et al., 
2012). Along with these pathways, recently the role of NKp46 in killing HSC 
has been described. It has been discovered using fusion proteins that HSC 
express on their surface the unknown ligand for NKp46, and can interact via 
this pathway to kill HSC (Gur et al., 2012). Expression of NKp46 on NK cells 
of CHB is higher compared to healthy controls and this is further augmented 
in CHB patients on peg-IFNα therapy (Micco et al., 2013; Rehermann, 2013). 
Whether any of these pathways contributes to killing of HSC in CHB still 
remains to be investigated. These various pathways are illustrated in the 
diagram below (Figure 6.4). 
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Figure 6-2: NK cell-HSC death inducing interactions. 
Diagramatic representation of all the known pathways by which NK cells can 
kill HSC: Fas-FasL, NKG2D-MICA-B/ULBP-2, NKp46-NKp46L and TRAIL-
TRAIL R2 (Gur et al., 2012; Radaeva et al., 2006). 
 
 
Killer immunoglobulin-related receptor (KIR) are expressed on NK cells. NK 
cells express both activatory KIRs (aKIRs) and inhibitory KIRs (iKIRs). Both 
types of KIRs on NK cells can interact with MHC Class I molecules on the 
target cell to either promote or inhibit their killing (Locatelli et al., 2013). 
Murine studies have shown that the aKIR:iKIR expression ratio is crucial in 
determining the HSC killing potential of NK cell (Melhem et al., 2006). 
Subsequent murine studies have also demonstrated that silencing iKIRs on 
NK cells improves their potential to kill HSC (Muhanna et al., 2011).  The 
expression levels of aKIRs and iKIRs on NK cells of CHB patients remain to 
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investigated. This could be another possible pathway that influences the 
killing potential of NK cells against HSC.  
 
In animal studies HSC have been shown to downregulate their MHC Class I 
(Melhem et al., 2006). However we observed expression of HLA-E on HSC as 
illustrated in Figure 6.5. HLA-E interacts with CD94/NKG2 complex including 
inhibitory receptor NKG2A on NK cells (Cheent et al., 2013; Sullivan et al., 
2007). NKG2A has been shown to be upregulated on NK cells of CHB 
patients on peg-IFNα therapy (Micco et al., 2013). This could plausibly be a 
mechanism by which NK cells – HSC cross talk may down-modulate NK cell 
killing by re-programming the balance of activatory and inhibitory signals. 
 
Figure 6-3: Primary human HSC express HLA-E. 
HLA-E on HSC could interact with inhibitory CD94/NKG2 complex on NK cells 
to modulate NK cell effector function. FACS histogram showing the 
expression of HLA-E on primary human HSC in red against matched isotype 
control in grey.  
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Reflecting on the results from this thesis, it can be stated that regardless of 
which of these pathways contribute to the killing of HSC in CHB, none of them 
are able to completely prevent progression of fibrosis. HSC hold the potential 
to escape apoptosis and contribute to fibrosis. 
 
 226 
Does the TRAIL - TRAIL-R4 interaction influence the proliferation of 
HSC? 
 
To investigate if the interaction of TRAIL with TRAIL-R4 on HSC influenced 
the proliferation of HSC, HSC were transduced with lentivirus containing short 
hairpin (sh) against TRAIL-R4 to knock-down its expression and then examine 
the proliferation potential of these cells.  
 
Using this system, we would like to examine the role of TRAIL-R4 in 
proliferation and survival of HSC. For this we will transduce cells, knock-down 
the expression of TRAIL-R4 and then compare their proliferative potential 
using the colorimetric MTT assay. We would investigate whether this is ligand 
dependent or independent by knocking down TRAIL-R2 (to avoid TRAIL-
mediated apoptosis) on HSC and then adding TRAIL in a dose dependent 
manner to the system and determining the proliferation of these cells using 
the Ki67 proliferation assay and analysing data using flow cytometry.  
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Future Outlook: 
 
The causes and factors initiating liver fibrosis in HBV infection and other liver 
etiologies have been researched over the past couple of decades. The 
conditions that perpetuate and sustain the pace of progression of fibrosis still 
remain to be fully explained and are an area of active research. This thesis 
has been able to identify some of the mechanisms that aid progression of 
fibrosis: the inability of NK cells from CHB patients to efficiently kill HSC and 
anti-apoptotic features of HSC. These pathways still need to be investigated 
further. They represent potential targets for novel therapies. It will be 
particularly important to study the capacity of activated NK cells from CHB 
patients on peg-IFNα to kill HSC.  
 
Along with activating patient NK cells, studying the characteristics of an 
individual’s HSC may be able to help predict their chances of developing liver 
fibrosis and the rate at which it will progress. For this, histological expression 
of apoptosis inducing TRAIL-R2 and apoptosis inhibiting TRAIL-R3 and 
TRAIL-R4 on HSC of patients with CHB could be studied on liver sections 
from diagnostic biopsies, allowing direct ex vivo assessment of a larger 
cohort.  This would allow us to examine whether the expression of these 
receptors correlated with the degree of fibrosis in these patients. If a 
correlation was found, in the future a longitudinal study could be setup to 
study the histological expression of these receptors on patient HSC together 
with the capacity of their NK cells to mediate apoptosis of HSC to see if these 
predicted the rate of fibrosis progression over the following year or more of 
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follow-up. If this longitudinal study gave promising results, expression of 
TRAIl-R2, TRAIL-R3 and TRAIL-R4 on HSC  and the phenotype of NK cells of 
an individual could potentially be used as future biomarkers of fibrosis 
progression. It is noteworthy that this approach could potentially be of utility 
for any liver disease leading to fibrosis and not just CHB. 
 
Another ambitious yet possible approach to understand stellate cell biology 
better could be to target HSC to downregulate their anti-apoptotic receptors. 
This could potentially be achieved by transducing HSC in an in vivo model 
with lentivirus containing short hairpin to knock-down TRAIL-R4 and/or cFLIP. 
We have demonstrated that HSC can be successfully and effectively 
transduced with lentivirus. An adjuvant could be attached to the lentivirus that 
targets them specifically to HSC. In this way activated HSC could be targeted 
to knock-down TRAIL-R4 and cFLIP expression in order to promote their 
sensitization to apoptosis by NK cells, and possibly also to reduce their 
proliferative potential.  
 
However therapeutic manipulation of stellate cells would need to take into 
consideration their other putative functions. Other than their indispensible role 
in fibrogenesis, HSC play other homeostatic roles in maintaining an effective 
framework to facilitate liver tissue repair in case of acute injury. In a quiescent 
state they also form the reservoir of vitamin A storage in the body. HSC also 
play a role in regulating the liver vasculature; activation of HSC has been 
shown to interfere with the normal sinusoidal endothelial fenestrations by 
depositing extracellular matrix and create an imbalance between 
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vasoconstriction and dilation that leads to increased hepatic vascular 
resistance, further leading to intrahepatic portal hypertension (Iwakiri et al., 
2014). HSC may be able to present antigen to T cells (Winau et al., 2007).  
HSC also play a key immunomuodulatory role since they have been 
demonstrated to regulate the expansion of immune cells such as myeloid 
derived suppressor cells (MDSC) and T regs, which can exert crucial 
immunoregulatory functions (Chou et al., 2011; Dunham et al., 2013; Hochst 
et al., 2013).   
 
From the work presented here, the TRAIL pathway emerges as one 
mechanism by which the fate of hepatic stellate cells is tightly regulated. An 
exciting area of future work will be to further define the importance of this 
alongside other interactions between stellate cells and liver-resident NK cells 
and the potential to apply this as a biomarker or therapeutic target in liver 
fibrosis.  
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